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1. Introduction:	  therapeutic	  potential	  of	  protein	  toxins	  as	  cargo	  delivery	  vehicles†	  
1.1. Bacterial	  protein	  toxins	  
Many	  bacterial	  protein	  toxins	  have	  been	  identified	  and	  characterized	  due	  to	  the	  awful	  
illnesses	   they	   cause,	   including	   anthrax,	   botulism,	   and	   antibiotic-­‐associated	   diarrhea.	   Through	  
evolution,	   these	   proteins	   have	   developed	   mechanisms	   to	   disturb	   mammalian	   cellular	  
processes,	  often	  subsequent	  to	  gaining	  access	  to	  the	  cytosol.	  	  Researchers	  have	  recognized	  the	  
value	   in	   such	  a	   system	  and	  have	  much	   to	   learn	   from	  these	  proteins	  either	  by	  coopting	   them	  
directly	  or	  by	  minimizing	  their	  function.	  
Great	  therapeutic	  potential	  lies	  in	  the	  toxic	  proteins	  released	  by	  bacteria.	  	  As	  a	  means	  of	  
survival,	  bacteria	  secrete	  small	  molecules,	  polypeptides,	  and	  large	  proteins.	  Gram-­‐positive	  and	  
Gram-­‐negative	   bacteria	   often	   release	   small	   molecules	   as	   a	   means	   of	   communication,	   or	  
quorum	   sensing,	   to	   regulate	   gene	   expression	   in	   response	   to	   population	   density.	   	   Quorum	  
sensing	  controls	  processes	  such	  as	  virulence,	  sporulation,	  biofilm	  aggregation,	  and	  motility	  (1).	  	  
In	   pathogenic	   bacteria,	   quorum	   sensing	   regulates	   the	   expression	  of	   virulence	   factors	   such	   as	  
toxic	  proteins	  and	  polypeptides.	   	  Although	  parasitic	  bacteria	  require	  the	  host	   for	  survival,	   the	  
toxic	  effects	  are	  beneficial	  to	  the	  infecting	  species	  because	  they	  induce	  the	  immediate	  release	  
of	  nutrients	  at	  a	   time	  when	   the	   thriving	  colonies	  are	  growing	  and	  depleting	  other	   sources	  of	  
food.	  There	  are	  two	  main	  classes	  of	  bacterial	  protein	  toxins:	  endotoxins	  and	  exotoxins.	  
1.1.1.	  	  Endotoxins	  
Endotoxins	  are	  usually	  a	  component	  of	  the	  outer	  membrane	  of	  Gram-­‐negative	  bacteria	  
that	   are	   released	  upon	   lysis	   of	   the	   cell	   (Figure	   1.1).	   Examples	   include	   lipopolysaccharide	   and	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2	  
lipooligosaccharide,	   which	   are	   both	   very	   important	   structural	   components	   of	   Gram-­‐negative	  
species,	  such	  as	  Escherichia,	  Salmonella,	  Shigella,	  Pseudomonas,	  and	  Bordetella.	   	  These	  toxins	  
have	  no	  inherent	  enzymatic	  activity,	  and	  cannot	  be	  inactivated	  by	  heat.	  	  In	  humans,	  endotoxins	  
trigger	   an	   immune	   response	   that	   results	   in	   septic	   shock	   characterized	   by	   fever,	   low	   blood	  
pressure,	  rapid	  heart	  rate,	  restlessness,	  confusion,	  shortness	  of	  breath,	  skin	  discoloration,	  and	  
multiple	  organ	  failure	  (2).	  	  
1.1.2.	  	  Exotoxins	  
The	   second	   category	   of	   protein	   toxins	   is	   the	   exotoxins	   (Figure	   1.1).	   	   Exotoxins	   are	  
soluble	   polypeptides	   or	   proteins	   that	   are	   excreted	   by	   pathogenic	   bacteria.	   	   They	   are	   further	  
grouped	   based	   on	  where	   they	   are	  when	   they	   induce	   their	   physiological	   response,	   acting	   (A)	  
extracellularly	   (superantigens),	   (B)	   at	   the	   cell	  membrane	   (pore-­‐forming),	   or	   (C)	   intracellularly	  
(enzymatic)	  (Figure	  1.2).	  	  	  
	   Gram-­‐positive 
	   	  
	   	  
	  
	  
	   	  	  
	  
Exotoxin 
Gram-­‐negative 	  	  
	   	  











Figure	  1.1.	  Endotoxin	  and	  exotoxin	  release.	  	  Endotoxins	  are	  structural	  components	  of	  the	  cell	  
wall	   that	  are	   released	   upon	   lysis,	  most	  often	  associated	  with	  Gram-­‐negative	  bacteria,	   and	  




Pore-­‐forming	  exotoxins,	  such	  as	  streptolysin	  O	  from	  S.	  pyogenes	  and	  alpha	  toxin	  from	  S.	  
aureus,	  insert	  into	  the	  cell	  membrane	  and	  disrupt	  the	  regulation	  and	  control	  of	  influx	  and	  efflux	  
that	   is	   so	   crucial	   to	   cell	   survival	   (3).	   	   Superantigens,	   such	   as	   the	   large	   family	   of	   pyrogenic	  
exotoxins	   produced	   by	   Staphylococci	   and	   Streptococci	   species,	   are	   toxins	   that	   impair	   the	  
immune	   system	   by	   directly	   targeting	   T	   cells	   and	   antigen	   presenting	   cells,	   stimulating	   the	  
immune	  system	  (4).	   	  This	  review	  will	  focus	  on	  intracellular	  enzymatic	  toxins,	  highlighting	  their	  
medicinal	  and	  biotechnological	  value.	  	  
Enzymatic	  toxins	  can	  be	  further	  sorted	  based	  upon	  structure,	  such	  as	  single	  vs.	  multiple	  
polypeptide	   subunits,	   and	   route	   of	   cellular	   entry	   via	   either	   the	   long	   or	   short	   intracellular	  
pathway	   (Figure	   1.3	   and	   Table	   1.1).	   	   Anthrax	   and	   C2	   toxins	   are	   composed	   of	   two	   protein	  
subunits,	   and	   follow	   a	   short	   intracellular	   pathway	   via	   escape	   from	   early	   to	   late	   endosomes	  
(5,6).	  	  Binary,	  or	  A/B	  toxins,	  are	  terms	  used	  to	  describe	  such	  proteins;	  one	  protein	  fragment	  has	  
cell	   binding	   and	   translocation	   function	   (subunit	   B)	  while	   the	   other	   holds	   the	   activity	   domain	  
(subunit	   A).	   	   Following	   cell	   entry,	   the	   enzymatic	   A	   fragment	   is	   released	   intracellularly	   and	  
disrupts	   healthy	   cellular	   functions	   leading	   to	   cell	   damage	   and	   apoptosis.	   	   As	   opposed	   to	   the	  
binary	   toxins,	   the	  Clostridial	  glucosylating	   toxins	  are	  single	  polypeptide	  proteins,	  whereas	   the	  
Clostridial	   neurotoxins,	   C2	   toxin,	   and	   diphtheria	   toxin	   consist	   of	   two	   separate	   proteins	   held	  
together	   by	   a	   disulfide	   linkage	   prior	   to	   cell	   entry.	   	   They	   retain	   binary-­‐like	   cellular	   entry	   and	  
internalization,	   followed	   by	   the	   release	   of	   an	   activity	   domain	   into	   the	   cytosol,	   by	   disulfide	  
reduction	  or	  proteolysis.	  	  This	  proteolysis	  event	  has	  been	  observed	  for	  multiple	  toxins,	  including	  
the	  glucosylating	  toxins	  A	  and	  B	  from	  Clostridium	  difficile	  (7).	  	  An	  intrinsic	  protease	  domain,	  	  
	  	  
4	  


































































































































































































































































































































































































































































activated	   by	   a	   cytosolic	   cofactor,	   releases	   the	   enzymatic	   domain	   only	   after	   translocation.	  	  
Structurally,	   toxins	  A	  and	  B	   feature	   four	  domains	  on	  one	  very	   large	  protein:	   receptor	  binding	  
(B),	   delivery	   (D),	   cutting	   (C),	   and	   activity	   (A)	   leading	   to	   the	   descriptive	   nomenclature,	   ABCD	  
toxin	  (8).	  	  	  
1.2. Enzymatic	  bacterial	  protein	  toxins	  as	  valuable	  research	  tools	  
1.2.1.	  	  Background	  
For	   over	   a	   century	   now,	   the	   unique	   properties	   of	   protein	   exotoxins	   have	  made	   them	  
attractive	   to	   researchers.	   	   Protein	   toxins	   have	   been	   at	   the	   center	   of	   the	   search	   for	   novel	  
therapeutics	   for	   many	   years	   (9)	   (Figure	   1.4).	   	   First,	   their	   extremely	   potent	   cytotoxicity	   was	  
recognized	  as	  a	  valuable	  tool	  that	  could	  be	  exploited	  for	  a	  variety	  of	  purposes	  such	  as	  targeted	  
cell	  therapy.	  	  Next,	  with	  additional	  awareness	  of	  how	  toxins	  function,	  the	  ability	  to	  bypass	  the	  
cell	  membrane	   for	   transport	   of	   therapeutic	  macromolecules,	   at	  will	   and	  with	  high	  efficiency,	  
into	  mammalian	  cells	  is	  an	  area	  of	  research	  now	  gaining	  popularity.	  	  
1.2.2.	  	  Immunotoxins	  
Immunotoxins	   are	   currently	   the	   largest	   area	  of	   research	   involving	   toxin	   therapy.	   	   The	  
proposal	  of	  a	  “magic	  bullet”	  came	  over	  a	  hundred	  years	  ago	  from	  the	  theories	  of	  Paul	  Ehrlich,	  
an	   established	   multidisciplinary	   German	   scientist	   (10,11).	   	   The	   original	   immunotoxin	   design	  
included	  chemical	  conjugation	  of	  two	  fragments,	  the	  enzymatic	  domain	  of	  a	  protein	  toxin	  and	  a	  
cell-­‐selective	  moiety,	  often	  an	  immunoglobulin.	  With	  current	  technology,	  chimeric	  proteins	  are	  
constructed	   genetically,	   alleviating	   the	   challenges	   of	   low	   yields	   and	   potentially	   toxic	   side	  
products.	   The	   cell-­‐binding	   domain	   is	   most	   commonly	   targeted	   to	   receptors	   that	   are	  
overexpressed	  on	  tumor	  cells.	  	  Interleukin	  2	  (IL2),	  the	  alpha	  chain	  of	  IL2	  (CD25),	  and	  epidermal	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growth	   factor	   receptor	   (EGFP)	   are	   common	   targets	   for	   treating	   non-­‐Hodgkin	   lymphoma	   (IL2	  
and	  CD25),	  cytotoxic	  lymphocytic	  leukemia	  (IL2	  and	  CD25),	  cutaneous	  T-­‐cell	  lymphoma	  (IL2	  and	  
CD25),	  adult	  T-­‐cell	  leukemia	  (CD25),	  hairy-­‐cell	  leukemia	  (CD25),	  and	  glioblastomas	  (EGFR)	  (12).	  	  
Following	   the	   directed	   binding	   event,	   the	   toxin	   domain	   mediates	   cytotoxicity.	   	   The	   most	  
notable	  success,	  and	  thus	  far	  the	  only	  FDA	  approved	  immunotoxin	  is	  Denileukin	  diftitox	  (Ontak)	  
engineered	  from	  IL2	  and	  diphtheria	  toxin	  (13,14).	  	  In	  1999,	  Ontak	  was	  approved	  for	  treatment	  
of	   cutaneous	   T-­‐cell	   lymphoma,	   extending	   life	   expectancy	   significantly	   longer	   than	   any	   other	  
available	   treatments.	   	   For	   additional	   information	   on	   this	   topic,	   see	   current	   immunotoxin	  
reviews	  (12,15-­‐17).	  	  
1.2.3.	  	  Eliciting	  immunological	  responses	  
A	  second	  therapeutic	  opportunity	  utilizing	  bacterial	  protein	  toxins	   is	  the	  stimulation	  of	  
an	   immune	   response.	   	   The	   immune	   response	   is	   important	   in	   self-­‐defense	   against	   harmful	  
invaders	  such	  as	  viruses	  and	  pathogenic	  bacteria.	  	  Immune	  cell	  recognition	  of	  foreign	  antigens	  
is	   a	   vital	   step	   in	   this	   process,	   and	   is	   dependent	   upon	   cell	   surface	   display.	   	   Cytotoxic	   T	  
lymphocytes	   (CTL)	   play	   a	  major	   role	   in	   clearing	   infections	  by	  hunting	  down	  and	  destroy	   cells	  
displaying	  non-­‐native	  antigens.	  	  The	  display	  of	  non-­‐native	  antigens	  results	  from	  degradation	  of	  
foreign	  material	  packaged	  and	  processed	  via	  the	  histocompatibility	  complex,	  to	  activate	  the	  CTL	  
response.	  
One	   method	   of	   immunization	   involves	   displaying	   antigens	   from	   the	   major	  
histocompatability	   complex	   (MHC)	   class	   I	   pathway	   as	   a	   mean	   to	   provide	   a	   prophylactic	  
immunity.	   	   Presentation	   from	   this	   pathway	   can	   be	   challenging	   as	   the	   displayed	   peptides	   are	  
derived	  from	  cytosolic	  proteins,	  therefore	  cytosolic	  delivery	  is	  essential.	  	  Successful	  transport	  of	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exogenous	  proteins	  into	  the	  cytosol	  sends	  the	  non-­‐native	  peptides	  into	  the	  MHC	  I	  pathway	  to	  
be	   displayed	   for	   T	   cell	   recognition	   and	   response.	   	   Vaccine	   development	   can	   utilize	   this	  
immunological	  response;	  however,	  a	  system	  to	  transport	  antigens	  into	  the	  cytosol	  is	  required.	  	  
Successful	  delivery	  of	  antigens	  by	  protein	  toxins	  have	  resulted	  in	  CTL	  activation	  (17-­‐22),	  and	  are	  
discussed	  further	  in	  section	  1.5.	  
1.2.4.	  	  Toxin	  directed	  therapy	  
Third,	   directed	   therapy	   using	   the	   binding	   domains	   of	   protein	   toxins	   that	   have	   high	  
specificity	   for	   receptors	   that	   are	   overexpressed	   in	   cancer	   cells	   have	   been	   investigated.	  	  
Examples	   include	   shiga,	   chlorotoxin,	   botulism,	   and	   anthrax	   toxins.	   	   Shiga	   toxin	   targets	   the	  
globotriaosylceramide	  (Gb3)	  receptor	  (23),	  which	  is	  overexpressed	  by	  many	  tumor	  cells	  (17,24).	  	  
Chlorotoxin	  is	  a	  4	  kD	  peptide	  that	  specifically	  recognizes	  glioma	  cells	  and	  can	  target	  tumors	  in	  
animal	   models	   (25,26).	   Botulism	   and	   tetanus	   neurotoxins	   specifically	   target	   human	  
neuroblastoma	   cells	   (27).	   	   Anthrax	   toxin	   receptors,	   endothelial	  marker-­‐8	   (TEM-­‐8	   or	   ANTXR1)	  
(28)	  and	  capillary	  morphogenesis	  gene-­‐2	  (CMG-­‐2	  or	  ANTXR2)	  (29)	  are	  involved	  in	  regulation	  of	  
cell	   migration	   and	   proliferation	   (30).	   	   Modified	   forms	   of	   the	   anthrax	   toxin	   have	   been	  
investigated	  in	  cancer	  models	  and	  demonstrate	  potent	  anti-­‐tumorigenic	  activity,	  yet	  safety	  is	  a	  
major	  concern	  since	  toxicity	  to	  non-­‐tumorigenic	  tissue	  is	  possible	  (30).	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1.2.5.	  	  Cargo	  delivery	  
Fourth,	  various	  groups,	  including	  ours,	  have	  reported	  on	  biomolecular	  delivery	  systems	  
mediated	   by	   protein	   toxins.	   	   The	   ability	   to	   move	   biological	   macromolecules	   across	   the	   cell	  
membrane	  would	  benefit	  medicine	  and	  research,	  however	  the	  oral	  delivery	  of	  polypeptides	  is	  
hampered	   by	   extremely	   low	   bioavailability	   (31),	   therefore	   a	   better	   system	   is	   needed.	   	   This	  
review	   will	   focus	   on	   delivery	   systems	   developed	   utilizing	   domains	   of	   intracellularly	   acting	  
exotoxins,	  emphasizing	  successful	  systems	  and	  how	  they	  can	  still	  be	  improved.	  	  
1.3. Benefits	  of	  a	  cargo	  delivery	  system	  
1.3.1.	  	  Background	  
Many	  debilitating	  and	  fatal	  diseases	  are	  the	  result	  of	  genetic	  mutations	  that	  alter	  gene	  
expression	  and	  affect	  cellular	  processes	  and	  overall	  health.	  Many	  genetic	  diseases	  are	  managed	  
with	  strict	  diet	   regulations	  or	  drug	  combinations	   for	   treatment	  of	   symptoms.	   	  The	   traditional	  
ideologies	   of	   curing	   such	   diseases	   have	   focused	   on	   gene	   therapy,	   importing	   DNA	   into	   the	  
defective	  cells	  to	  replace	  the	  altered/damaged	  gene(s).	  	  However,	  protein	  therapy	  may	  provide	  
advantages,	   compared	   to	   gene	   therapy,	   and	   is	   also	   under	   investigation	   (32).	   Significant	  
differences	  between	  the	  two	  methods	  are	  discussed	  in	  section	  1.3.2.	  	  An	  additional	  challenge	  of	  
cargo	   delivery,	   whether	   it	   is	   DNA	   or	   protein,	   is	   crossing	   the	   blood-­‐brain	   barrier.	   	   This	   task	  
currently	  relies	  on	  direct	  injection	  into	  the	  central	  nervous	  system	  (CNS)	  using	  viral	  vectors	  (33-­‐
36).	  	  	  
1.3.2.	  	  Protein	  therapy	  	  
Protein	  therapy	  provides	  a	  potentially	  safer	  approach	  to	  genetic	  disorder	  therapy	  when	  
replacement	   of	   biological	   proteins	   and/or	   enzymes	   is	   sufficient.	   	   The	   delivery	   of	   functional	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biological	  polypeptides	  into	  diseased	  cells	  would	  not	  provide	  sustained	  treatment,	  which	  is	  the	  
major	  disadvantage	  of	  this	  approach	  compared	  to	  gene	  therapy.	  	  However	  the	  many	  benefits	  of	  
such	   a	   system	  make	   this	   method	   attractive	   to	   researchers	   and	   the	   medical	   field;	   importing	  
proteins	  does	  not	  modify	  host	  chromosomal	  DNA	  which	  can	  give	  rise	  to	  cancer,	  but	  can	  provide	  
cell	  specificity,	  and	  low	  toxicity	  since	  the	  delivered	  cargo	  is	  endogenous	  to	  the	  cell.	  	  The	  first	  US	  
FDA	  approved	  recombinant	  protein	  was	  insulin,	  in	  1982,	  and	  has	  since	  been	  a	  major	  treatment	  
for	  diabetes	  mellitus	  type	  I	  (DM-­‐I)	  and	  type	  II	  (DM-­‐II)	  to	  regulate	  cellular	  glucose	  homeostasis	  
(37,38).	  	  FDA-­‐approved	  medications	  also	  include	  antibodies,	  interferons,	  hormone	  and	  enzyme	  
replacement,	   immunotoxins,	   protease	   inhibitors	   (sitagliptin),	   and	  many	   ongoing	   clinical	   trials	  
(32).	   	   Several	   factors	   currently	   limit	   protein	   therapeutic	   applications	   including:	   solubility,	  
immune	   response,	   and	  production	  of	   sufficient	  quantities	   for	   clinical	   demand,	   required	  post-­‐
translational	  modifications,	  and	  route	  of	  delivery.	  
1.3.3.	  	  Gene	  therapy	  
The	  concept	  of	  gene	  therapy	  proposed	  in	  1970	  (39)	  resulted	  in	  a	  1972	  article,	  in	  Science,	  
which	   described	   the	   intellectual	   concepts	   and	   the	   ethical	   issues	   of	   genetic	   engineering	   in	  
humans.	  	  With	  ethical	  issues	  still	  under	  debate	  today,	  the	  ability	  to	  prevent	  and	  cure	  illness	  by	  
replacing	  non-­‐functional	  genes	  with	  healthy	  ones	  has	  been	  investigated	  in	  innumerable	  animal	  
and	  human	  studies.	  	  	  
The	  first	  report	  of	  successful	  gene	  therapy	  was	  in	  1990,	  by	  William	  French	  Anderson.	  A	  
4-­‐year-­‐old	   girl	   with	   the	   autosomal	   recessive	   metabolic	   disorder	   adenosine	   deaminase	  
deficiency	   which	   is	   characterized	   by	   a	   severely	   compromised	   immune	   response	   (ADA-­‐
deficiency,	   or	   ADA-­‐SCID)	   was	   provided	   a	   short-­‐term	   cure	   (http://gene-­‐therapy.yolasite.com,	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accessed	  2011,	  Nov.).	  	  A	  few	  years	  later,	  in	  1999,	  the	  scientific	  community	  was	  shocked	  when	  
gene	   therapy	   caused	   the	   death	   of	   Jesse	   Gelsinger,	   and	   gene	   therapy	   protocols	   came	   under	  
increased	  scrutiny.	  	  His	  death	  was	  suspected	  to	  be	  caused	  by	  an	  extreme	  inflammatory	  reaction	  
to	  the	  viral	  treatment	  used	  for	  gene	  delivery.	  	  Overall,	  clinical	  results	  vary	  greatly	  form	  case	  to	  
case,	   exemplified	  by	   the	  development	  of	   leukemia	   in	  one	   young	  boy	   that	   received	   the	   same	  
treatment	  that	  had	  cured	  a	  previous	  patient,	  in	  a	  Great	  Britain	  hospital.	  	  	  Again,	  the	  cancer	  was	  
suspected	  to	  be	  the	  result	  of	  the	  viral	  method	  of	  gene	  delivery.	  	  Although	  some	  successes	  have	  
been	  reported,	  there	  are	  clearly	  major	  safety	  risks;	  therefore	  safer	  alternatives	  for	  protein	  and	  
DNA	  delivery	  are	  needed.	  Various	  methods	  of	  gene	  therapy	  are	  discussed	  below	  in	  section	  1.4.	  
1.4. Non-­‐toxin	  derived	  delivery	  systems	  
There	  are	  multiple	  delivery	  systems	  under	   investigation,	  many	  of	  which	  do	  not	  exploit	  
protein	   toxins.	   	   Viral	   vectors,	   short	   basic	   peptide	   tags,	   and	   nanoparticle	   and	   lipid	   carrier	  
systems	   represent	   the	  bulk	  of	   research	   in	   this	   field.	   	   There	  are	  advantages	  and	   limitations	  of	  
each	  system	  (Figure	  1.3).	  
1.4.1.	  	  Viral	  vectors	  
Genetic	  mutations	   are	   known	   to	   interrupt	  normal	   cell	   function	  and	   cause	  disease.	   	   In	  
this	  case,	   introduction	  of	  a	  functional	  gene	  may	  repair	  healthy	  cellular	  functions.	  Viral	  vectors	  
have	  become	  popular	  in	  gene	  therapy	  development	  for	  genetic	  illnesses	  such	  as	  cystic	  fibrosis,	  
Gaucher’s	  disease,	  and	  adenosine	  deaminase	  deficiency	  (40).	  	  Murine	  leukaemia	  viruses	  (MuLV)	  
and	   lentiviruses	  are	  the	  most	  popular	  retroviral	  systems,	  or	  RNA	  viruses,	  which	   infect	  cells	  by	  
carrying	  genomic	  RNA	  that	  is	  reverse-­‐transcribed	  into	  double	  stranded	  DNA	  and	  stably	  inserted	  
into	  the	  genomic	  DNA	  of	  a	  host	  cell	  (40).	  	  As	  opposed	  to	  retroviruses,	  DNA	  viral	  vectors	  package	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single	  or	  double	  stranded	  genomic	  DNA	  and	  have	  the	  ability	  to	  directly	  transfer	  genes	  into	  host	  
genomes	   for	   expression.	   	  DNA	   viruses	   include	   adenovirus,	   adeno-­‐associated	   virus	   (AAV),	   and	  
herpes	   simplex	   virus.	   	   	  Many	   reviews	   are	   available	   for	   detailed	   descriptions	   of	  mechanisms,	  
gene	  transfer,	  and	  clinical	  applications	  (40-­‐42).	  	  	  
Although	  viral	  vectors	  are	  efficient	  vehicles	  for	  gene	  transfer	  and	  provide	  great	  research	  
tools	   in	   vitro,	   there	   are	  many	   safety	   concerns	   that	   hinder	   therapeutic	   applications	   in	   clinical	  
trials.	  There	  is	  a	  potential	  of	  mutagenesis	  arising	  from	  insertion	  of	  foreign	  DNA	  into	  the	  genome	  
and	  the	  human	  immune	  response	   limits	  the	  possibility	  of	  multiple	  treatments.	   	  Toxicity	  and	  a	  
lack	  of	  cell	  and	  tissue	  specificity	  are	  also	  concerns	  using	  viral	  vectors	  that	  justify	  searching	  for	  
safer	  alternatives.	  	  	  
1.4.2.	  	  Non-­‐viral	  vectors	  
Non-­‐viral	  gene	  delivery	  systems	  have	  been	  extensively	  explored.	  	   	  The	  most	  frequently	  
used	  methods	  include	  cationic	  liposome-­‐mediated	  gene	  transfer	  (lipofection)	  (43)	  and	  cationic	  
polymers	   that	   form	   nanosized	   complexes	   when	   mixed	   with	   DNA	   (polyplexes)	   (44).	  	  
Modifications	   include	  functional	  group	  addition	  for	  pH-­‐sensitivity	  (45)	  and	  cell	  specificity	  (46).	  	  
Other	   methods	   of	   transfection	   cited	   in	   the	   literature	   include	   localized	   intramuscular	   DNA	  
injection	   (47),	   hydrodynamic	   or	   rapid	   tail	   vein	   injection	   of	   high	   volumes	   of	   DNA	   (48),	  
electroporation	   to	   alter	   cell	   permeability	   and	   drive	   gene	   transfer	   via	   electric	   pulses	   (49,50),	  
gene	  gun	  delivery	  by	  DNA-­‐coated	  heavy	  metal	  particle	  bombardment	   (51),	   and	   sonoporation	  
using	  ultrasound	  waves	   to	   enhance	  penetration	   (52).	   	   In	   some	   cases,	  DNA	  delivery	  has	  been	  
successfully	   accomplished	   after	   conjugation	   with	   protein	   toxin	   based	   systems,	   discussed	   in	  







































































































































































1.4.3.	  	  Cell	  penetrating	  peptides	  
The	   enhanced	   uptake	   of	   cationic	   macromolecules	   by	   mammalian	   cells,	   noting	   that	  
polybasic	   compounds	  may	   be	   relevant	   as	   carrier	   systems,	  was	   described	   in	   a	   Science	   review	  
article	   by	   Ryser	   in	   1968	   (54).	   	   In	   the	   late	   1980s,	   and	   early	   1990s,	   natural	   protein	   signaling	  
sequences	  with	  the	  ability	  to	  cross	  the	  cell	  membrane	  were	  identified	  (55,56).	  The	  first	  reports	  
of	   cationic-­‐peptide	   mediated	   cell	   delivery	   came	   soon	   after	   (57,58).	   	   These	   peptides	   are	  
commonly	   called	   cell-­‐penetrating	   peptides	   (CPP),	   but	   have	   also	   been	   known	   as	   protein	  
translocation	   domains	   (PTD),	   membrane	   translocating	   sequences,	   and	   Trojan	   peptides.	  	  
Physically	  they	  are	  defined	  as	  short,	  cationic	  peptide	  tags	  with	  the	  ability	  to	  cross	  mammalian	  
cell	   membrane	   barriers	   and	   to	   tow	   attached	   cargo.	   	   The	  most	   extensively	   studied	   CPPs	   are	  
derived	  from	  the	  human	  immunodeficiency	  virus	  type	  1	  (HIV-­‐1)	  trans-­‐activator	  of	  transcription	  
(Tat)	   peptide	   or	   the	   penetratin	   peptide	   from	   the	   amphiphilic	   Drosophila	   Antennapedia	  
homeodomain.	   	   Many	   reviews	   have	   addressed	   the	   important	   issues	   that	   limit	   CPP	   utility	  
including	  poor	  methods	  for	  intra-­‐cellular	  targeting,	  cargo	  limitations,	  and	  toxicity	  (59-­‐62).	  	  	  The	  
mechanism	   by	   which	   they	   enter	   cells	   is	   still	   debated.	   	   Studies	   with	   many	   CPPs,	   including	  
penetratin	  and	  tat,	  have	  indicated	  toxic	  side	  effects	  (63-­‐65)	  and	  variations	  in	  route	  of	  cell	  entry	  
are	  dictated	  by	  properties	  in	  the	  cargo	  domain,	  such	  as	  conformation,	  size,	  and	  charge	  (66,67).	  	  
Another	  concern	  when	  employing	  CCPs	  to	  internalize	  cargo	  is	  their	  overall	  cell	  type	  promiscuity	  






1.5. Cargo	  delivery	  by	  protein	  toxins	  
1.5.1.	  	  Introduction	  
Multifunctional	  exotoxins	  have	  a	  key	   feature	   that	  may	  prove	  be	  an	   indispensable	   tool	  
for	  science,	  facilitating	  the	  transfer	  of	  a	  cargo,	  such	  as	  protein,	  DNA,	  drug,	  or	  molecular	  probes,	  
through	   the	   cell	   wall	   and	   into	   the	   cytoplasm	   with	   high	   efficiency	   and	   low	   toxicity.	   	   The	  
mechanism	  of	   cell	   entry,	   receptor	   specificity,	   and	   potency	   is	   individual	   to	   each	   protein	   toxin	  
(Figure	  1.3	  and	  Table	  1.1).	  	  Determining	  the	  most	  effective	  engineering	  strategy,	  whether	  to	  use	  
the	   entire	   protein,	   a	   truncation,	   or	   to	   patch	   together	   the	   functional	   domains	   from	  multiple	  
sequences,	   holds	   the	   potential	   for	   an	   efficient	   and	   versatile	   cargo	   delivery	   system.	   	   An	  
adaptable	  delivery	  system	  would	  also	  be	  valuable	  as	  a	  tool	  in	  biotechnology	  fields,	  providing	  a	  
technique	  to	  probe	  cellular	  functions	  in	  the	  native	  environment.	  	  Importing	  molecules	  with	  light	  
emitting	   and/or	   imaging	  properties	  has	   the	  potential	   to	   significantly	   improve	   techniques	   and	  
technology.	  	  Protein	  therapy,	  gene	  therapy,	  gene	  silencing,	  and	  the	  ability	  to	  promote	  a	  specific	  
immune	  response	  would	  greatly	  benefit	  from	  an	  effective	  bacterial	  toxin	  delivery	  system.	  	  
Investigations	  spanning	  twenty	  years	  have	  established	  an	  appreciation	  for	  the	  potential	  
of	   protein	   toxins	   as	   delivery	   systems.	   	   Our	   focus	   is	   limited	   to	   some	   of	   the	   most	   frequently	  
explored	  and	  well-­‐defined	  systems	  including	  anthrax	  and	  C2	  toxins,	  the	  Clostridial	  neurotoxins,	  
diphtheria	  toxin,	  exotoxin	  A,	  and	  the	  Clostridial	  glucosylating	  toxins	  A	  and	  B.	  	  The	  mechanistic	  
details	   of	   cell	   entry	   and	   membrane	   translocation	   have	   been	   identified	   and	   discussed	  
throughout	   this	   section.	   	   Remarkably,	   toxins	   have	   been	   fused	   as	   carrier	   systems	   to	   DNA,	  
enzymes,	  proteins,	  and	  small	  peptides	  for	  transport	  into	  mammalian	  cells.	   	  Table	  1.1	  provides	  
information,	   such	   as	   source	   and	   function,	   for	   each	   native	   toxin,	   and	   Table	   1.2	   presents	   a	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summary	  of	  published	  reports	  of	  cargo	  delivery.	   	   	   	  None	  of	  the	  described	  vehicles	   is	  a	  perfect	  
“holy	  grail”	  carrier	  system;	  however,	  with	  further	  investigation	  and	  an	  improved	  understanding	  
of	   required	   interactions,	   the	   resulting	   systems	   will	   inevitably	   have	   an	   enormous	   scientific	  
impact.	  	  	  
1.5.2.	  	  Anthrax	  toxin	  
Bacillus	   anthracis	   releases	   three	   single	   proteins	   responsible	   for	   a	   life-­‐threatening	  
infection	  in	  animals	  that	  is	  transmittable	  to	  humans	  through	  contact.	  The	  infection	  is	  generally	  
referred	   to	   as	   anthrax	   and	   has	   gained	   public	   attention	   as	   a	   potential	   weapon	   in	   biological	  
warfare	   via	   spreading	   of	   the	   acute	   disease	   through	   robust	   endospores,	  which	   are	   extremely	  
hard	  to	  eradicate	  and	  readily	  vaporized	  and	  inhaled	  (71).	  	  After	  bacterial	  colonization,	  virulence	  
factors	   are	   released	  and	   responsible	   for	  disease.	   	   The	   three	  protein	   virulence	   factors	   include	  
protective	  antigen	  (PA;	  83	  kD),	  edema	  factor	  (EF;	  89	  kD),	  and	  lethal	  factor	  (LF;	  90	  kD).	  	  None	  of	  
the	   three	   virulence	   factors	   are	   toxic	   on	   their	   own,	   however,	   when	   mixed	   together,	   they	  
undergo	   self-­‐assembly	   and	   cell	   intoxication	   by	   after	   cytosolic	   delivery	   of	   EF,	   a	   calcium	   and	  
calmodulin-­‐dependent	  adenylate	  cyclase	  (72),	  and	  LF,	  a	  zinc-­‐dependent	  protease	  (73).	  
Two	   receptors	   for	   anthrax	   have	   been	   identified,	   tumor	   epithelial	   marker	   8	   (TEM8	   or	  
ANTXR1)	   and	   capillary	   morphogenesis	   factor	   2	   (CMG2	   ANTXR2)	   (28,29).	   	   PA	   is	   activated	   by	  
surface	  proteases	  after	  receptor	  binding.	  	  Crystal	  structures	  have	  revealed	  four	  domains	  within	  
PA	   including	  a	   furan	   recognition	   site,	  RKKR,	  within	  an	  accessible	   loop	   (74),	   a	  disordered	   loop	  
responsible	   for	  pore	   formation	  during	  membrane	   translocation	   (75),	  and	  oligomerization	   (76)	  
or	  receptor	  binding	  (77)	  features.	  	  	  Proteolysis	  yields	  a	  20	  kD	  N-­‐terminal	  and	  a	  63	  kD	  C-­‐terminal	  
fragment	   (PA20	   and	   PA63).	   	   PA20	   is	   suspected	   to	   play	   a	   role	   in	   infection,	   yet	   PA63	   mediates	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toxicity	  (78).	   	  PA63	  oligimerizes	  to	  form	  heptameric	  rings	  called	  the	  prepore	  (79).	  The	  prepore	  
bind	  up	  to	  three	  effector	  molecules,	  EF,	  LF,	  or	  a	  combination,	  and	  the	  complex	  is	  endocytosed.	  	  
Binding	   of	   the	   effector	   molecules	   occurs	   via	   a	   homologous,	   highly	   charged,	   disordered	   N-­‐
terminal	  domain	  within	  PA63	  (80).	  	  Theoretical	  studies	  predict	  a	  binding	  orientation	  in	  which	  the	  
effector	  domain,	  EF	  or	  LF,	  is	  positioned	  with	  its	  N-­‐terminus	  over	  the	  lumen	  of	  the	  prepore.	  	  This	  
provided	  evidence	  for	  transmembrane	  pore	  formation;	  protein	  translocation	  was	  expected	  to	  
occur	  via	  threading	  through	  the	  pore	  (81).	  	  A	  truncated	  LF	  protein,	  devoid	  of	  twenty	  N-­‐terminal	  
residues,	   retained	   PA63	   binding;	   however,	   the	   protein	   was	   unable	   to	   enter	   the	   pore	   for	  
translocation,	  demonstrating	  that	  its	  N-­‐terminus	  initiates	  translocation	  (82).	  	  	  
The	  mechanisms	  of	  channel	  formation	  and	  protein	  translocation	  have	  been	  extensively	  
studied	  in	  the	  anthrax	  system.	  	  The	  prepore	  undergoes	  a	  conformational	  change	  at	  low	  pH	  to	  
form	  an	  ion-­‐conducting	  pore	  through	  the	  membrane	  (83).	  	  	  The	  mushroom-­‐shaped	  pore	  has	  a	  
globular	   cap,	   remaining	   in	   the	   endosome	   bound	   to	   effector	   proteins,	   connected	   to	   a	  
transmembrane	  14	   strand	  β–barrel	   ~100	  Å	   long	  and	  ~15	  Å	  wide	   (84,85).	   	   The	   interior	  of	   the	  
pore	  has	  a	  high	  composition	  of	  hydrophilic	  residues,	  however	  one	  hydrophobic	  residue,	  F427,	  is	  
conserved	   in	   the	   pore	   forming	   domain	   of	   homologous	   toxins	   and	   is	   essential	   for	   protein	  
translocation	   (75,86).	   	   During	   the	   prepore	   to	   pore	   conversion,	   the	   seven	   hydrophobic	   F427	  
residues	   (one	  per	  monomer)	  converge	   to	   form	  a	  “ring	  of	   rings”	  within	   the	   lumen.	  This	   site	   is	  
called	   the	   φ	   clamp	   for	   its	   role	   in	   binding	   the	   N-­‐terminus	   of	   the	   effector	   protein	   to	   initiate	  
translocation.	  Collectively,	  data	  presented	  suggests	  the	  opening	  of	  the	  pore	  is	  conducive	  to	  the	  
passing	   of	   an	   α-­‐helix,	   but	   unfolding	  would	   be	   necessary	   for	   larger	   structural	   features	   during	  
translocation	   through	   the	   pore	   (87-­‐89).	   	   The	   anthrax	   toxin	   system	   has	   been	   exploited	   to	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characterize	   other	   protein	   toxins	   and	   translocate	   attached	   cargo	   proteins.	   	   These	   data	   are	  
useful	   in	   further	   defining	   the	   translocation	   properties	   and	   requirements	   within	   the	   anthrax	  
system,	   as	   well	   as	   identifying	   novel	   therapeutics	   should	   large-­‐scale	   biological	   warfare	   via	  
anthrax	  ever	  come	  to	  surface.	  
To	  assess	   the	  anthrax	  system	  for	  delivery	  of	  biological	  macromolecules,	  various	   fusion	  
proteins	  have	  been	  studied.	   	  One	   important	  and	  convenient	   feature	  of	   the	  anthrax	   system	   is	  
coercion	  of	  translocation.	  Endocytosis	  can	  be	  bypassed	  by	  reducing	  the	  extracellular	  pH,	  after	  
the	  prepore/EF/LF	   complex	   forms,	  driving	   cell	  membrane	   translocation	   (89).	   	   This	  method	  of	  
cell	  delivery	  has	  been	  used	  to	  probe	  the	  translocation	  efficiency	  by	  comparing	  the	  delivery	  of	  
radiolabeled	   EF,	   LF,	   LFN	   (a	   nontoxic	   N-­‐terminal	   truncation	   of	   LF),	   and	   various	   cargo	   proteins	  
fused	   to	   LFN.	   	   Translocation	   of	   LFN	   ranges	   between	   35-­‐50%,	   whereas	   EF,	   LF,	   and	   LFN-­‐fusion	  
proteins	   range	   between	   15-­‐20%.	   	   	   Interestingly,	   dihydrofolate	   reductase	   (DHFR)	   and	   the	  
enzymatic	  subunit	  of	  diphtheria	  toxin	  (DT-­‐A)	  were	  translocated	  when	  fused	  to	  either	  terminus	  
of	  LFN,	  with	  a	  slightly	  greater	  efficiency	  observed	  when	  fused	  in	  the	  domain	  order	  analogous	  to	  
that	  of	  LF	  or	  EF	  (fusions	  to	  the	  C-­‐terminus	  of	  LFN)	  (89).	  	  A	  report	  in	  1995	  by	  John	  Collier’s	  group	  
at	  Harvard	  Medical	  School	  also	  described	  the	  successful	  translocation	  of	  active	  DT-­‐A,	  by	  either	  
LFN-­‐DT-­‐A	   or	   DT-­‐A-­‐LFN,	   in	   the	   presence	   of	   PA63	   (90).	   	   These	   results	   are	   fascinating	   as	   they	  
indicate	  that	  the	  cargo	  can	  be	  expressed	  N-­‐	  or	  C-­‐	  terminal	  to	  LFN.	   	  As	  discussed	  above,	  the	  N-­‐
terminus	  of	  the	  effector	  protein	  is	  required	  to	  bind	  PA	  in	  a	  specific	  orientation	  to	  facilitate	  pore	  
entry.	  	  However,	  it	  has	  been	  shown	  that	  a	  cationic	  peptide	  fused	  to	  the	  N-­‐terminus	  of	  DT-­‐A	  is	  
sufficient	  to	  direct	  PA63-­‐dependent	  cell	  delivery	  (91).	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Several	   other	   fusion	  proteins,	   including	   a	  DT-­‐A	   construct	  with	   increased	   steric	   rigidity	  
(introduced	  by	  mutagenesis),	  were	  examined	  and	  did	  not	  translocate	  at	  all	  (90).	  A	  conceivable	  
explanation,	   and	   favored	   by	   the	   authors,	   is	   that	   the	   constructs	   that	   are	   incapable	   of	  
translocation	  are	  unable	  to	  fulfill	  the	  requirement	  to	  partially,	  or	  fully,	  unfold	  to	  fit	  through	  the	  
pore	  (89,90).	  	  A	  second	  possibility	  is	  that	  the	  chimeric	  proteins	  are	  unstable	  and	  therefor	  unable	  
to	  undergo	  anthrax	  toxin-­‐mediated	  cell	  entry.	  
Since	   its	   initial	   discovery,	   the	   LFN/PA63	   delivery	   system	   has	   been	   used	   to	   studying	  
enzymatic	  domains	  of	  other	  protein	  toxins.	  	  Individual	  activities	  can	  be	  difficult	  to	  study	  in	  the	  
context	   of	   a	   full	   protein	   due	   to	   the	   large	   size,	   so	   there	   is	   need	   to	   isolate	   domains	   for	  
independent	   characterization.	   	   There	   are	   two	   well-­‐defined	   examples	   of	   this	   challenge.	   	   The	  
multifunctional	  RTX	  toxin	  from	  Vibrio	  cholerae	  is	  a	  large	  toxin	  with	  multiple	  activity	  domains.	  	  A	  
chimeric	   protein	  with	   LFN	   fused	   to	   an	   isolated	   fragment	  of	   RTXVc	   allowed	   a	   newly	   identified	  
activity	  domain	  to	  be	  studied	  independent	  of	  the	  rest	  of	  the	  RTX	  protein	  (92,93).	  	  Additionally,	  
the	  enzymatic	  domain	  of	  toxin	  B	  (residues	  1-­‐556)	  from	  Clostridium	  difficile	  was	  characterized	  in	  
cellulo	  and	   in	  a	  mouse	  model	  using	   this	   system	  (94).	   	  This	  method	  was	   later	  used	   to	   identify	  
novel	  intracellular	  TcdB	  inhibitors.	  	  Inactive	  catalytic	  TcdB	  mutants	  were	  granted	  cell	  entry	  via	  
fusion	  to	  LFN,	  and	  found	  to	  	  provide	  cell	  protection,	  in	  cellulo,	  against	  native	  TcdB	  (95).	  	  	  	  	  
1.5.3.	  	  C2	  toxin	  
In	   addition	   to	   the	   well-­‐known	   botulinum	   neurotoxins,	   virulent	   strains	   of	   Clostridium	  
botulinum	   produce	   the	   binary	   C2	   toxin.	   This	   cytotoxic	   protein	   is	   made	   up	   of	   two	   separate,	  
unlinked	   proteins,	   C2I	   and	   C2II.	   	   C2I	   (49	   kD)	   contains	   the	   catalytic	   ADP-­‐ribosyltransferase	  
enzyme	  and	  C2II	  (80	  kD)	  includes	  the	  receptor	  binding	  and	  translocation	  domains	  (96,97).	  	  After	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proteolytic	   activation	   of	   C2II,	   a	   60	   kD	   fragment	   (C2IIa)	   recognizes	   cell	   surface	   glycoproteins,	  
such	  as	  N-­‐acetylglucosaminyltransferase	   I	   (98,99).	   	  At	   the	  cell	   surface,	  C2IIa	  oligomerizes	   into	  
heptamers,	   forms	   a	   complex	  with	   C2I,	   and	   is	   internalized	   via	   receptor-­‐mediated	   endocytosis	  
(100).	   	  Upon	  acidification	  of	  the	  endosome,	  the	  C2IIa	  heptamers	  form	  a	  narrow	  pore	  through	  
the	  membrane	   and	   translocate	   C2I	   into	   the	   cytosol.	   	   One	   report	   found	   very	   little	   structural	  
change	  in	  the	  C2I	  fragment	  at	  pH	  3	  vs.	  pH	  6,	  leading	  to	  the	  hypothesis	  that	  this	  domain	  does	  not	  
unfold	  during	  translocation	  (6).	  	  It	  is	  conceivable,	  and	  more	  likely,	  that	  unfolding	  is	  essential	  and	  
facilitated	  by	  interactions	  with	  residues	  within	  the	  pore	  during	  translocation.	  An	  abundance	  of	  
asparagine	  residues	  have	  been	  modeled	  to	  line	  the	  pore	  and	  are	  suggested	  to	  be	  involved	  in	  C2I	  
translocation	   (6,101).	   The	   host	   chaperone	   heat	   shock	   protein	   90	   (Hsp90)	   (102)	   and	   the	  
peptidyl-­‐prolyl	   cis/trans	   isomerase	   (PPIase)	   (103)	   are	   essential	   for	   C2I	   delivery,	   providing	  
further	  evidence	  for	  C2I	  unfolding.	  	  In	  the	  cytosol,	  active	  C2I	  catalyzes	  the	  ADP-­‐ribosylation	  of	  
G-­‐actin	   at	   position	   Arg-­‐177	   (104,105),	   leading	   to	   actin	   filament	   depolymerization	   and	  
cytoskeleton	  collapse	  triggering	  apoptosis.	  	  	  
An	  N-­‐terminal	  truncation	  of	  C2I	  (C2IN)	  eliminated	  enzymatic	  activity,	  while	  retaining	  C2II	  
recognition	  and	  specificity.	  	  A	  C2IN-­‐fusion	  protein	  sequence	  facilitated	  intracellular	  transport	  of	  
streptavidin	   into	  mammalian	   cell	   lines	   (106),	  macrophages,	   and	   cancer	   cell	   lines	   (107)	   in	   the	  
presence	  of	  C2II.	   In	   these	   reports,	   the	  delivered	  cargo,	   fluorophore-­‐labeled	  biotin,	  was	  easily	  
followed	   and	   detected	   by	  microscopy	   and	   immunostaining.	   	   Additional	   reports	   have	   further	  
optimized	   this	   system	   by	   increasing	   the	   solubility	   of	   the	   fusion	   protein,	   and	   reducing	   the	  
streptavidin-­‐biotin	   affinity	  by	   streptavidin	  mutagenesis	   (108).	  Macrophage	  gene	   therapy	   is	   of	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interest	  because	  it	  allows	  manipulation	  of	  the	  host	  immune	  response,	  whereas	  cancer	  cell	  lines	  
provide	  targets	  for	  drug	  and	  gene	  therapy.	  	  	  
The	   C2IN/	   C2II	   system	   has	   been	   adapted	   to	   deliver	   active	   enzymes	   as	   well	   (109).	  	  
Salmonella	   enterica	  virulence	   factor	   SpvB	   was	   identified	   as	   an	   ADP-­‐ribosyltransferase,	   yet	  
studies	   of	   its	   in	   cellulo	   activity	   proved	   difficult	   since	   the	   virulence	   factor	   is	   not	   taken	   up	   by	  
cultured	   cells.	   	  When	   the	   enzymatic	   domain	   of	   SpvB	  was	   fused	   to	   C2IN,	   the	   resulting	   fusion	  
protein	   was	   cytotoxic	   in	   the	   presence	   of	   C2II.	   This	   study	   demonstrated	   that	   the	   C2	   toxin	   is	  
capable	   of	   delivering	   cargo	   proteins	   that	   retain	   enzymatic	   function;	   yet,	   delivery	   efficiency	  
should	  be	  further	  explored.	   	   It	  should	  also	  be	  noted	  that	  any	  delivered	  molecules	  would	  have	  
the	  C2IN	  sequence	  appended	  to	  them,	  which	  may	  interfere	  with	  cellular	  activity.	  
1.5.4.	  	  Clostridial	  neurotoxins	  
The	   Clostridial	   neurotoxins,	   tetanus	   toxin	   (TeNT)	   and	   the	   seven	   (A-­‐G)	   serologically	  
distinct	   serotypes	  of	  botulinum	  toxin	   (BoNT),	  are	  among	  the	  most	   toxic	   substances	  known	  to	  
humans	   having	   a	   leathal	   dose,	   causing	   50%	   death	   (LD50),	   of	   ~1	   ng·∙kg-­‐1	   (110).	   	   These	   potent	  
neurotoxins	   share	   a	   high	   degree	   of	   sequence	   and	   structural	   homology	   yet	   their	   biological	  
functions	  differ	   somewhat.	   	  After	  exposure,	  TeNT	  and	  BoNTs	  diffuse	   into	  body	   fluids	  and	  are	  
transported	  to	  the	  presynaptic	  membrane,	  where	  they	  bind	  to	  cholinergic	  terminals	  and,	  in	  the	  
case	   of	   TeNT,	   sympathetic	   adrenergic	   fibers	   (111).	   	   Toxicity	   of	   these	   substances	   comes	   from	  
their	  ability	  to	  block	  neurotransmitter	  release	  at	  synaptic	  vesicles.	  	  Clinically,	  botulism	  presents	  
as	  ensuing	   flaccid	  paralysis	  causing	  death	  once	  respiratory	  muscles	  are	  affected,	   the	  result	  of	  
blocked	   neuromuscular	   junction	   acetylcholine	   release.	   	   Tetanus	   is	   characterized	   by	   spastic	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paralysis,	  a	  consequence	  of	  the	  inhibition	  of	  neurotransmitter	  release	  of	  spinal	  cord	  inhibitory	  
interneurons,	  affecting	  the	  CNS	  (112,113).	  
Clostridial	   neurotoxins	   are	   produced	   as	   large	   single	   chain	   proteins	   (150	   kD)	   that	   later	  
undergo	  proteolytic	  activation	  by	  intrinsic	  or	  host	  proteases	  to	  form	  a	  structure	  made	  up	  of	  two	  
polypeptide	  chains,	  a	  heavy	  chain	  (HC;	  100	  kD)	  and	  light	  chain	  (LC;	  50	  kD),	  held	  together	  by	  a	  
disulfide	   bond	   prior	   to	   cell	   internalization.	   The	   HC	   fragment	   holds	   the	   receptor	   binding	   and	  
translocation	  function,	  while	  the	  LC	  contains	  the	  enzymatic	  activity.	  	  	  
One	   distinctive	   feature	   of	   the	   Clostridial	   neurotoxins,	   compared	   to	   other	   bacterial	  
protein	  exotoxins,	   is	   the	  receptor	  binding	  specificity	  to	  neuronal	  cells.	  The	  HC	  fragment	  binds	  
polysialo-­‐gangliosides	  and	  glycosphingolipids,	  which	  are	  found	  in	  the	  outer	  leaflet	  of	  neuronal	  
cell	   membranes	   (46,114,115).	   	   BoNT/B	   and	   BoNT/G	   specifically	   bind	   Syt-­‐I	   and	   Sty-­‐II	  	  
(synaptotogmin)	  membrane	  proteins	  of	  synaptic	  vesicles	  (116,117),	  the	  receptor	  for	  BoNT/A	  is	  
the	  synaptical	  vesicle	  protein	  SV2	  (118),	  BoNT/E	  utilizes	  glucosylated	  SV2A	  and	  SV2B	  (119),	  and	  
TeNT	  receptor	  binding	  is	  lipid	  raft	  dependent	  (120).	  	  This	  observed	  receptor	  specificity	  provides	  
a	  unique	  opportunity	   to	   functionalize	   recombinant	  proteins	   for	   targeted	  delivery	   to	  neuronal	  
tissue.	  
Receptor	  mediated	  endocytosis	  of	   the	  Clostridial	  neurotoxins	   results	   in	   the	  delivery	  of	  
the	  enzymatic	  domain	   into	  the	  cytosol.	   	  There	   is	  evidence	  that,	  upon	  endosome	  acidification,	  
HC	  integrates	  into	  the	  membrane	  and	  forms	  a	  cation-­‐selective	  channel	  similar	  to	  anthrax	  toxin.	  	  
A	   belt	   region	   within	   the	   pore,	   containing	   54	   residues	   (492-­‐545	   for	   BoNT/A	   and	   481-­‐532	   for	  




Clostridial	  neurotoxins	  harbor	  zinc	  endoprotease	  activity	  within	  their	  LC	  fragments	  that	  
exhibits	   strict	   substrate	   specificity.	   	   Known	   substrates	   are	  members	  of	   the	   large	   family	   of	  N-­‐
ethylmaleimide-­‐sensitive	   factor	   attachment	   protein	   receptors	   (SNARE).	   	   The	   proteolysis	   of	  
these	   SNARE	   proteins	   results	   in	   blocked	   synaptic	   cleft	   neutotransmitter	   release	   resulting	   in	  
clinical	  symptoms	  observed	  during	  infection.	  	  	  
BoNTs	  
BoNTs	  have	  proven	  to	  be	  valuable	  tools	  in	  therapeutics	  with	  many	  popular	  uses	  such	  as	  
the	   introduction	  of	   aesthetic	   improvements	   and	   the	   treatment	  of	  debilitating	  neuromuscular	  
disease	   (124,125).	   Linking	   reporter	   proteins	   to	   BoNTHC,	   such	   as	   the	   fusion	   protein	   GFP-­‐
BoNT/AHC,	  led	  to	  successful	  targeting	  of	  neuronal	  cells	  via	  the	  native	  retrograde	  transneuronal	  
pathway	   (126).	   	   The	   fusion	   protein	   GFP-­‐BoNT/AHC	   specifically	   targets	   neuronal	   cells,	   a	  
fascinating	   result	   that	  was	  demonstrated	  by	   the	  observation	  of	  GFP	   localization	  at	   the	  nerve	  
end	   plates	   subsequent	   to	   injection	   at	   the	   peroneal	   nerve	   of	   mice	   (126).	   	   The	   presence	   of	  
punctate	  spots	  indicated	  the	  accumulation	  of	  GFP	  in	  endosomes	  or	  perinuclear	  compartments,	  
as	   expected	   since	   GFP	   is	   not	   released	   nor	   expected	   to	   translocate	   since	   it	   is	   not	   fused	   to	  
BoNTLC.	   In	  addition	  to	  successful	   reporter	  protein	   targeting,	   this	   research	  provides	  a	  mode	  to	  
study	  the	  delivery	  of	  inhibitors	  to	  the	  direct	  site	  of	  the	  target	  toxin	  via	  linkage	  to	  BoNTHC.	  Fusing	  
BoNTHC	   to	   inhibitors	   directed	   toward	   the	   BoNTLC	   catalytic	   activity	   has	   the	   potential	   to	   be	   an	  
effective,	  and	  much	  needed,	  therapeutic	  option.	  	  In	  the	  face	  of	  a	  bioterrorism	  attack	  facilitated	  
by	   BoNT,	   these	   recombinant	   proteins	  would	   need	   to	   be	  made	   on	   a	   large	   scale	   to	   be	   of	   use	  
(127).	  	  There	  remains	  much	  potential	  for	  an	  improved	  system	  utilizing	  Clostridial	  neurotoxins	  on	  
the	  basis	  of	  desired	  target	  and/or	  required	  action.	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In	   addition	   to	   targeted	  delivery	   to	  neuronal	   cells,	   BoNT	  has	  been	  explored	  as	   a	   cargo	  
transport	   system.	   	   Four	  different	  enzymes	  have	  been	   fused	   to	  BoNTLC,	   resulting	   in	   successful	  
intracellular	  delivery,	  with	  efficiency	  explored	  through	  cargo	  with	  various	  structural	  constraints;	  
thesis	   experiments	   provided	   further	   information	   about	   the	   translocation	   and	   delivery	  
requirements	  of	  BoNTs	  (128).	  	  The	  assumption	  that	  replacing	  the	  enzymatic	  domain	  of	  BoNTLC	  
with	   a	   cargo	   protein	   would	   disrupt	   cooperation	   among	   residues	   necessary	   for	   successful	  
delivery	   led	   to	   constructs	   with	   reporter	   genes	   fused	   to	   full-­‐length	   BoNTLC.	   	   Authors	   also	  
considered	  the	  BoNT	  serotype;	  BoNT/A	  and	  BoNT/B	  are	  most	  often	  used	  in	  current	  therapies,	  
therefore	   it	   is	   possible	   that	   the	   immunological	   response	   will	   be	   greater	   toward	   these	   two	  
serotypes	  in	  the	  general	  public,	  therefore	  BoNT/D	  was	  explored	  as	  a	  delivery	  vehicle.	  	  	  
As	   a	   control,	   active	   BoNT/ALC	  was	   fused	   to	   full-­‐length,	   non-­‐enzymatic	   BoNT/DLC.	   	   The	  
cytotoxic	   protein	   that	   resulted	   indicated	   that	   BoNT/DLC	   is	   capable	   of	   traslocating	   an	   active	  
enzyme.	   	  Firefly	   luciferase	  (FLuc),	  DHFR,	  and	  GFP	  reporter	  proteins	  were	  successfully	  fused	  to	  
enzymatically	   active	   BoNT/DLC,	   creating	   three	   fusion	   constructs,	   Fluc-­‐BoNT/DLC,	   DHFR-­‐	  
BoNT/DLC,	  and	  GFP-­‐	  BoNT/DLC.	  The	  assumption	  was	  made	  that	  delivery	  of	  enzymatically	  active	  
BoNT/DLC,	  indicated	  by	  cytotoxicity,	  also	  implied	  successful	  transport	  of	  a	  fused	  cargo	  protein.	  	  
All	  three	  fusion	  proteins	  were	  cytotoxic,	  although	  with	  reduced	  toxicity	  compared	  to	  BoNT/DLC	  
without	  cargo.	  	  
Delivery	  alone	  is	  not	  as	  useful	  as	  the	  import	  of	  biologically	  active	  molecules.	  	  Unfolding	  
is	   a	   predicted	   requirement	   for	   translocation;	   therefore	   it	   is	   pertinent	   to	   assess	   activity	   of	   an	  
enzyme	  after	  cellular	  delivery	  to	  determine	  whether	  accurate	  refolding	  occurs	  once	  the	  cargo	  
reaches	   the	   cytoplasm.	   	   Only	   one	   of	   the	   addressed	   fusion	   proteins,	   Fluc-­‐	   BoNT/DLC,	   was	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confirmed	  as	  an	  active	  enzyme	  in	  the	  cytosolic	  fraction	  of	  cell	  lysates	  after	  infection.	  	  There	  are	  
three	   reasonable	   explanations	   for	  why	   the	   two	  other	   constructs,	   assumed	   to	  be	   intracellular	  
based	  on	  the	  toxicity	  assay,	  are	  not	  detectable	   in	   lysates.	   	  First,	   the	  proteins	  are	  expected	  to	  
unfold	   during	   translocation	   so	   it	   is	   possible	   they	   are	   unable	   to	   refold	   into	   an	   active	  
conformation	   post-­‐translocation.	   	   Second,	   the	   delivery	   efficiency	   varies	   based	   on	   the	   cargo	  
protein,	  as	  has	  been	  observed	   in	  other	   reports.	   	  A	   third	  possibility	   is	   that	   some	  of	   the	   fusion	  
proteins	   are	   unstable	   and	   subject	   to	   rapid	   proteolysis.	   	   Also	   notable,	   detection	   limits	   differ	  
between	  reporters,	  for	  example	  Fluc	  has	  a	  lower	  detection	  limit	  than	  DHFR.	  
Taking	   into	   account	   the	   structural	   constraints	   of	   each	   reporter	   protein,	   pore	  
translocation	   requirements	   were	   also	   examined	   by	   assessing	   cargo	   delivery	   efficiency.	   	   GFP,	  
clearly	  the	  most	  rigid	  structure	  with	  an	  extremely	  stable	  β-­‐barrel	  motif,	   is	  not	   likely	  to	  unfold	  
for	   movement	   through	   a	   sterically	   hindered	   pore;	   correspondingly,	   this	   fusion	   construct	  
demonstrated	  the	  lowest	  toxicity.	  	  Remarkably,	  fluorescent	  microscopy	  of	  cells	  incubated	  with	  
GFP-­‐BoNT/DLC	   demonstrated	   that	   GFP	   escaped	   the	   endosome	   and	   follows	   the	   same	  
translocation	   pathway	   as	   BoNT/DLC.	   	   This	   observation	   provided	   evidence	   that	   structured	  
molecules	   may	   be	   accommodated	   under	   some	   circumstances	   and	   called	   into	   question	   the	  
absolute	  requirement	  for	  protein	  unfolding.	  	  	  
Although	   these	   investigations	   focused	   on	   fusion	   proteins	  with	   the	   full-­‐length	   BoNT/D	  
toxin	   that	   was	   enzymatically	   inactivated	   by	   a	   single	   amino	   acid	   mutation	   (E230A),	   worry	   of	  
partial	   toxicity	   from	   incomplete	   inactivation	   is	   justified.	   	   To	   circumvent	   this	   issue,	   further	  
deletion	  analysis	  could	  be	  used	  to	  identify	  the	  sequence	  essential	  for	  delivery	  while	  removing	  
those	  that	  may	  affect	  cell	  or	  tissue	  health.	  	  Further	  consideration	  when	  contemplating	  BoNTs	  as	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a	   delivery	   vehicles	   is	   that	   fusion	   protein	   construction	   requires	   the	   addition	   of	   the	   BoNTLC	  
subunit,	   a	   50	   kD	   structured	   domain,	   to	   the	   cargo	  which	  may	   affect	   desired	   outcomes.	   	   One	  
solution	   to	   this	   problem,	   modeled	   after	   the	   Clostridial	   glucosylating	   toxins	   from	   Clostridium	  
difficile,	   would	   be	   to	   include	   an	   auto-­‐proteolytic	   cleavage	   domain,	   such	   as	   the	   cysteine	  
protease	  domain	  (129),	  situated	  within	  the	  fusion	  protein	  to	  release	  the	  freight	  after	  cytosolic	  
delivery.	  	  Designing	  such	  a	  motif	  might	  be	  challenging,	  however,	  and	  a	  detailed	  understanding	  
of	  the	  specificity	  determinants	  from	  autolytic	  processing	  is	  still	  lacking.	  
TeNT	  
Early	   studies	   developed	   chemical	   conjugation	   techniques	   to	   probe	   cargo	   delivery	  
capabilities	   by	   the	   TeNT	   system	   (130-­‐132).	   	   Today,	   recombinant	   technology	   is	   prefered	   as	   it	  
eliminates	  possible	  side	  products	  resulting	  from	  conjugation	  reactions.	   	  The	  fusion	  between	  a	  
non-­‐toxic	  TeNTLC	  and	  β-­‐galactosidase	  (β-­‐gal),	  superoxide	  dismutase	  (SOD),	  or	  GFP	  resulted	  in	  β-­‐
gal-­‐TeNTLC,	  SOD-­‐TeNTLC	  ,	  and	  GFP-­‐TeNTLC.	  	  Similar	  to	  BoNT	  studies,	  these	  constructs	  were	  used	  
to	  probe	  the	  delivery	  capabilities	  of	  TeNT.	  	  Successful	  delivery	  of	  β-­‐gal	  allowed	  authors	  to	  study	  
and	  monitor	  membrane	  trafficking	  of	  tetanus	  toxin	  by	  following	  the	  reporter	  protein	  (133,134).	  	  
Intramuscular	   injection	   of	   β-­‐gal-­‐TeNTLC	   resulted	   in	   brainstem	   hypoglossal	   nuclei	   protein	  
localization	  within	  a	  couple	  hours,	  demonstrating	  rapid	  transport	  through	  the	  motor	  neuronal	  
axon	   even	   with	   attached	   cargo.	   	   Results	   were	   similar	   with	   the	   other	   constructs,	   also	  
demonstrating	   the	   ability	   of	   biological	   macromolecules	   to	   be	   transported	   across	   the	   blood-­‐




In	   addition	   to	   studies	   focused	   on	   protein	   translocation,	   TeNT	   has	   been	   assessed	   as	   a	  
DNA	   transport	   system.	   	   As	   a	   transfection	   system,	   the	   catalytically	   inactive	   TeNTLC	   was	  
chemically	   conjugated	   to	   poly(K)	   using	   N-­‐succinimidyl-­‐3-­‐[2-­‐pyridyldothio]	   propionate.	   	   The	  
complex	   was	   subsequently	   bound	   to	   plasmid	   DNA	   through	   electrostatic	   interactions	   (137).	  
Reporter	  expression	  of	  genes	  encoded	  by	  the	  DNA	  cargo	  was	  used	  to	  demonstrate	  successful	  
DNA	  delivery	  into	  a	  neuronal	  cell	   line,	  N18	  RE	  105.	   	   	  Although	  conjugation	  reactions	  carry	  the	  
risk	   of	   side	   products,	   this	   method	   may	   prove	   to	   alleviate	   risks	   associated	   with	   viral	   vector	  
transfection.	   	  Additional	   investigations	  are	  necessary	  to	  provide	  evidence	  as	  to	  which,	  viral	  or	  
protein,	  system	  is	  safer	  for	  therapeutic	  use.	  
1.5.5.	  	  Diphtheria	  toxin	  
Most	   often	   diphtheria	  presents	   as	   an	   acute	   nose	   and	   throat	   infection	   causing	   a	   dark	  
colored	   fiber-­‐like	   covering	   that,	   in	   severe	   cases,	   blocks	   airways.	   	   The	   infection	   is	   due	   to	  
toxigenic	   strains	   of	   Corynebacterium	   diphtheria,	   spread	   from	   an	   infected	   person	   to	   others	  
through	  respiratory	  droplets.	  	  Disease	  causing	  strains	  also	  produce	  a	  toxin,	  diphtheria	  toxin	  (DT)	  
with	  an	  LD50	  of	  ~100	  ng·∙kg-­‐1	  body	  weight	  (110,138).	  	  
A	  single	  chain	  precursor	  protein,	  60	  kD,	  undergoes	  proteolysis	  yielding	  two	  fragments,	  
DT-­‐A	  and	  DT-­‐B,	  held	  together	  by	  a	  disulfide	  linkage.	  DT-­‐B	  (37	  kD)	  carries	  the	  receptor	  binding	  
domain	   and	   translocation	   sequence,	   whereas	   DT-­‐A	   (21	   kD)	   is	   the	   enzymatic	   ADP-­‐
ribosyltransferase.	   	  Catalysis	   involves	  NAD+-­‐dependent	  ADP-­‐ribosylation	  of	  elongation	  factor	  2	  
(EF-­‐2),	   an	  essential	   elongation	   factor,	   to	   inhibit	  mammalian	   cell	   protein	   synthesis	   and	   trigger	  
apoptosis	  (139-­‐141).	  	  Diphtheria	  toxin	  is	  well	  studied	  and	  historically	  served	  as	  a	  model	  system	  
during	  the	  analysis	  of	  other	  protein	  toxins	  (142).	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Cytotoxicity	  by	  diphtheria	   toxin	  begins	  with	   receptor	  binding;	  DT-­‐B	   specifically	   targets	  
the	  membrane	  bound	  heparin	   binding	   epidermal	   growth	   factor-­‐like	   precursor	   (HB-­‐EGF)(143).	  	  
The	   receptor	   is	   expressed	   in	   proliferating	   and	   post-­‐mitotic	   cells	   and	   widely	   distributed	   in	  
neuronal	  and	  neuroglia	  of	  pre-­‐	  and	  post-­‐natal	  rats	  (144,145).	  	  Clathrin	  coated	  pits	  are	  required	  
to	  internalize	  the	  toxin,	  resulting	  in	  endocytosis.	  Acidification	  of	  the	  vesicle	  triggers	  unfolding	  of	  
the	   translocation	   domain	   within	   DT-­‐B	   (146,147).	   	   Membrane	   insertion	   and	   pore	   formation	  
result	   in	   the	   18-­‐22	   Å	  wide	   channel	   required	   for	   DT-­‐A	   translocation,	   (148,149).	   	   Debate	   over	  
mechanism	   and	   translocation	   requirements	   continue,	   although	   there	   is	   evidence	   for	   protein	  
threading	  through	  the	  pore	  facilitated	  by	  a	  complex	  containing	  a	  cytosolic	  translocation	  factor	  
(149,150)	  as	  well	  as	  a	  chaperone-­‐like	  activity	  of	  the	  translocation	  domain	  (151,152).	  	  No	  matter	  
the	   driving	   force	   of	   translocation,	   it	   is	   well	   established	   that	   pore	   formation	   alone	   is	   not	  
sufficient	  for	  cytosolic	  delivery	  (153,154);	  a	  protein	  complex	  with	  cytosolic	  translocation	  factors	  
is	   also	   required,	   including	   Hsp90	   or	   thioredoxin	   reductase	   (150,155).	   	   Subsequent	   to	   DT-­‐A	  
delivery	   into	   the	   cytosol,	   the	   disulfide	   bond	   connecting	   the	   two	   subunits	   is	   reduced	   and	  
releases	  the	  protein	  fragment	  which	  refolds	  into	  its	  active	  conformation	  and	  is	  capable	  of	  ADP-­‐
ribosylating	  its	  cellular	  targets	  in	  the	  cytosol	  (139).	  	  	  
Recombinant	   proteins	   have	   been	   constructed	   by	   exchanging	   the	   receptor	   recognition	  
domain	   of	   DT	   for	   directed	   cytotoxicity	   (156,157).	   	   The	   most	   notable	   chimeric	   toxin	   was	  
approved	   in	   1999	   by	   the	   U.S.	   Food	   and	   Drug	   Administration	   (FDA)	   for	   the	   treatment	   of	  
cutaneous	   T	   cell	   lymphoma	   by	   targeting	   the	   toxin	   to	   a	   receptor	   over	   expressed	   on	   CD25	  
positive	  cells,	  IL-­‐2	  receptors,	  with	  high	  affinity	  (13,158-­‐160).	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DT	  has	  also	  been	  explored	  as	  a	  method	  to	  provoke	  antigen	  specific	   immune	  activation	  
by	  delivering	  peptides	   into	   the	  MHC	   I	  pathway.	   	   Short	  peptides,	  12-­‐30	   residues,	  with	  various	  
electrostatic	   and	   hydrophobic	   properties	  were	   internalized	  with	   the	   DT-­‐A	   subunit	   (161).	   	   All	  
peptides	  explored	  were	  able	  to	  cross	  the	  membrane,	  indicating	  the	  usefulness	  of	  DT	  as	  a	  carrier	  
system.	  	  	  
One	   very	   interesting	   study	   utilized	   sequences	   from	   several	   protein	   sources,	   including	  
DT,	   to	   create	   a	   patchwork	   of	   functional	   domains	   and	   created	   a	   targeted	   DNA	   transfection	  
system	  (162).	  	  At	  the	  N-­‐terminus,	  a	  DNA-­‐binding	  domain	  from	  a	  yeast	  transcription	  factor	  was	  
located.	  	  The	  central	  region	  of	  the	  fusion	  protein	  contained	  the	  translocation	  domain	  from	  DT,	  
and	  the	  C-­‐terminus	  was	  comprised	  of	  an	  antibody	  fragment	  specific	  for	  the	  ErbB2	  antigen.	  	  This	  
antigen	  is	  over-­‐expressed	  in	  many	  cancer	  cells.	  	  A	  plasmid	  encoding	  a	  reporter	  gene,	  luciferase,	  
formed	   a	   complex	  with	   the	   fusion	   protein	   for	   DNA	   delivery,	   and	   excessive	   negative	   charges	  
were	   neutralized	   by	   poly-­‐L-­‐lysine.	   	   The	   expression	   of	   the	   reporter	   gene	   was	   confirmed	   by	  
luciferase	  activity	  in	  harvested	  cells	  after	  transfection.	  	  	  
Chloroquine	   was	   used	   to	   describe	   the	   efficiency	   and	   specificity.	   	   Chloroquine	   is	   an	  
acidotropic	   reagent	   that	   is	   known	   to	   enhance	   delivery	   via	   endosome	   escape.	   	   Although	  
chloroquine	  blocks	  endosomal	  acidification,	  it	  is	  suggested	  that	  accumulation	  of	  this	  reagent	  in	  
intracellular	   vesicles	   induces	   endosomal	   osmotic	   swelling	   and	   destabilization,	   releasing	   the	  
contents	  of	   the	  endosome.	   	   In	   the	  presence	  of	  control	  cells,	   the	  addition	  of	  chloroquine	  with	  
DNA	  only	   resulted	   in	   	   ~20-­‐fold	   increased	   reporter	   expression,	  whereas	  wen	   chloroquine	  was	  
added	   to	   the	   fusion	   protein:DNA	   complex,	   only	   two-­‐fold	   enhanced	   reporter	   activity	   was	  
observed.	   	   This	   experiment	  proved	   the	   fusion	  protein:	  DNA	  complex	  already	  had	  an	  efficient	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endosome	   escape	   mechanism,	   mediated	   by	   the	   DT	   translocation	   domain	   after	   inhibiting	  
endosomal	   acidification	   reduced	   reporter	   protein	   expression.	   A	   very	   similar	   construct	   was	  
created	   by	   replacing	   the	   DT	   domain	   with	   the	   translocation	   domain	   from	   a	   different	   protein	  
toxin,	  Pseudomonas	   exotoxin	  A.	   	   This	   construct	   also	  mediated	   cell-­‐specific	  DNA	   transfer,	   and	  
proved	  the	  dynamics	  of	  such	  a	  system	  while	  highlighting	  the	  exciting	  possibilities	  of	  exploring	  
chimeric	  delivery	  proteins	  (163).	  
1.5.6.	  	  Pseudomonas	  exotoxin	  A	  
Many	   nosicomial	   infections,	   including	   burn	   and	   post-­‐surgical	   infections,	   infections	   in	  
hospitalized	  immune-­‐compromised,	  and	  cystic	  fibrosis	  patients,	  are	  the	  result	  of	  virulent	  strains	  
of	   Pseudomonas	   aeruginosa	   (164).	   The	   most	   toxic	   virulence	   factor	   from	   this	   Gram-­‐negative	  
opportunistic	  pathogen	  is	  exotoxin	  A	  (PE).	  	  Crystal	  structures	  of	  PE	  have	  identified	  three	  distinct	  
domains:	   receptor-­‐binding	   (domain	   I),	   translocation	   (domain	   II),	   and	   the	   catalytic	   ADP-­‐
ribosyltransferase	   (domain	   III)	   (165).	   	   As	   a	   single	   chain	   protein	   (66	   kD),	   also	   called	   the	  
proenzyme,	   domain	   I	   targets	   low	   density	   lipoprotein	   receptor-­‐related	   protein	   1	   or	   1B	   (also	  
referred	  to	  as	  CD91	  or	  the	  α–macro-­‐globulin	  receptor)	  (166,167).	  	  Activation	  is	  essential	  for	  cell	  
toxicity	   and	   occurs	   via	   a	   furan	   proteolytic	   event	   between	   Arg279	   and	   Gly280	   in	   domain	   II	  
(168,169),	   followed	   by	   endocytosis	   (170).	   There	   is	   evidence	   of	   unfolding	   for	   delivery	   of	   the	  
enzymatically	  active	  domain	  (37	  kD)	  into	  the	  cytosol	  where	  the	  reducing	  environment	  (171)	  is	  
suspected	   to	   play	   a	   role	   in	   reduction	   of	   an	   intramolecular	   disulfide	   bond,	   releasing	   the	   C-­‐
terminus	   into	   the	  cytosol	   (172).	   	   Similar	   to	  DT,	   the	  PE	  enzymatic	  domain	  catalyzes	   the	  NAD+-­‐




At	   least	   16	   PE-­‐based	   immunotoxins	   are	   under	   investigation	   in	   clinical	   and	   preclinical	  
trials	   for	   therapy	   of	   B	   cell	   malignancies	   (targeting	   CD22	   receptors),	   brain	   and	   CNS	   tumors	  
(targeting	   epidermal	   growth	   factor	   receptor),	   and	   glioblastoma	   multiforme	   (targeting	  
interleukin-­‐13	  receptor	  or	  glycoprotein	  NMB)	  (174).	  	  In	  addition	  to	  immunotoxin	  development,	  
PE	   has	   been	   utilized	   as	   a	   DNA	   transfection	   system	   and	   to	   elicit	   immunological	   responses	   to	  
epitopes	  of	  interest.	  
Attaching	   an	   epitope	   from	   influenza	  A	   protein	   to	   PE	   domains	   I	   and	   II,	   in	   place	   of	   the	  
enzymatic	  domain,	  results	  in	  translocation	  of	  the	  epitope	  into	  the	  cytosol	  where	  it	  is	  processed	  
by	   the	  MHC	   I	   pathway	   and	  displayed	   for	   immune	   response	   (175).	   	   After	   incubation	  with	   the	  
epitope-­‐PE	   fusion	   protein,	   cells	   were	   sensitive	   to	   T	   lymphocytes	   specific	   for	   the	   introduced	  
peptide	   sequence,	   demonstrating	   cytosolic	   delivery	   and	   peptide	   presentation	   on	   MHC	   I	  
molecules.	   	   Aside	   from	   PE	   as	   a	   delivery	   tool	   to	   elicite	   an	   immune	   response	   by	   passage	   of	  
peptides	  into	  a	  desired	  pathway,	  PE	  is	  also	  reported	  to	  deliver	  active	  enzymes.	  
Similar	   to	  constructs	  discussed	   for	  DT,	  PE	  domains	   I	  and	   II	  have	  been	  reported	  to	   tow	  
active	  enzymes	  intracellularly,	  via	  fusion	  constructs.	   	  Delivery	  of	  an	  extracellular	  ribonuclease,	  
barnase,	   was	   assessed	   using	   a	   PE-­‐Barnase	   (PE-­‐Bar)	   chimeric	   protein.	   	   The	   fusion	   protein	  
retained	  intrinsic	  cytotoxicity	  from	  the	  catalytic	  ADP-­‐ribosyltransferase	  of	  PE	  in	  addition	  to	  the	  
ribonuclease	  action	  of	  Bar	   (176).	   	  Cytotoxicity	  attributed	  to	  barnase	  delivery	  was	  verified	  two	  
ways:	   First,	   a	   construct	   with	   inactivated	   ADP-­‐ribosyltransferase	   was	   created	   through	  
mutagenesis,	   PEΔ553-­‐Bar.	   	   Both	   constructs,	   PE-­‐Bar	   and	   PEΔ553-­‐Bar,	   displayed	   cytotoxic	   activity	  
when	   incubated	   with	   a	   PE	   sensitive	   cell	   line,	   murine	   fibroblast	   L929.	   	   Since	   the	   ADP-­‐
ribosyltransferase	   is	   inactive	   in	   the	   PEΔ553-­‐Bar	   construct,	   cytotoxicity	   is	   attributed	   to	   the	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successful	   delivery	  of	   active	  Bar.	   	   RNA	  degradation	  was	   also	  observed	  and	  presented	   further	  
evidence	  that	  cell	  death	  resulted	  due	  to	  Bar	  activity.	  	  Second,	  a	  PE-­‐resistant	  subclone	  of	  murine	  
hybridoma	   OVB3	   cells,	   carrying	   a	  mutated	   ef-­‐2	   gene	   for	   a	   protein	   product	   that	   is	   not	   ADP-­‐
ribosylated	  by	  PE,	  was	  sensitive	  to	  PE-­‐Bar.	  	  Also	  recognized	  from	  this	  study	  is	  the	  advantage	  of	  
multiple	  enzymatic	  domains	  to	  target	  several	  cellular	  activities.	   	  Such	  a	  tool	  would	  reduce	  the	  
development	  of	  mutational	  resistance	  when	  cytotoxicity	  is	  desired.	  	  	  
Addition	  of	  PE	  domain	  II	  to	  the	  central	  region	  of	  a	  chimeric	  protein	  with	  terminal	  DNA	  
binding	  and	  cell	  receptor	  domains	  has	  the	  advantage	  of	  targeting	  specific	  cell	  types	  (exchange	  
of	  receptor	  binding	  domain),	  as	  well	  as	  targeting	  specific	  intracellular	  targets	  (exchange	  of	  the	  
enzymatic	  domain).	  	  Plasmid	  DNA	  was	  successfully	  conjugated	  to	  the	  DNA	  binding	  domain,	  and,	  
following	   receptor	  binding	  and	  endocytosis,	   the	  PE	   translocation	  domain	   retained	  activity,	   as	  
demonstrated	   by	   host	   cell	   expression	   of	   a	   reporter	   gene,	   FLuc,	   encoded	   on	   the	   transfected	  
plasmid	   (53,163).	   	   This	   result	   reveals	   the	   independence	   of	   functional	   toxin	   domains	   and	  
provides	  a	  plausible	  theory	  that	  expansion	  in	  this	  area	  of	  research	  has	  the	  potential	  to	  give	  rise	  
to	  an	  efficient	  delivery	  system	  for	  protein	  and	  gene	  therapy	  with	  vast	  medicinal	  improvements.	  	  
1.5.7.	  	  Toxins	  A	  and	  B	  
The	   most	   common	   cause	   of	   antibiotic-­‐associated,	   or	   nosicomial,	   diarrhea	   is	   the	   rod-­‐
shaped,	  Gram-­‐positive,	  spore	  forming,	  pathogenic	  Clostridium	  difficile	  (177).	  Infection,	  ranging	  
from	  non-­‐complicated	  mild	  diarrhea	  to	  life-­‐threatening	  toxic	  megacolon,	  is	  caused	  by	  two	  main	  
virulence	  factors,	  toxins	  A	  and	  B	  (TcdA	  and	  TcdB)	  (178-­‐180).	  	  	  
TcdA/B	  are	  similar	  to	  one	  another	  in	  sequence,	  structure,	  route	  of	  cell	  entry,	  and	  mode	  
of	   intoxication,	   but	   have	   some	   significant	   differences.	   	   The	   greatest	   difference	   is	   in	   their	   C-­‐
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terminal	   receptor	   binding	   domains.	   	   These	   differ	   in	   length,	   overall	   structure,	   and	   receptor	  
specificity	   (181).	   	  Multiple	   receptors	  have	  been	   identified	   for	  TcdA	   (182-­‐184)	  and	   it	  has	  been	  
proposed	  that	  TcdA	  receptor	  recognition	  tolerates	  a	  significant	  amount	  of	  variation	  within	  the	  
cell	  surface	  glycan	  (185).	   	  Receptors	  for	  TcdB	  have	  not	  yet	  been	  identified	  (185).	   It	   is	  possible	  
TcdA/B	  are	  capable	  of	  binding	  host	  cells	  through	  an	  additional	  mechanism,	  supported	  by	  data	  
where	  removing	  the	  receptor	  binding	  domain	  yielded	  cytotoxic	  proteins	  (186).	  	  	  
Subsequent	  to	  protein	  binding,	  receptor	  mediated	  endocytosis	  internalizes	  both	  toxins.	  
Endosomal	   acidification	   drives	   a	   conformational	   rearrangement	   of	   the	   centrally	   located	  
translocation	  domain,	  which	   is	   believed	   to	   form	  a	   pore	   through	   the	  membrane	   and	  mediate	  
translocation	   of	   the	   N-­‐terminus	   (187).	   	   The	   N-­‐terminal	   glucosyltransferase	   domain	   is	  
transferred	  through	  the	  pore	  and	  into	  the	  cytosol	  along	  with	  a	  cysteine	  protease	  domain	  (CPD).	  	  
The	   CPD	   is	   positioned	   between	   the	   enzymatic	   domain	   and	   the	   translocation	   domain	   and	   is	  
activated	   by	   a	   cytosolic	  molecule,	   inositol	   hexakisphosphate	   (IP6)	   (7,188,189),	   to	   process	   the	  
toxin	   and	   release	   the	   enzymatic	   domain	   after	   translocation	   (190).	   	   The	   enzymatic	   domain	  
catalyzes	  the	  O-­‐linked	  glucosylation	  of	  target	  proteins	  in	  the	  Rho	  family	  of	  small	  GTPases	  (Rho,	  
Rac,	  and	  Cdc42).	  	  Inactivation	  of	  these	  signaling	  proteins	  disrupts	  cell	  processes,	  including	  actin	  
dynamics,	  and	  triggers	  apoptosis.	  	  
From	  a	  protein	  delivery	  perspective,	  Toxins	  A	  and	  B	  are	  attractive	  because	  of	  their	  CPD	  
activity,	  a	  feature	  that	  also	  makes	  them	  distinct	  from	  the	  other	  toxins	  discussed	  in	  this	  chapter.	  
Fusion	  proteins	  that	  include	  the	  CPD	  not	  only	  deliver	  cargo,	  but	  also	  have	  the	  ability	  to	  release	  





Two	   TcdA	   fusion	   constructs	   have	   been	   reported	   where	   the	   N-­‐terminal	   enzymatic	  
domain	  was	  replaced	  with	  Gaussia	  luciferase	  or	  emerald	  GFP,	  yielding	  GFP-­‐TcdA	  and	  Luc-­‐TcdA,	  
respectively	   (191).	   In	   vitro,	   the	   cargo	   domain	   of	   each	   fusion	   protein	   retained	   its	   reporter	  
property,	  as	  well	  as	  TcdA	  CPD	  auto-­‐processing.	  	  In	  cellulo,	  binding	  and	  endocytosis	  was	  verified	  
by	   cytoimmunochemisty.	   Analysis	   of	   cell	   lysates	   identified	   active	   luciferase	   after	   incubation	  
with	  Luc-­‐TcdA.	  	  Further	  analysis	  confirmed	  CPD	  release	  of	  active	  luciferase	  into	  the	  cytosol.	  	  The	  
inability	  to	  detect	  GFP	  in	  cell	  lysates	  via	  delivery	  by	  the	  GFP-­‐TcdA	  protein	  indicates,	  once	  again,	  
the	   structural	   constraints	   of	   GFP	   may	   hinder	   the	   unfolding	   even	   that	   is	   required	   for	   toxin	  
movement	  though	  the	  transmembane	  pore.	  
TcdB	  
A	  similar	  construct	  was	  described	  utilizing	  TcdB.	  	  One	  major	  difference	  is	  that	  the	  TcdA	  
constructs	  were	   void	   of	   the	   enzymatic	   domain,	   replaced	   by	   a	   reporter	   protein,	  whereas	   the	  
TcdB	   construct	   included	   the	   full-­‐length	   protein	   (192).	   	   AGT-­‐TcdB	   was	   described	   as	   a	   fusion	  
between	  TcdB	  and	  a	  DNA	  guanine	  alkyltransferase	  (AGT).	   In	  vitro,	  AGT-­‐TcdB	  had	  AGT	  activity.	  	  
In	   cellulo,	   cellular	   delivery	   by	   TcdB	   invoked	   cytotoxicity,	   permitting	   the	   assumption	   that	   the	  
AGT	  was	  also	  delivered	  to	  the	  cytosol	  along	  with	  the	  enzymatic	  domain	  of	  TcdB.	  	  Similar	  toxicity	  
was	   observed	   when	   TcdB	   was	   compared	   to	   AGT-­‐TcdB,	   indicating	   efficient	   cytosolic	   delivery	  
even	   with	   an	   attached	   protein.	   	   Unfortunately,	   AGT	   activity	   was	   not	   described	   following	  
cytosolic	   delivery.	   	   This	   study	   is	   another	   confirmation	   of	   the	   inherent	   technology	   offered	   by	  





The	   cell	   membrane	   acts	   as	   a	   barrier	   to	   keep	   intracellular	   processes	   from	   being	  
disrupted,	  protecting	  the	  overall	  health	  of	  the	  cell.	   	  The	  transport	  of	  molecules	  across	  the	  cell	  
membrane	   is	   tightly	   regulated	   for	   the	   same	   reasons.	   	   It	   is,	   however,	   desirable	   from	   a	  
biotechnology	   standpoint	   to	   move	   macromolecules	   across	   the	   membrane	   for	   research	   and	  
medicine.	   	   For	   this	   function,	   CPPs,	   liposome	   carrier	   systems,	   and	   viral	   vectors	   have	   been	  
immensely	   studied.	   	   Concerns	   over	   delivery	   efficiency,	   limitations,	   and	   safety	   have	   driven	  
discovery	  of	  additional	  methods.	  	  
Bacterial	   exotoxins	   are	   excreted	   from	   pathogenic	   bacteria	   and	   have	   historically	   been	  
considered	  a	  nuisance,	  causing	  fatal	  disease	  and	  wide	  spread	  pandemics.	  	  Decades	  of	  research	  
have	   expanded	   our	   knowledge	   of	   how	   many	   of	   these	   toxins	   function,	   leading	   to	   a	   better	  
understanding	  of	  the	  diseases	  they	  cause,	  but	  also	  generating	  an	  appreciation	  for	  the	  absolute	  
brilliant	   mechanisms	   these	   toxins	   have	   evolved	   to	   execute	   cell	   intoxication	   and	   membrane	  
translocation	   through	   the	   cooperation	   of	   a	   collection	   of	   individual	   domains.	   	   Several	  
researchers	  have	  now	  picked	  up	  on	  the	  opportunities	  presented	  within	  bacterial	  protein	  toxins.	  	  
This	   chapter	   outlines	   the	   accomplishments	   in	   mammalian	   cell	   cargo	   delivery	   using	   protein	  
toxins	  and	  the	  effect	  this	  technology	  will	  have	  on	  multiple	  fields	  of	  study.	  	  	  
The	   eight	   toxins	   discussed	   here	   have	   been	   cited	   in	   the	   literature	   after	   successful	  
chimeric	  proteins	  have	  effectively	  moved	  cargo	  into	  mammalian	  cells.	  	  The	  research	  potential	  is	  
particularly	  obvious	  in	  the	  case	  of	  anthrax	  toxin,	  where	  many	  reports	  of	  single	  activity	  domains,	  
independent	  of	  the	  larger	  holotoxins	  from	  which	  they	  come,	  are	  evaluated	  in	  cellulo	  via	  fusion	  
to	   anthrax	   toxin.	   	   This	   system	   has	   been	   extremely	   useful	   in	   determining	   the	   function,	   and	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targeted	  substrates,	  of	  newly	  identified	  activity	  domains.	  	  Anthrax	  toxin	  is	  clearly	  able	  to	  deliver	  
active	   enzymes;	   however,	   one	   disadvantage	   to	   this	   system,	   should	   it	   be	   explored	   as	   a	  
therapeutic	  option,	   is	  the	  need	  to	  administer	  two	  separate	  subunits	  required	  to	   interact	  after	  
injection.	   	   A	   solution	   to	   this	   potential	   problem	   would	   be	   to	   use	   a	   toxin	   with	   either	   linked	  
domains,	  or	  expressed	  as	  a	  single	  polypeptide.	  	  	  
A	  variety	  of	   intoxication	  pathways	  are	  utilized	  by	  exotoxins,	  yet	  slight	  differences	  have	  
been	   unveiled.	   	   Unique	   aspects	   of	   each	   toxin	   are	   extremely	   valuable	   in	   cargo	   delivery	  
engineering.	   	   There	   are	   two	   important	   characteristics	   that	   must	   be	   highlighted;	   first,	  
neurotoxins	   have	   the	   ability	   to	   target	   brainstem	   neurons	   after	   muscle,	   tongue,	   or	   hind	   leg	  
injection	  even	  when	  fused	  to	  cargo	  domains.	  	  This	  is	  a	  highly	  desirable	  achievement	  as	  crossing	  
the	  blood-­‐brain	  barrier	   is	  a	  difficult	  step	  necessary	  for	  many	  therapeutic	  targets.	   	  Second,	  the	  
glucosylating	   toxins,	  TcdA/B,	  have	  a	  self-­‐cleaving	  protease	   for	   release	  after	  cytosolic	  delivery.	  	  
This	   is	   an	   attractive	   feature	   providing	   a	   mechanism	   for	   delivery	   and	   release	   of	   the	   chosen	  
sequence.	  	  	  
Research	  and	   clinical	   applications	  are	  greatly	   advanced	  by	   intercellular	   cargo	  delivery,	  
however,	   increased	   efficiency	   and	   safer	   methods	   are	   needed.	   	   Bacterial	   protein	   toxins	   are	  
under	   investigation	   for	   this	   purpose,	   although	   still	   a	   relatively	   new	   field,	   with	   potential	  
advantages	   over	   CPPs,	   viral	   vectors,	   and	   lipid	   directed	   translocation.	   	   A	   more	   detailed	  
understanding	  of	  the	  cell	  entry,	  translocation,	  and	  cargo	  release	  mechanisms	  will	  play	  a	  role	  in	  
defining	  construction	  of	  an	  adaptable	  delivery	  system.	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Table	  1.1.	  	  Protein	  toxins.	  
Toxin	   Classification	   Source	   Receptor	   Substrate	   Disease	   Ref.	  







(LF)	  and	  ATP	  
(EF)	  	  
Anthrax	  	   (193)	  








G-­‐actin	  	   Botulism	  	   (6)	  











Botulism	  	   (194,
195)	  




SV2	  	   VAMP	  	   Tetanus	  	   (194,
195)	  




HB-­‐EGF	  	   EF-­‐2	  	   Diphtheria	  	   (196)	  




CD91	  	   EF-­‐2	  	   Nosocomial	  
infection	  	  
(174)	  









CDI	  	   (197)	  








CDI	  	   (197)	  
Botulinum	  neurotoxin	  (BoNT);	  tetanus	  neurotoxin	  (TeNT);	  diphtheria	  toxin	  (DT);	  Pseudomonas	  
exotoxin	   A	   (PE);	   toxin	   A	   (TcdA);	   toxin	   B	   (TcdB);	   tumor	   epithelial	   marker	   8	   (TEM8,	   ANTXR1);	  
capillary	  morphogenesis	  factor	  2	  (CMG2,	  ANTXR2);	  synaptotogmin	  (Syt-­‐I	  and	  Sty-­‐II);	  synaptical	  
vesicle	   protein	   (SV2);	   heparin	   binding	   epidermal	   growth	   factor-­‐like	   precursor	   (HB-­‐EGF);	  
Mitogen-­‐activated	   protein	   kinase	   kinases	   (MEKs/MKKs);	   adenosine	   triphosphate	   (ATP);	   N-­‐
ethylmaleimide-­‐sensitive	   factor	   attachment	   protein	   receptors	   (SNARE);	   vesicle	   associated	  
membrane	  protein	  (synaptobrevin-­‐2,	  VAMP);	  elongation	  factor	  2	  (EF-­‐2);	  low	  density	  lipoprotein	  
receptor-­‐related	  protein	  1	  or	  1B	  (CD91);	  Clostridium	  difficile	  infection	  (CDI).	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Table	  1.2.	  Exotoxin	  cargo	  delivery.	  








DT-­‐A DT-­‐A	  mediated	  
cytotoxicity	   
DT-­‐LFN	  and	  LFN-­‐DT	  are	  cytotoxic	  





mouse	  lethality	  via	  
TcdB	  
glucosyltransferase 
LFN-­‐TcdB	  is	  cytotoxic	  and	  causes	  






enzyme	  activity	  via	  
RTXVc	  actin	  cross-­‐
linking	  domain 
ACD	   was	   delivered	   into	   cells	  
and	   characterized	   using	   LFN-­‐
ACD,	   with	   PA.	   The	   fusion	  





enzyme	  activity	  via	  
RTXVc	  actin	  cross-­‐
linking	  domain 
Similar	   to	   above	   report,	   with	  







Cytotoxicity	  via	  TcdB	  
and	  cell	  protection	  
from	  TcdB	  via	  
mutants 
Identification	  of	   non-­‐toxic	   TcdB	  
enzymatic	   domain	   mutations	  
used	   the	   LFN/PA63	   system	   to	  
enter	  cells	  and	  challenge	  native	  














GFP	  was	   delivered	   to	   neuronal	  
cells	   by	   GFP-­‐BoNT/A	   fusion	  
protein;	   a	   linker	   was	   required	  





activity	  in	  lysate 
Reporter-­‐BoNT/DLC	   (Fluc,	   GFP,	  
and	   DHR)	   resulted	   in	   reduced	  
toxicity	   compared	   to	  BoNT/DLC.	  	  
The	  greatest	  reduction	  was	  due	  













C2IN-­‐streptavidin/C2II	   system	  
facilitates	   intracellular	   biotin	  
transport.	   Biotin-­‐fluorescein	   or	  
biocytin-­‐Alexa488	   is	   delivered	  







C2IN-­‐streptavidin/C2II	   system	  
facilitates	   biotin-­‐fluorescein	   or	  
biocytin-­‐Alexa488	   and	   delivery	  









Variants	   of	   streptavidin	   were	  
analyzed	   for	   solubility	   and	  
biotin	   affinity	   to	   improve	   the	  
C2IN-­‐streptavidin/	   C2II	   system.	  
Bioytin-­‐Alexa488	   was	   delivered	  
as	  cargo	  into	  mammalian	  cells. 
(108) 
SpvB SpvB	  mediated	  
cytotoxicity 
SpvB	  was	  cytotoxic	  to	  cells	  after	  
C2IN/C2II	   directed	   cell	   entry.	  	  
Specific	   proline	   residues	   were	  









n  Reporter	  genes Reporter	  gene	  
expression 
The	   DT	   translocation	   domain	  
mediates	   delivery	   of	   a	   fusion	  
protein	   and	   attached	   plasmid	  
DNA	  to	  targeted	  cells 
(162) 
Peptides Cytotoxicity Peptide-­‐DT	   fusion	   proteins	  
translocate	   various	   sequences,	  














Peptides CTL	  activation Peptide	  epitopes	  from	  influenza	  
A	  proteins	  were	  fused	  to	  PE,	   in	  
place	  of	  the	  enzymatic	  domain,	  
and	   delivered	   for	   display	   from	  
MHC	   I	   pathway,	   eliciting	  
specific	  CTL	  activation 
(175) 
Reporter	  genes Reporter	  gene	  
expression 
A	   plasmid	   encoding	   a	   reporter	  
gene	  was	  delivered	  by	  a	   fusion	  
protein	   where	   the	   enzymatic	  
domain	  of	  PE	  was	  replaced	  with	  
a	   DNA	   binding	   domain	   from	  
human	  DNA	  topoisomerase	  I	   
(53) 
Reporter	  genes Reporter	  gene	  
expression 
The	   PE	   translocation	   domain	  
mediates	   delivery	   of	   a	   fusion	  
protein	   and	   attached	   plasmid	  
DNA	  to	  targeted	  cells	  	  
(163) 
Barnase Cytotoxicity The	   chimeric	   protein,	   PE-­‐Bar	   is	  








Reporter	  genes Reporter	  gene	  
expression,	  activity 
Plasmid	   DNA	   was	   transfected	  
after	   conjugation	   to	   poly(K)	  









Following	   tongue	   or	   hind	   leg	  




protein,	   TeNTHC-­‐SOD,	   SOD	   was	  
identified	   in	   hypoglossial	  
nucleus,	   indicating	   retrograde	  
axonal	  transport.	  	  SOD	  retained	  
higher	   activity	   expressed	   as	  
TeNTHC-­‐SOD	  vs.	  SOD-­‐TeNTHC. 
β-­‐galactosidase X-­‐gal	  activity	  assay After	   intramuscular	   injection	  of	  
the	   fusion	  protein	   LacZ-­‐TeNTHC,	  
LacZ	   activity	   is	   detectable	   in	  
neurons	  in	  the	  brainstem	  area. 
(134) 
β-­‐galactosidase X-­‐Gal	  activity	  assay Fusion	   protein	   β-­‐gal-­‐TeNTHC	  
was	   injected	   into	   the	   tongue	  
and	   found	   to	   rapidly	   localize	   in	  
the	   brainstem	   hypoglossal	  
nuclei,	   demonstrating	   rapid	  
transport	   through	   the	  
motoneuronal	   axon	   even	   with	  
attached	  cargo. 
(133) 
GFP Confocal	  and	  
immuno-­‐gold	  
electron	  microscopy 
GFP-­‐TeNTHC	   accumulated	   in	  
axonal	   compartments,	   and	  was	  










Luciferase Luciferase	  activity	   Active	   luciferase	   was	   delivered	  
and	   intracellularly	   released	   by	  






Cytotoxicity	   AGT	  retained	  in	  vitro	  activity	  as	  
AGT-­‐TcdB.	   	   AGT	   was	   cytotoxic,	  
indicating	  delivery	  of	   the	   cargo	  
along	   with	   TcdB	   enzymatic	  
domain. 
(192) 
Lethal	   factor	   N-­‐terminal	   residues,	   1-­‐255	   (LFN);	   Botulinum	   neurotoxin	   (BoNT)	   heavy	   chain	  
(BoNTHC)	   and	   light	   chain	   (BoNTLC);	   tetanus	   neurotoxin	   (TeNT)	   heavy	   chain	   (TeNTHC)	   and	   light	  
chain	   (TeNTLC);	   diphtheria	   toxin	   (DT)	   A-­‐subunit	   (DT-­‐A);	   Pseudomonas	   exotoxin	   A	   (PE);	  
Clostridium	  difficile	  toxin	  A	  (TcdA);	  Clostridium	  difficile	  toxin	  B	  (TcdB);	  Vibrio	  cholerae	  RTX	  Toxin	  
actin	  cross-­‐linking	  domain	  (RTXVc	  and	  ACD);	  5-­‐bromo-­‐4-­‐chloro-­‐3-­‐indolyl	  	  beta	  -­‐D-­‐galactoside	  (X-­‐
Gal);	  Superoxide	  dismutase	  (SOD);	  Alkylguanine	  DNA	  alkyltransferase	  (AGT);	  Green	  fluorescent	  
protein	   (GFP);	   Cytotoxic	   T	   lymphocytes	   (CTL);	   actin	   ADP-­‐ribosylating	  toxin	  of	   Salmonella	  





2. Introduction:	  Clostridium	  difficile	  and	  virulence	  factors	  
2.1. Background	  
The	   opportunistic	   pathogen	   Clostridium	   difficile	   (C.	   difficile)	   is	   responsible	   for	   the	  
majority	  of	  nosocomial	  antibiotic	  associated	  diarrheal	  cases	   (177,180).	   	   Intestinal	  colonization	  
of	   C.	   difficile,	   a	   rod-­‐shaped,	   gram-­‐positive,	   spore-­‐forming	   anaerobic	   bacterium	   (Figure	   2.1),	  
results	   in	   intestinal	   damage	   with	   symptoms	   ranging	   from	   mild	   diarrhea	   to	   life-­‐threatening	  
colitis.	   	   The	   spread	   of	   C.	   difficile	  
infection	   (CDI)	   occurs	   most	   often	   in	  
healthcare	   settings	   and	   is	   transmitted	  
from	  patient	  to	  patient	  via	  ingestion	  of	  
spores	   excreted	   from	   infected	  
individuals.	   	   Decontamination	   is	   a	  
challenge	   since	   C.	   difficile	   spores	   are	  
extremely	  robust	  and	  resistant	  to	  most	  
disinfectants.	   	   In	   some	   cases,	   the	  
bacteria	   are	   detected	   in	   healthy	   and	   asymptomatic	   adults	   where	   the	   normal	   flora	   provides	  
competition	  and	  prevents	  C.	  difficile	  from	  colonization.	  	  
Multiple	   risk	   factors	   have	   been	   identified	   for	   CDI	   including	   a	   compromised	   immune	  
system,	   age,	   visitation	   or	   residence	   in	   a	   healthcare	   facility,	   and	   current	   or	   recent	   use	   of	  
antibiotic	   therapy.	   Broad-­‐spectrum	   antibiotic	   treatment,	   which	   suppresses	   the	   healthy	   gut	  
bacteria,	  is	  the	  main	  culprit	  since	  C.	  difficile	  is	  resistant	  to	  almost	  all	  antibiotics.	  	  If	  C.	  difficile	  is	  
present	   during	   treatment,	   it	   welcomes	   the	   opportunity	   to	   colonize,	   and	   in	   the	   absence	   of	  
	  
Figure	   2.1.	   	   Micrograph	   of	   the	   Gram-­‐positive	  
opportunistic	   pathogen,	   C.	   difficile.	   	  Photo	   credit:	  
CDC/Lois	  S.	  Wiggs	  (phil.cdc.gov). 
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competition,	   colonies	  quickly	  overgrow	  and	  deplete	  available	  nutrient	   sources.	   	  At	   this	  point,	  
the	  bacterium	   releases	   virulence	   factors	   that	   attack	  host	   cells,	  which	   cause	   cell	   lysis	   and	   the	  
release	   of	   supplements	   for	   the	   growing	   colonies.	   	   These	   virulence	   factors	   also	   stimulate	   an	  
immune	   response,	  which,	   added	   to	   the	  mucosal	   damage	   by	   the	   toxins,	   presents	   clinically	   as	  
antibiotic-­‐associated	   diarrhea.	   	   A	   number	   of	   factors	   determine	   the	   success	   of	   subsequent	  
treatment.	  	  In	  the	  worst	  cases,	  the	  infection	  can	  develop	  into	  a	  life-­‐threatening	  condition	  calling	  
for	  emergency	  surgery	  or	  overwhelming	  infection	  and	  death.	  	  	  
This	   chapter	   will	   introduce	   C.	   difficile.	   Background	   on	   its	   identification,	   strain	   typing	  
techniques,	  as	  well	  as	   the	  healthcare	  challenges	   involving	  CDI	  highlight	  the	  need	  for	  effective	  
treatments.	  	  The	  current	  treatment	  protocols	  and	  novel	  treatments	  currently	  under	  exploration	  
are	   discussed.	   	   The	   chapter	   is	   brought	   to	   conclusion	   after	   a	   review	   of	   the	   most	   current	  
information	  is	  presented	  on	  the	  virulence	  factors.	  	  The	  goal	  here	  is	  to	  recognize	  the	  importance	  
of	  studying	  such	  a	  system.	  	  	  	  
2.2. Strain	  typing	  
Several	   methods	   are	   used	   to	   classify,	   or	   type,	   C.	   difficile	   isolates.	   	   Strain	   typing	   is	  
essential	  in	  monitoring	  the	  disease	  over	  time	  and	  location,	  drawing	  relations	  between	  genomic	  
variations	  and	  epidemiology.	  	  Restriction	  endonuclease	  analysis,	  pulse	  field	  gel	  electrophoresis,	  
polymerase	   chain	   reaction	   ribotyping	   (PCR	   ribotyping),	   toxinotyping,	   and	   multiple-­‐locus	  
variable	  number	  tandem	  repeat	  analysis,	  summarized	  in	  Table	  2.1,	  are	  most	  often	  utilized	  and	  





Table	  2.1.	  C.	  difficile	  typing.	  
	   	  
Typing	  
method	   Target	   Technique	  notes	   Outcome	  
C.	  difficile	  
ref.	  
PFGE	   Whole	  genome	   Large	  DNA	  fragments	  




few	  large	  MW	  
bands.	  
(198)	  
REA	   Whole	  genome	   Rare-­‐cutting	  restriction	  
enzyme	  (commonly	  





large	  number	  of	  
bands.	  
(199)	  
RFLP	   Whole	  genome	   REA	  followed	  by	  southern	  






Toxinotyping	   PaLoc	   Amplification	  of	  six	  
variable	  regions	  of	  the	  
PaLoc	  is	  followed	  by	  
endonuclease	  digestion	  








MLVA	   Genomic	  STRs	   STRs	  are	  identified	  by	  
genome	  sequencing	  (202).	  	  
After	  amplification,	  the	  
variable	  STRs	  are	  analyzed	  








Housekeeping	  genes,	  and	  
later	  virulence-­‐associated	  
genes,	  are	  amplified	  and	  
analyzed	  for	  
polymorphisms.	  










spacer	  in	  RNA	  
operon	  
Design	  of	  primers	  for	  PCR	  
of	  a	  variable	  length	  linker	  
region	  between	  16S	  and	  
23S	  rRNA	  genes.	  Band	  









Pulse	   field	   gel	   electrophoresis	   (PFG);	   Restriction	   endonuclease	   analysis	   (REA);	   REA	   restriction	  
fragment	   length	   polymorphism	   (RFLP);	   Multi-­‐locus	   variable	   number	   tandem	   repeat	   analysis	  
(MLVA);	  Multi-­‐locus	  sequence	  typing	  (MLST);	  short	  tandem	  repeats	  (STRs).	  
	  
Restriction	  endonuclease	  analysis	  
Restriction	  endonuclease	  analysis	  (REA)	  is	  a	  technique	  to	  analyze	  DNA	  based	  on	  the	  size	  
of	   fragments	   after	   digestion	   with	   a	   particular	   nuclease.	   	   The	   first	   reports	   describing	   the	  
classification	   of	  C.	   difficile	   isolates	   described	   the	   extraction	   of	   chromosomal	  DNA,	   sequential	  
endonuclease	   digestion	   by	   Cof1	   or	   HindIII,	   followed	   by	   agarose	   gel	   electrophoresis	   analysis	  
(199,209).	  	  This	  technique	  was	  later	  improved,	  increasing	  throughput	  and	  bacterial	  lysis	  yields,	  
while	  decreasing	  interference	  of	  background	  proteins	  by	  degradation	  (210).	  	  Application	  of	  this	  
method	  arranges	  groups	  by	  band	  patterns,	  with	  a	  letter	  designation.	  	  	  
Pulse	  field	  gel	  electrophoresis	  
Pulse	  field	  gel	  electrophoresis	  (PFGE)	  is	  a	  method	  used	  to	  separate	  large	  pieces	  of	  DNA	  
by	   alternating	   the	   voltage	   gradient	   during	   electrophoresis,	   resulting	   in	   higher	   resolution.	  	  
Employed	  as	  a	  strain	  typing	  method	  for	  C.	  difficile,	  chromosomal	  DNA	  is	  collected	  from	  isolates	  
and	  digested	  with	  rare	  cutting	  endonucleases,	  yielding	  very	  few	  fragments	  that	  are	  large	  in	  size	  
(198,211,212).	   	   The	   gel	   electrophoresis	   conditions	   are	   carefully	   determined	   to	   provide	   the	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greatest	  separation	  and	  resolution.	  	  Software	  can	  be	  employed	  to	  analyze	  results;	  BioNumerics	  
(Applied	  Maths	  Inc.)	  is	  commonly	  referenced	  for	  this	  task	  (213,214).	  	  Problems	  with	  this	  system	  
include	   DNA	   degradation	   during	   preparation	   of	   samples	   that	   are	   not	   handled	   properly	  
(211,215).	  	  	  	  
PCR	  ribotyping	  
PCR	  ribotyping	  was	  employed	  as	  a	  rapid	  and	  accurate	  way	  to	  group	  C.	  difficile	   isolates	  
(206).	   	   Ribotypes	   are	   identified	  by	  band	  patterns	   in	   agarose	   gel	   electrophoresis	   analysis	   of	   a	  
spacer	  region	  within	  the	  rRNA	  operon.	  	  	  Products	  of	  the	  PCR	  reaction,	  using	  a	  specific	  16S	  rRNA	  
and	  a	  23S	  rRNA	  primer	  set,	  are	  variable	  in	  size	  and	  correlate	  to	  the	  different	  alleles	  present	  on	  
the	  chromosomal	   rRNA	  operon.	   	  Modifications	   to	   the	  primers	  have	   improved	   the	  method	  by	  
reducing	  the	  size	  of	  DNA	  fragments	  for	  better	  resolution	  and	  easier	  analysis	  by	  electrophoresis	  
(216-­‐218).	  	  	  
Toxinotyping	  
Toxinotyping	   classifies	   isolates	   by	   restriction	   fragment	   length	   polymorphisms	   (RFLPs)	  
within	  the	  pathogenicity	  locus	  (PaLoc)	  (201).	  	  The	  PaLoc	  is	  described	  in	  section	  2.5.2.	  	  The	  entire	  
PaLoc	  is	  amplified	  by	  a	  set	  of	  primers,	  and	  the	  ten	  PCR	  products	  are	  grouped	  according	  to	  size	  
and	   restriction	   site	  polymorphisms.	   	   For	   screening	  of	   isolates,	   the	   two	  most	  variable	   regions,	  
one	  at	  the	  5’-­‐end	  of	  tcdB	  and	  one	  at	  the	  3’-­‐end	  of	  tcdA,	  can	  be	  used	  (213,219).	   	  Twenty-­‐four	  
toxinotypes	  have	  been	  established	   (I-­‐XXIV,	  with	   the	   reference	  strain	  VPI	  10463	  designated	  as	  
toxinotype	  0)	  by	  differences	  in	  the	  PaLoc	  coding	  and	  non-­‐coding	  sequence	  (220).	  	  Variations	  in	  
the	  gene,	  promoter,	  or	  terminator	  sequence	  of	  the	  virulence	  factors	  are	  common	  and	  impact	  
the	  protein	  product	  and	   therefore	   influence	  clinical	  virulence	  via	   toxin	   truncations,	  deletions,	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mutations,	  antibody	  reactivity,	  and	  intracellular	  substrates.	  	  Mutations	  are	  detected	  by	  RFLPs	  of	  
the	   PCR	   fragments,	   and	   data	   collected	   thus	   far	   suggest	   tcdB	   is	   more	   variant,	   tcdA	   is	   more	  
conserved,	  and	  mutations	  are	  most	  likely	  to	  occur	  in	  the	  catalytic	  region	  of	  the	  protein	  toxins	  
(220).	   	   Variation	   in	   the	   other	   three	   genes	   of	   the	   PaLoc,	   tcdC,	   tcdR,	   and	   tcdE,	   can	   also	   be	  
identified	   by	   this	  method	   and	   typed	   accordingly.	   All	   strains	   classified	   by	   a	   single	   toxinotype	  
produce	  the	  same	  toxins,	  variations	  of	  TcdA+/-­‐,	  TcdB+/-­‐,	  and	  CDT+/-­‐,	  with	  a	  few	  exceptions.	  Some	  
toxinotypes	   are	   more	   common	   than	   others	   (III,	   IV,	   V,	   VIII,	   IX,	   and	   XII),	   and	   only	   two	   are	  
identified	   in	   strains	  worldwide	   (VIII	   and	   IIIb,	   of	   the	   BI/NAPI/027	   strain	   discussed	   in	   the	   next	  
section),	   but	   a	   given	   group	   does	   not	   correlate	   with	   population	   nor	   disease	   severity.	   	   For	  
example,	  toxinotype	  VIII	  strains	  were	  first	   isolated	  from	  asymptomatic	  neonates	  and	  children,	  
and	  found	  to	  be	  nonvirulent	  when	  investigated	  in	  a	  hamster	  model	  (221),	  yet	  seven	  years	  later	  
severe	   psuedomembranous	   colitis	   outbreaks	  were	   reported	   and	   identified	   as	   toxinotype	   VIII	  
(222-­‐224).	   	   Nonetheless,	   toxinotyping	   is	   helpful	   in	   recording	   the	   genetic	   evolution	   and	  
continuing	  to	  define	  the	  relationship	  between	  pathogenesis	  and	  variations	  in	  the	  coding	  region	  
of	  virulence	  factors.	  
Multiple-­‐locus	  variable	  number	  tandem	  repeat	  analysis	  
The	   automated	   technique	   multiple-­‐locus	   variable	   number	   tandem	   repeats	   analysis	  
(MLVA)	   is	   used	   to	   find	   short	   tandem	   repeats,	   in	   several	   regions	   of	   the	   genome.	   Capillary	  
electrophoresis	   is	   used	   to	   separate	   the	   PCR	   products	   after	  multicolored	   primers	   are	   used	   to	  
label	   individual	   reactions,	   allowing	   multiple	   amplifications	   to	   be	   carried	   out	   in	   one	   tube	  
(203,225).	   	   Although	   still	   a	   relatively	   new	   method,	   it	   can	   discriminate	   between	   isolates	   of	  
different	  PCR	  ribotype	  groups,	  and	  requires	  relatively	  simple	  sample	  preparation	  and	  definitive	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analysis.	   	   A	   similar	   technique	   that	   is	   gaining	   strength	   as	   a	   dependable	   typing	   method	   is	  
multilocus	  sequence	  typing	  analysis	  (MLST)	  and	  is	  described	  elsewhere	  (205,226).	  	  	  	  
Serotyping	  and	  phage	  typing	  
Serotyping	  C.	  difficile	  strains	  is	  done	  by	  a	  slide	  agglutination	  method	  using	  the	  antisera	  
of	   immunized	  animals,	  historically	  rabbit	  antisera	  was	  used	  (227).	   	  Diluted	  antiserum	  is	  mixed	  
with	   Formol-­‐treated	   isolates	   on	   a	   slide.	   	   After	   3	   minutes	   of	   gentle	   agitation	   the	   degree	   of	  
clumping	  is	  graded,	  and	  isolates	  are	  grouped	  by	  a	  letter	  system.	  	  Phagetyping	  is	  used	  to	  classify	  
isolates	   based	   on	   bacteriophage	   susceptibility	   (208).	   	   Both	   methods,	   serotyping	   and	   phage	  
typing,	  are	  classic	  methods	  not	  often	  employed	  any	  longer.	  	  	  
2.3. Strains	  
Worldwide	   C.	   difficile	   infections	   are	   on	   the	   rise	   and	   researchers	   are	   determined	   to	  
understand	   why.	   	   Clearly,	   variation	   in	   any	   of	   the	   virulence	   factors,	   transcription	   regulation	  
factors,	   antibiotic	   resistance	  elements,	  or	   genes	   involved	   in	  proliferation	  play	  a	  major	   role	   in	  
host	  virulence	  and	  bacterium	  survival.	   	  The	  genome	  of	  C.	  difficile	   is	  highly	  dynamic	  with	   large	  
regions	   of	  mobile	   genetic	   elements,	   arising	   from	  horizontal	   gene	   transfer,	   and	   high	   levels	   of	  
recombination.	  	  Strains	  630	  and	  027	  have	  been	  given	  the	  most	  attention	  in	  recent	  sequencing	  
studies	  and	  genome	  comparisons.	  	  
The	  complete	  genome	  of	  C.	  difficile	  strain	  630	  was	  determined	  in	  2005	  (202).	  	  Isolated	  in	  
1982	  during	  an	  outbreak	   in	  Switzerland,	   sequencing	  data	   reveal	   that	   strain	  630	  bears	  an	  A/T	  
rich	  (~70%),	  circular	  chromosome	  containing	  ~4.3	  million	  base	  pairs,	  and	  a	  plasmid	  that	   is	  ~	  8	  
kb.	  	  Many	  conjugative	  transposons	  and	  other	  mobile	  elements	  were	  identified	  constituting	  11%	  
of	   the	   entire	   genome.	   	   This	   strain	   is	   highly	   virulent	   and	  multidrug	   resistant.	   	   Increased	   drug	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resistance,	  virulence	  and	  disease	  severity	   is	  observed	   in	  PCR	  ribotype	  027	  strains,	  which	  have	  
become	  prevalent	  in	  recent	  and	  current	  epidemics.	  
C.	   difficile	   strain	   of	   the	   PCR	   ribotype	   027	  was	   first	   recorded	   in	   1985,	   isolated	   from	   a	  
patient	  with	  CDI	   in	  Paris	   (228).	   	   This	   strain,	  CD196,	   is	  not	   associated	  with	  epidemics	  and	  has	  
notable	  differences	   from	  the	  630	  strain	  and	  the	  epidemic	  027	  strains	  currently	  being	   isolated	  
from	  outbreaks	  worldwide.	   	   To	  date,	  at	   least	   twenty	  027	   strains	  have	  been	   isolate	   (229)	  and	  
characterized	  by	  strain	  typing	  tests	  and	  classified	  as	  REA	  type	  BI,	  PFGE	  NAP1	  (North	  American	  
pulsotype	  1),	  toxinotype	  IIIb	  or	  VIII,	  and	  indistinguishable	  by	  MLSA.	  	  	  
Compared	   to	   630,	   the	   027	   isolates	   have	   234	   additional	   genes,	   increased	   mobility,	  
antibiotic	   resistance,	   and	   toxicity	   (229).	   	   An	   epidemic	  NAP1/027	   strain	   has	   been	   reported	   to	  
sporulate	  more	  readily,	  suggested	  to	  be	  the	  reason	  for	   increasing	  rates	  of	  transmission	  (230).	  
This	  proposal	  was	   later	  contested	  by	  a	  report	  of	  027	   isolates	  that	  produce	  fewer	  spores	  than	  
non-­‐027	  strains	  (231).	  	  	  
The	  mode	  of	  hypervirulence	  is	  still	  under	  debate.	  	  The	  increased	  prevalence	  of	  C.	  difficile	  
binary	   toxin	   (section	   2.5.3)	   is	   of	   interest	   since	   it	   has	   also	   been	   linked	   to	   an	   increase	   in	   CDI	  
severity	  (232,233).	  	  One	  study	  reported	  that	  41%	  of	  027	  strains	  examined	  contained	  the	  binary	  
toxin,	   compared	   to	   the	   native	   abundance	   of	   <9%	   (234,235).	   	   The	   role	   of	   binary	   toxin	   during	  
infection	   is	   not	   well	   understood.	   	   Although	   it	   has	   been	   proposed	   to	   affect	   disease	   severity,	  
binary	  toxin	  alone	  is	  not	  sufficient	  for	  infection	  (236).	  	  	  
The	  main	   virulence	   factors,	   TcdA	   and	   TcdB,	   are	   also	   altered	   in	   027	   strains.	   	   	   Unique	  
hybridization	  patterns	  detected	  an	  altered	  tcdB	  sequence	  compared	  to	  non-­‐027	  strains	  (237);	  in	  
addition	   this	   strain	   produces	   higher	   concentrations	   of	   TcdA	   and	   TcdB,	   offering	   a	   possible	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explanation	   for	   increased	   virulence	   (238).	   	   Increased	   toxin	   production	   was	   attributed	   to	   a	  
frameshift	  in	  tcdC,	  resulting	  in	  a	  truncation	  (239,240),	  but	  dismissed	  by	  reports	  that	  hypertoxin	  
production	  is	  observed	  in	  isolates	  void	  of	  any	  tcdC	  mutations	  (241).	  	  Most	  recently	  a	  report	  by	  
Sirard	  et.	  al.	  provides	  data	  that	  suggests	  that,	  although	  027	  isolates	  produce	  more	  toxins	  than	  
other	  strains,	  there	  is	  not	  an	  association	  with	  increased	  disease	  severity	  nor	  CDI	  related	  deaths	  
(231).	  	  This	  suggestion	  was	  refuted	  by	  a	  report	  in	  the	  same	  year	  by	  Carter	  et	  al.	  (242).	  
2.4. Animal	  models	  for	  CDI	  investigations	  
Animal	  model	  systems	  contribute	  to	  the	  understanding	  of	  disease	  and	  have	  been	  very	  
useful	   in	  TcdA	  and	  TcdB	  characterization.	   	   It	   is	  most	  desirable	  that	  pathogenicity	   in	  an	  animal	  
model	   mimics	   C.	   difficile	   infection	   in	   humans.	   	   Several	   animals	   have	   been	   assessed	   as	   CDI	  
infection	   models,	   including	   hamsters,	   guinea	   pigs,	   rabbits,	   piglets,	   germfree	   mice,	   and	   rats	  
(243-­‐251).	  	  	  
Hamsters	   have	   been	   a	   successful	   model	   used	   since	   the	   late	   1970s	   when	   it	   was	   first	  
reported	  that	  antibiotic	  treatment	  produced	  high	  amounts	  of	  toxigenic	  C.	  difficile	  excretes	  and	  
enterocolitis-­‐induced	  death	   (252).	   	  We	  now	  know	  disease	   in	  hamsters	   can	  be	  provoked	  by	   a	  
variety	  of	  antibiotics,	  causing	  localized	  intestinal	  damage	  and	  diarrhea	  which	  is	  rapidly	  followed	  
by	  severe	  enterocolitis	  and	  death.	  	  The	  finding	  that	  infant	  hamsters	  are	  insensitive	  to	  C.	  difficile	  
infection,	   a	   phenomenon	   also	   observed	   in	   human	   infants,	   has	   never	   been	   well	   understood	  
(253).	   	  One	   concern	   brought	   forth	   by	   the	   hamster	  model	   is	   the	   observation	   of	   lung	   damage	  
(254),	   which	   is	   not	   observed	   during	   human	   infection.	   Another	   is	   the	   rapid	   onset	   of	   death,	  
indicating	   higher	   sensitivity	   in	   hamsters.	   However,	   the	   overall	   similarity	   of	   the	   hamster	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infection	  route	  to	  humans	  has	  led	  to	  extensive	  use	  of	  the	  hamster	  model,	  which	  is	  currently	  still	  
used	  as	  a	  popular	  model	  for	  CDI	  (252,255,256).	  
Swine	  are	  naturally	   susceptible	   to	  CDI	  so	   it	  makes	  sense	   that	  a	  piglet	  model	  has	  been	  
found	   to	   mimic	   many	   of	   the	   characteristics	   observed	   in	   human	   CDI	   (257).	   	   Following	   oral	  
challenge	  with	  infectious	  strains	  of	  C.	  difficile	  isolated	  from	  human	  infections,	  the	  piglet	  models	  
have	  been	  reported	  to	  discriminate	  between	  acute	  fatal	  and	  chronic	  infection.	  In	  addition,	  toxin	  
excretion,	   and	   elevated	   levels	   of	   serum	   interleukin	   8	   (IL-­‐8)	   are	   consistently	   observed,	   and	  
portray	  human	  infection	  characteristics.	  
In	  mid-­‐2011,	  a	  new	  mouse	  model	   for	  C.	  difficile	   infection	  was	  described	  (258).	   	  This	   is	  
the	   first	   reported	   relapse	   model	   for	   CDI,	   and	   more	   closely	   resembles	   human	   infection	   and	  
symptoms	  than	  the	  hamster	  (258).	   	  C57BL/6	  mice	  that	  survive	  and	  recover	  from	  an	  initial	  CDI	  
episode,	   induced	   by	   spore	   inoculation	   under	   antibiotic	   therapy,	   undergo	   relapse	   during	   a	  
second	   antibiotic	   treatment,	   or	   reinfection	   when	   re-­‐challenged	   with	   spores	   under	   antibiotic	  
therapy,	   30	   days	   later.	   	   This	   observed	   relapse	   and	   reinfection	   is	   a	   major	   challenge	   when	  
treating	   CDI	   in	   humans	   and	   the	   model	   system	   will	   aid	   in	   a	   further	   understanding.	   	   The	  
similarities	  between	  animal	  models	  and	  human	  CDI	  demonstrate	  that	  they	  are	  suitable	  systems	  
to	  study	  CDI	  and	  investigate	  novel	  treatments.	  
2.5. Virulence	  factors	  
2.5.1. History	  and	  identification	  
Early	   investigations,	   before	   1980,	   alleged	   that	   C.	   difficile	   cytotoxicity	   was	   the	  
consequence	  of	  one	  enterotoxin,	   called	   cytotoxic	   factor	   (252,255,259).	   Soon	  after,	   there	  was	  
evidence	  of	  at	   least	   two	  distinct	   toxins	  when	  a	   report	  described	  separation	  of	  cytotoxicity	  by	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anion-­‐exchange	  chromatography	  (260).	   	  The	  two	  toxins	  were	  referred	  to	  as	  toxin	  A	  (TcdA),	  an	  
enterotoxin	  characterized	  by	  fluid	  response	  in	  animal	  ileal	  loop	  models,	  and	  toxin	  B	  (TcdB),	  the	  
cytotoxin	  detected	  in	  fecal	  samples.	  Designation	  of	  A	  and	  B	  originated	  from	  the	  elution	  pattern	  
of	   the	   toxins	   from	  anion-­‐exchange	   resin,	   earlier	   elution	  of	   TcdA	   indicates	   it	   binds	   less	   tightly	  
than	  TcdB.	  	  Subsequent	  analysis	  of	  the	  protein	  toxins	  discovered	  a	  high	  degree	  of	  similarity	  to	  
other	  large	  protein	  toxins	  from	  various	  Clostridia	  species.	  	  Further	  use	  of	  the	  cyto-­‐	  and	  exotoxin	  
terminology	  comes	  from	  the	  similarity	  between	  TcdB	  and	  the	  cytotoxic	  lethal	  toxin	  (TcsL)	  from	  
C.	   sordellii,	   early	   observations	   of	   antiserum	   cross-­‐reactivity,	   more	   recent	   sequence	   analysis	  
(85%	   homology	   and	   74%	   identity),	   and	   the	   suggestion	   that	   TcdA	   is	   most	   similar	   to	   the	  
enterotoxic	   hemorrhagic	   toxin	   (TcsH)	   produced	   by	   C.	   sordellii;	   sequence	   of	   TcsH	   is	   not	   yet	  
known	  (261,262).	  	  	  
Both	  toxins	  are	  cytotoxic	  to	  most	  cultured	  mammalian	  cells,	  however,	  TcdB	  is	  commonly	  
recognized	   to	   be	   about	   1000-­‐fold	   more	   potent	   than	   TcdA	   (263-­‐265).	   	   The	   toxins	   activate	  
proinflammatory	   and	   immunogenic	   responses	   (266-­‐268).	   	   Although	   TcdA	   was	   clearly	  
identifiable	  as	  an	  enterotoxin	  (269,270),	  TcdB	  was	  initially	  reported	  to	  be	  a	  cytotoxin,	  without	  
enterotoxic	   activity	   in	   animal	   models	   (254,271).	   	   Both	   toxins	   are	   now	   recognized	   as	  
enterotoxins	   after	   studies	   demonstrated	   that	   TcdB	  has	   enterotoxic	   activities,	   as	   do	   TcdA-­‐/B+	  
clinical	  isolates	  that	  cause	  disease	  (266,272,273).	  
Variant	   C.	   difficile	   isolates	   produce	   several	   combinations	   of	   virulence	   factors	   that	  
determine	   pathogenicity.	   	   The	   two	   main	   virulence	   factors,	   TcdA/B,	   have	   been	   well	  
characterized	   in	   terms	  of	   cell	   intoxication,	  while	  understanding	   specific	   roles	  during	   infection	  
require	  further	  insight.	  	  The	  roles	  of	  other	  virulence	  factors	  are	  less	  understood.	  	  Understanding	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these	   proteins	   and	   the	   involvement	   they	   have	   in	   human	   infection	   is	   necessary	   to	   improve	  
strategies	  for	  treating	  and	  preventing	  CDI.	  
2.5.2. Toxins	  A	  and	  B	  
TcdA/B	  are	  in	  a	  family	  with	  other	  large	  Clostridial	  toxins	  (LCT),	  collectively	  refered	  to	  as	  
the	  Clostridial	  glucosylating	  toxin	   family.	   	  Family	  members	   include	  TcsL,	  TcsH,	  and	  Clostridium	  
novyi	  alpha	  toxin	  (Tcnα)	  (274).	   	  The	  LCTs	  are	   large	  single	  chain	  proteins	  ranging	  from	  250-­‐308	  
kD;	   they	   share	  homology,	   undergo	   the	   same	   route	  of	   cell	   entry,	   and	   catalyze	   the	   transfer	  of	  
glucose	  from	  UDP-­‐glucose	  to	  Rho	  and	  Ras	  GTPases.	  TcsL	  and	  Tcnα	  cause	  the	  potentially	  deadly	  
gas	  gangrene	  infection	  in	  humans,	  whereas	  TcdA/B	  are	  the	  causative	  agents	  of	  CDI.	  	  TcdA/B	  are	  
of	   the	   highest	   clinical	   relevance	   and	   are	  well	   defined	   compared	   to	   the	   rest	   of	   the	   LCTs	   as	   a	  
result	  of	  their	  role	  in	  the	  growing	  epidemic	  of	  CDI.	  	  	  
PaLoc	  
A	  conserved	   chromosomal	   region,	   the	  pathogenicity	   locus	   (PaLoc),	   includes	   the	   genes	  
for	  toxins	  A,	  toxin	  B	  and	  three	  accessory	  proteins,	  tcdR,	  tcdC,	  and	  tcdE	  (Figure	  2.2)	  (275).	  	  Two	  
of	  the	  accessory	  proteins,	  tcdR	  and	  tcdC,	  regulate	  toxin	  expression.	  	  tcdR	  encodes	  an	  alternative	  
RNA	  polymerase	  sigma	  factor	  that	  is	  required	  for	  toxin	  synthesis	  (276),	  while	  tcdC	  codes	  for	  an	  
anti-­‐sigma	  factor	  that	  negatively	  regulates	  the	  expression	  of	  toxin	  genes	  (242,277).	  	  	  High	  levels	  
of	   tcdC	   and	   low	   levels	   of	   tcdA,	   tcdB,	   and	   tcdR	   transcription	   are	   observed	   during	   early	  
logarithmic	   phase,	   whereas	   low	   levels	   of	   tcdC	   and	   high	   levels	   of	   tcdA,	   tcdB,	   and	   tcdR	  
transcription	  are	   identified	   in	   stationary	  phase	   (277).	   	  A	  deletion	   in	   tcdC	  was	  discovered	   in	  a	  
hypervirulant	  strain,	  and	  predicted	  to	  be	  responsible	  for	  increased	  toxin	  production	  and	  disease	  
severity;	   discussed	   in	   greater	   detail	   in	   section	   2.3.	   	   Furthermore,	   TcdC	   is	   a	   membrane-­‐
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associated	  protein	  (278);	  	  tcdE	  codes	  for	  a	  holin	  protein	  homologue,	  suggested	  to	  help	  facilitate	  
the	  secretion	  of	  TcdA	  and	  TcdB	  (279).	  	  Additional	  studies	  are	  underway	  to	  further	  examine	  the	  
role	  of	  the	  accessory	  proteins	  in	  toxin	  regulation.	  	  	  
TcdA	  (308	  kD)	  and	  TcdB	  (270	  kD)	  share	  high	  sequence	  homology	  (63%),	  cross-­‐reactivity	  
of	  some	  monoclonal	  antibodies,	  and	  similar	  structures	  harboring	  multiple	  functional	  domains,	  
yet	  polyclonal	  antiserum	  is	  toxin	  specific	  (181).	   	  Because	  of	  the	  high	  degree	  of	  similarity,	  tcdA	  
and	   tcdB	   genes	   are	   predicted	   to	   have	   evolved	   by	   gene	   duplication,	   with	   subsequent	  
differentiation.	   These	  multifunctional	   proteins	   include	   a	   C-­‐terminal	   receptor	   binding	   domain	  
(RBD),	  translocation	  domain,	  cysteine	  protease	  domain	  (CPD),	  glucosyltransferase	  domain,	  and	  
a	   membrane	   localization	   domain	   (MLD).	   	   Due	   to	   the	   large	   size	   of	   the	   each	   holotoxin,	   the	  
structures	  have	  not	  successfully	  been	  determined	  in	  high	  resolution,	  however	  lower	  resolution	  
techniques	  have	  provided	  insights	  and	  overall	  structure	  information	  (280,281).	  	  High-­‐resolution	  
	  
Figure	   2.2.	  C.	   difficile	  PaLoc.	   Two	   toxins	   and	   three	   regulatory	   proteins	   are	   encoded	   in	   the	  
19.6	  kb	  C.	  difficile	  pathogenicity	  locus.	  	  TcdA	  and	  TcdB	  are	  the	  main	  virulence	  factors,	  TcdR	  is	  




crystal	   structures	   have	   been	   solved	   for	   the	   CPD,	   the	   glucosyltransferase	   domain,	   and	   a	  
truncated	  RBD	  (Figure	  2.4)	  	  (190,282,283).	  	  
Receptor	  binding	  domain	  
The	  receptor	  binding	  domain	  (RBD)	  is	  at	  the	  C-­‐terminus	  (amino	  acids	  1851-­‐2366	  in	  TcdB)	  
and	  is	  composed	  of	  combined	  repetitive	  oligopeptides	  (CROPs)	  (284,285).	  	  The	  highest	  degree	  
of	   sequence	   variation	   between	   TcdA	   and	   TcdB	   is	  within	   this	   region	   of	   the	   protein.	   	   The	   full-­‐
length	   RBD	   was	   modeled	   from	   the	   crystal	   structure	   of	   a	   C-­‐terminal	   truncation	   of	   TcdA	  
(282,286),	   revealing	   a	   β-­‐solenoid	   fold	   composed	   of	   30	   or	   38	   repeats,	   depending	   on	   the	  
modeling	  approach	  used	  in	  the	  analysis.	  	  In	  contrast,	  the	  much	  shorter	  TcdB	  RBD	  contains	  19	  or	  
24	  repeats	  (282,286).	  	  Each	  CROP	  repeat	  consists	  of	  a	  β-­‐hairpin	  followed	  by	  a	  loop	  arising	  from	  
a	   section	  of	   short	   repeats	   (SR)	   creating	   a	   left-­‐handed	  120°	   axis,	  which	   is	   interrupted	  by	   long	  
repeats	  (LR)	  introducing	  kinks	  in	  the	  structure.	  	  	  Low-­‐resolution	  structural	  data	  from	  SAXS	  and	  
electron	  microscopy	  are	  consistent	  with	   the	  models	   (280,281).	   	   Each	  kink	   introduced	  by	  a	   LR	  
produces	  a	  shallow	  carbohydrate-­‐binding	  pocket.	  	  Seven	  binding	  sites	  are	  predicted	  in	  TcdA	  and	  
four	  in	  TcdB,	  probably	  the	  source	  of	  differences	  in	  receptor	  specificity	  that	  is	  observed.	  
Investigations	  to	   identify	  toxin	  receptors	  began	  with	  animal	  model	  studies	  using	  TcdA,	  
since,	   at	   the	   time,	   toxin	   A	   was	   the	   only	   identified	   enterotoxin.	   	   Krivan	   et	   al.	   reported	   that	  
binding	  was	  not	  destroyed	  by	  heat,	  and	  therefore	  carbohydrate	  moieties	  were	  involved	  (184).	  	  
Additional	   examinations	   found	   that	   alpha-­‐galactosidase	   treatment	   of	   membranes	   destroyed	  
binding	   and	   led	   to	   the	   identification	   of	   Galα1-­‐3Galβ1-­‐4GlcNAc	   as	   the	   TcdA	   receptor	   in	  
hamsters.	  	  This	  trisacharide	  is	  present	  on	  many	  animal	  cells,	  including	  rabbit	  and	  calf,	  however	  
normal	   human	   cells	   do	   not	   have	   functional	   α-­‐galactosyltransferase	   and	   can	   not	   form	   α-­‐
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galactosyl	  bonds	  (182).	   	  Since	  Galα1-­‐3Galβ1-­‐4GlcNAc	   is	  not	  the	  human	   intestinal	   receptor	   for	  
TcdA,	  further	  analyses	  focused	  on	  the	  disaccharide,	  Galβ1-­‐4GlcNAc,	  which	  is	  present	  in	  humans	  
(287-­‐289).	  	  In	  addidtion,	  human	  intestinal	  epithelium	  carbohydrates,	  designated	  Lewis	  I,	  X,	  and	  
Y	  glycans	  (182)	  and	  	  glycosphingolipids	  (290)	  have	  been	  suggested	  as	  TcdA	  ligands.	  	  ES-­‐MS	  data	  
by	   Dingle	   et	   al.	   indicated	   that	   TcdA	   is	   a	   promiscuous	   glycan	   binder	   and	   can	   tolerate	   a	   high	  
	  
Figure	  2.3.	  	  Etiology	  of	  TcdA/B.	  After	  being	  exported	  from	  C.	  difficile,	  the	  CROP	  domain	  	  of	  the	  toxin	  
binds	  a	  receptor	  at	  the	  cell	  surface	  ,	  triggering	  endocytosis.	  	  The	  low	  pH	  of	  the	  endosome	  triggers	  a	  
conformational	   change	   in	   the	   translocation	   domain,	   insertion	   through	   the	   membrane	   and	  
translocation	   of	   the	   enzymatic,	   glucosyltransferase,	   domain.	   	   Cytosolic	   IP6	  binds	   a	   pocket	   on	   the	  
toxin,	   triggering	   an	   autocatalytic	   even	   to	   release	   the	   glucosyltransferase.	   	   Monoglucosylation	   of	  
target	  proteins,	  the	  family	  of	  small	  GTPases,	  effects	  downstream	  signaling	  leading	  to	  cell	  apoptosis. 
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degree	   of	   carbohydrate	   structural	   variation;	   this	   result	   concurs	   with	   previous	   findings	   of	  
multiple	   ligands.	   	   The	   receptor	   involved	   in	   TcdB	   cell	   binding	   is	   much	   less	   understood	  
(185,286,291).	  	  	  
The	  role	  of	  receptor	  binding	  in	  cytotoxicity	  is	  not	  clear.	  	  A	  previous	  report	  hypothesized	  
uptake	   of	   the	   toxins	   to	   be	   RBD-­‐independent	   (185);	   this	   hypothesis	   was	   recently	   confirmed	  
when	  C-­‐terminus-­‐deficient	  TcdA	  and	  TcdB	  constructs	  retained	  cytotoxic	  activity	  (186).	  	  Potency	  
of	   a	   truncated	   TcdA	   protein,	   without	   CROP	   repeats,	   was	   compared	   to	   the	   full-­‐length	   toxin.	  	  
Truncated	  TcdA	  exhibited	  a	  5-­‐10	  fold	  cytotoxicity	  decrease	  in	  3T3	  and	  HT29	  cell	   lines	  but	  was	  
comparable	   to	  wild	   type	   (WT)	   in	   CHO-­‐C6	   cells.	   	   The	   truncated	   and	   full-­‐length	   TcdB	   proteins	  
displayed	  identical	  cytotoxic	  activities.	  	  These	  findings	  refute	  other	  reports	  that	  the	  C-­‐terminus	  
of	   TcdA	   is	   absolutely	   necessary	   for	   cytotoxic	   effects;	   and,	   immunization	   using	   recombinant	  
CROPs	  has	  been	  successful	  in	  a	  mouse	  (292)	  and	  hamster	  model	  of	  infection	  (256).	  	  The	  RBD	  is	  
still	   under	   investigation	   to	   decipher	   its	   importance	   in	   human	   infection	   to	   provide	   a	   possible	  
target	  to	  block	  cell	  binding	  as	  a	  treatment	  of	  CDI	  (185,256).	  	  	  
Translocation	  domain	  
The	  translocation	  domain	  (amino	  acids	  807-­‐1851	  in	  TcdB)	   is	  situated	  N-­‐terminal	  of	  the	  
RBD,	  and	  is	  the	  least	  well-­‐defined	  and	  least	  understood	  domain	  in	  the	  toxin.	  	  At	  neutral	  pH,	  the	  
structure	  is	  globular	  (280,281).	  It	  is	  believed	  to	  undergo	  a	  conformational	  change	  at	  low	  pH,	  in	  
the	  presence	  of	  a	  lipid	  bilayer,	  cholesterol-­‐dependent	  membrane	  insertion,	  and	  pore	  formation	  
(293-­‐295).	   	   Probing	   the	   sequence	   requirements	   for	   toxin	   translocation	   through	  mutagenesis	  
resulted	  in	  the	  identification	  of	  a	  region	  (amino	  acids	  1501-­‐1753	  of	  TcdB)	  that	   is	  not	  required	  
for	   cytotoxicity.	   Additionally,	   a	  minimal	   pore-­‐forming	   region	   (amino	   acids	   830-­‐990)	   was	   also	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defined.	   	   Two	   aspartates	   (D970	   and	   D976)	   play	   a	   crucial	   role	   in	   pore-­‐formation	   (187).	  	  
Additional	   investigations	   are	   necessary	   to	   understand	   pore-­‐formation	   and	   the	  mechanism	  of	  
translocation	  responsible	  for	  delivery	  of	  the	  N-­‐terminus	  across	  the	  membrane.	  
Cysteine	  protease	  domain	  
A	   CPD	  was	   recently	   identified	   at	   the	   N-­‐terminus	   of	   the	   translocation	   domain	   (amino	  
acids	  544-­‐801	  of	  TcdB)	  (7,129).	  	  This	  domain	  is	  translocated	  across	  the	  endosomal	  membrane,	  
along	  with	  the	  N-­‐terminal	  enzymatic	  domain,	  and	  is	  activated	  by	  the	  binding	  of	  cytosolic	  myo-­‐
inositol	   hexakisphosphate	   (IP6).	   	   Crystal	   structure	   data	   indicate	   that	   binding	   of	   a	   positively	  
charged	   IP6	   molecule	   to	   a	   highly	   basic	   pocket	   results	   in	   a	   conformational	   change	   and	  
rearrangement	  of	   a	   β-­‐flap	   to	   expose	   the	   active	   site	   of	   the	  CPD.	   	   Active	   site	   residues	   	   (D587,	  
H653,	  and	  C698	  of	  TcdB)	  mediate	  the	  auto-­‐proteolysis	  between	  L543	  and	  G544	  (TcdB	  residue	  
numbering)	  to	  release	  the	  glucosyltranferase	  into	  the	  cytosol	  (190,296).	  	   	  Additionally,	  studies	  
have	  focused	  on	  targeting	  the	  CPD	  as	  a	  means	  of	  inactivating	  cytotoxicity	  (297,298).	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Figure	  2.4.	  	  Functional	  domains	  of	  TcdA/B.	  The	  solved	  crystal	  structures	  are	  shown	  for	  the	  MLD,	  GT,	  
and	   CPD.	   	   Lack	   of	   structural	   data	   for	   the	   TD	   implies	   an	   unorganized	   domain.	   	   A	   truncated	   CROP	  
domain	   was	   co-­‐crystallized	   with	  alpha-­‐Gal-­‐(1,3)-­‐beta-­‐Gal-­‐(1,4)-­‐beta-­‐GlcNAcO(CH(2))(8)CO(2)CH(3)	  
(black)	  (top)	  and	  used	  to	  model	  the	  entire	  domain	  (bottom).	  	  Membrane	  localization	  domain	  (MLD,	  
grey),	  glucosyltransferase	  (GT,	  red),	  cysteine	  protease	  domain	  (CPD,	  blue),	  translocation	  domain	  (TD,	  
orange),	   and	   combined	   repetitive	   oligopeptide	   receptor	   binding	   domain	   (CROP,	   green).	   Residue	  




After	  CPD	  catalyzed	  proteolysis,	   the	  N-­‐terminal	  GT	  domain	   (residues	  1-­‐544	  of	  TcdB)	   is	  
released	  (188,189)	  into	  the	  cytosol	  (299).	  	  The	  C.	  difficile	  glucosylating	  toxins	  transfer	  glucose,	  
from	   UDP-­‐glucose,	   to	   small	   GTPase	   signaling	   proteins	   with	   retention	   of	   the	   α-­‐anomeric	  
configuration.	  	  Crystal	  structures	  of	  the	  GT	  domains	  of	  TcdB,	  TcsL,	  and	  Tcnα	  have	  been	  solved	  
(283,300).	   	   Structurally	   they	   are	   very	   similar,	   organized	   in	   a	   conserved	   type-­‐A-­‐
glycosyltransferase	  fold	  with	  the	  catalytic	  motif,	  D286-­‐x-­‐D288	  (TcdB	  residue	  numbering),	  in	  the	  
substrate	  binding	  pocket.	  	  Analysis	  of	  active	  site	  residues,	  with	  co-­‐crystallized	  substrates	  in	  the	  
binding	  pocket,	  has	  provided	  evidence	  of	  a	  novel	  glucosyltransfer	  mechanism.	  The	  absence	  of	  a	  
carboxylate	   in	   close	   proximity	   to	   the	   reaction	   site,	   which	   would	   be	   necessary	   to	   stabilize	   a	  
carboxonium	  intermediate,	  led	  to	  the	  proposal	  that	  CGTs	  catalyze	  the	  reaction	  through	  a	  novel	  
mechanism	   without	   direct	   involvement	   of	   enzyme	   residues.	   	   The	   suggested	   scheme	   is	  
presented	  in	  Figure	  2.5,	  showing	  a	  circular	  electron	  transfer,	  predicted	  to	  start	  with	  glycosidic	  
bond	  cleavage.	   	  One	  of	  the	  β-­‐phosphoryl	  oxygen	  atoms	  is	  predicted	  to	  act	  as	  the	  base.	   	  Toxin	  
residues	  are	  important	  for	  positioning	  substrates	  in	  the	  correct	  orientation	  for	  catalysis,	  such	  as	  
the	  stacking	   interaction	  of	  uracil	  with	  TcdBW102,	  and	  Mn2+	  stabilization	  by	  TcdBD288	   and	  D286,	  but	  




Membrane	  localization	  domain	  
A	   membrane	   localization	   domain	   (MLD,	   amino	   acids	   1-­‐83	   of	   TcdB),	   was	   recently	  
identified	   after	   analysis	   and	   characterization	   of	   a	   domain	   with	   a	   high	   degree	   of	   sequence	  
conservation	   shared	   by	   a	   number	   of	   bacterial	   protein	   toxins	   (301).	   The	  MLD	   is	   suggested	   to	  
target	   the	   enzymatic	   domain	   of	   protein	   toxins	   with	   membrane	   associated	   substrates	   within	  
close	  proximity	  of	  their	  targets.	  	  For	  TcdA/B,	  substrates	  are	  members	  of	  the	  Rho	  family	  of	  small	  
GTPases.	   	   The	   Rho	   GTPases	   are	   signaling	   proteins	   that	   regulate	   intracellular	   actin	   dynamics,	  
affecting	   important	   cellular	   functions	   such	   as	   cell	   proliferation,	   apoptosis,	   and	   actin	  
	  
Figure	  2.5.	  	  Catalytic	  active	  site	  and	  proposed	  mechanism	  for	  C.	  difficile	  GT	  domain.	  	  Residues	  
involved	   in	   UDP-­‐glucose	   orientation	   (blue),	   the	   serine	   residue	   of	   the	   substrate	   (red),	   and	  
proposed	   electron	  movement	   of	   the	  GT	   reaction	   (magenta	   arrows).	   	   Pi-­‐stacking	   (between	  
W102	  and	  uracil)	  and	  H-­‐bonds	  within	  the	  active	  site	  are	  indicated	  by	  dashed	  lines. 
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polymerization	   necessary	   for	   structural	   support	   for	   the	   cell.	   	   Specifically,	   substrates	   include	  
Rho,	  Rac,	  and	  Cdc42,	  which	  are	  inactivated	  by	  O-­‐linked	  glucosylation	  catalyzed	  by	  TcdA/B	  from	  
intracellular	  UDP-­‐glucose.	  	  Inactivation	  of	  these	  molecular	  switch	  proteins	  affects	  downstream	  
regulation	  and	  causes	  actin	  depolymerization,	  cell	  rounding,	  and	  apoptosis.	  	  	  
2.5.3. Binary	  toxin	  
A	  third	  toxin,	  the	  CDT	  binary	  toxin,	  is	  found	  in	  some	  strains	  of	  C.	  difficile,	   including	  the	  
strains	  implicated	  in	  the	  current	  worldwide	  epidemic.	  	  CDT	  is	  encoded	  by	  two	  genes,	  cdtA	  and	  
cdtB,	   on	   a	   region	   of	   the	   chromosome	   separate	   from	   the	   PaLoc,	   called	   the	   CdtLoc	   (302).	   	   A	  
regulatory	   gene,	  cdtR,	   is	   also	  encoded	   in	   this	   region.	   The	  binary	   toxin	   is	   found	   in	  <10%	  of	  C.	  
difficile	  isolates	  (236),	  however	  the	  genes	  are	  present	  more	  often	  in	  severe	  CDI	  infections.	  	  One	  
study,	  comparing	  a	  collection	  of	   Italian	  C.	  difficile	   isolates	  over	  time,	  reported	  a	  rise	   in	  binary	  
toxin-­‐positive	   strains	   (303).	   	   Before	   1990,	   binary	   toxin	   was	   not	   identified	   in	   clinical	   isolates,	  
between	  1991	  and	  1999	  there	  was	  a	  24%	  increase	  in	  prevalence,	  and	  between	  2000	  and	  2001	  
45%	   of	   strains	   examined	   were	   positive	   for	   binary	   toxin.	   	   The	   role	   of	   binary	   toxin	   has	   been	  
investigated	   (236).	   	   The	   two	   separate	   proteins	   of	   CDT	   are	   CDTa,	   the	   enzymatic	   ADP-­‐
ribosyltransferase,	  and	  CDTb,	  the	  receptor	  binding	  and	  translocation	  domains.	  Toxin	  expression	  
is	  regulated	  by	  CdtR	  (302).	  	  Animal	  studies	  indicate	  that	  C.	  difficile	  strains	  that	  only	  produce	  CDT	  
(TcdA-­‐/	  TcdB-­‐)	  do	  not	  cause	  disease	  (236).	  	  However,	  it	  is	  theorized	  that	  CDT	  increases	  severity	  
of	  infection	  when	  present,	  possibly	  by	  interacting	  with	  other	  virulence	  factors.	  	  However,	  more	  






The	   most	   recently	   reported	   virulence	   factor,	   Srl,	   was	   identified	   in	   C.	   difficile	   culture	  
filtrates	  (304).	  	  Srl	  was	  previously	  an	  uncharacterized	  hypothetical	  protein	  product	  with	  a	  KDEL-­‐
like	   signaling	   sequence	  now	   identified	  as	  a	  protein	   that	   is	  able	   to	   trigger	  F-­‐actin	  aggregation,	  
termed	  actin	  aggregate,	  at	  the	  juxtanuclear	  region	  in	  cultured	  epithelial	  cells.	  	  Actin	  aggregation	  
is	  rarely	  observed	  after	  treatment	  with	  TcdA	  or	  TcdB,	  therefore	  Srl,	  which	  is	  not	  cytotoxic	  alone,	  
is	  suggested	  to	  enhance	  the	  cytotoxicity	  of	  TcdA/B	  and	  could	  possibly	  explain	  why	  TcdB	  is	  not	  
enterotoxic	   in	   ileal	   loops	  of	   animal	  models	  while	   TcdA-­‐/B+	   strains	  do	   cause	  disease	   in	   animal	  
models	  (305,306).	  	  	  	  
2.5.5. Putative	  virulence	  factors	  
Other	   putative	   virulence	   factors	   are	   not	   directly	   involved	   in	   toxicity	   or	   stimulating	   an	  
immune	  response,	  but	  are	  speculated	  to	  be	  important	  for	  the	  role	  they	  play	  in	  adherence	  and	  
intestinal	   colonization.	   	   These	   include	   the	   S-­‐layer	   proteins	   (SLPs)	   (307),	   a	   cell	   wall	   protein	  
(Cwp66)	   (308),	   a	   chaperone	   protein	   (GroEL,	   also	   called	   heat	   shock	   protein	   60)	   (309,310),	   a	  
fibronectin-­‐binding	  protein	  (Fbp68)	  (311),	  and	  two	  flagella	  proteins	  (FliC	  and	  FliD)	  (312).	  
2.6. CDI	  and	  healthcare	  challenges	  
2.6.1. Background	  	  
During	  a	  visit	  or	  stay	  at	  a	  hospital	  for	  an	  unrelated	  illness,	  patients	  on	  broad-­‐spectrum	  
antibiotic	  therapy	  are	  at	  high	  risk	  for	  nosocomial	   infection.	   	  Once	  contracted,	  these	  infections	  
are	  not	  only	  life	  threatening,	  but	  also	  have	  a	  huge	  impact	  on	  healthcare	  costs.	  	  A	  conservative	  
estimate	  in	  2002	  reported	  that	  the	  U.S.	  was	  spending	  more	  than	  $1.1	  billion/year	  prior	  to	  the	  
year	  2000	  (313,314),	  with	  current	  spending	  estimated	  to	  be	  $3.2	  billion/year	  due	  to	  C.	  difficile	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(315).	   	   Infected	   patients	   are	   prone	   to	   a	   range	   of	   complications	   and	   symptoms,	   and	   the	  
increasing	  prevalence	  of	  this	  disease	  is	  directly	  related	  to	  the	  rise	  of	  health	  care	  costs.	  	  
C.	  difficile	   is	  most	  often	  spread	  in	  healthcare	  settings,	  commonly	  hospitals	  and	  nursing	  
homes,	   to	   vulnerable	   people	   (Figure	   2.6).	   	   Although	   community-­‐acquired	   reports	   of	   CDI	   are	  
known,	  there	  are	  risk	  factors	  that	  make	  people	  most	  susceptible	  to	  C.	  difficile	   infections,	  such	  
as	  age,	  underlying	  health	  conditions,	  antibiotic	  use,	  and	  frequency	  in	  health	  care	  settings.	  	  The	  
risk	  of	  CDI	  is	  increased	  in	  people	  over	  65	  years	  old,	  and	  is	  further	  increased	  by	  hospitalization	  
for	  extended	  periods,	  or	  residence	  in	  a	  long-­‐term	  care	  facility,	  such	  as	  a	  nursing	  home.	  	  Specific	  
classes	   of	   antibiotics,	   such	   as	   fluoroquinolones,	   have	   been	   associated	  with	   higher	  C.	   difficile	  
infections	  (316),	  yet	  broad	  spectrum	  antibiotics	  are	  still	  a	  main	  concern.	  	  A	  weakened	  immune	  
system,	  underlying	  illness	  such	  as	  cancer	  or	  a	  colon	  disease,	  and	  previous	  episodes	  of	  C.	  difficile	  
infection	  can	  each	  be	  responsible	  for	  increased	  risk.	  	  It	  is	  important	  to	  be	  aware	  of	  factors	  that	  
increase	   the	   possibility	   of	   contracting	   the	   infection,	   however,	   once	   infected,	   patients	  
experience	  a	  wide	  range	  of	  symptoms.	  
2.6.2. Symptoms	  of	  CDI	  
The	  most	   common	   symptom	  of	  CDI	   is	   diarrhea	  and	   lower	   abdominal	   pain.	   	   Infections	  
may	  present	  as	  a	  mild	  case	  of	  watery	  stool,	  or	  become	  much	  worse	  if	  not	  properly	  treated	  in	  
early	   stages.	   	   Severe	   diarrhea	   can	   lead	   to	   dehydration	   from	   significant	   fluid	   loss	   causing	  
deterioration	  of	  kidney	   function.	   	   In	  addition,	  at	   the	  site	  of	   infection,	   toxins	  are	   released	  and	  
responsible	  for	  damage	  to	  the	  large	  intestinal	  lining.	  	  	  If	  severe	  infection	  persists,	  a	  hole	  in	  the	  
lining	   will	   develop	   and	   bacteria	   will	   move	   into	   the	   abdominal	   cavity	   resulting	   in	   a	   life	  
threatening	   infection	   called	   peritonitis.	   	   Another	   route	   of	   severe	   infection	   results	   in	   toxic	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megacolon,	   or	   a	   rupture	   of	   the	   colon,	   allowing	   bacteria	   to	   enter	   the	   abdominal	   cavity;	  
megacolon	  requires	  emergency	  surgery.	  	  All	  cases	  of	  CDI,	  from	  mild	  to	  severe,	  are	  estimated	  to	  
prolong	  hospital	  stays,	  and	  consequently	  cause	  increases	  in	  healthcare	  costs,	  which	  continue	  to	  
grow	  each	  year.	  	  
2.6.3. Costs	  of	  CDI	  infection,	  reinfection/relapse,	  and	  hypervirulent	  strains	  
Many	   studies	   have	   found	   CDI	   to	   double	   the	   average	   hospital	   bill	   per	   admission,	  with	  
relapse	   having	   even	   higher	   costs	   (317,318).	   	   C.	   difficile	   infections	   have	   a	   high	   relapse	   rate,	  
which	   is	  most	   likely	   caused	   by	   the	   reinoculation	   of	   spores	   present	   in	   the	   gut	   that	  were	   not	  
eradicated	  during	  previous	  antibiotic	  treatment,	  as	  discussed	  further	  in	  the	  next	  section	  (319).	  	  
Important	  to	  note	  here	   is	   that	  each	  cycle	  of	  relapse	   increases	  the	   likeliness	  of	   future	  relapse,	  
and	  therefore	  a	  continuous	  cycle	  of	  extremely	  high	  cost	  burden	  can	  arise	  due	  to	  this	  infection.	  	  
	  
Figure	  2.6.	  	  Pathway	  of	  CDI	  infection.	  	  Exposure	  to	  C.	  difficile	  spores	  (orange)	  in	  a	  healthcare	  
or	  community	  setting	  (blue)	  often	  lead	  to	  colonization	  and	  toxin	  release	  (pink),	  which	  cause	  
symptoms	  of	  CDI	  (red).	  	  Multiple	  risk	  factors	  increase	  the	  chance	  of	  colonization	  (yellow),	  and	  
immune	   response	   (green).	   	   High	   antibody	   titers	   have	   been	   observed	   to	   inhibit	   C.	   difficile	  
colonization	  or	  damage. 
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In	  addition	  to	  relapse	  rates,	  a	  hypervirulent	  strain	  has	  been	  spreading	  rapidly,	  worldwide	  over	  
the	  last	  ten	  years,	  increasing	  prevalence	  and	  severity.	  
The	   hypervirulent	   strain	  NAP1/BI/027	   first	   emerged	   in	   Canada,	   in	   2003,	   and	   has	   now	  
been	  observed	  worldwide	   including	   the	  UK,	   Europe,	   and	   the	  U.S.	   	   This	  NAP1/BI/027	   strain	   is	  
typically	  found	  to	  encode	  the	  genes	  for	  the	  CDT	  binary	  toxin	  and	  an	  altered	  tcdC	  repressor	  gene	  
that	   is	  assumed	  to	  play	  a	  role	   in	  expression	  of	   the	  main	  virulence	   factors.	   	  This	  hypervirulent	  
strain	   has	   been	   characterized	   by	   higher	   toxin	   production,	   enhanced	   disease	   severity,	   higher	  
rates	  of	  vancomycin	  and	  metronidazole	  resistance,	  and	  greater	  frequency	  of	  community	  onset	  
(314,320).	   	   To	   better	   control	   the	   overwhelming	   costs	   associated	   with	   diagnostic	   testing,	  
required	   isolation	   of	   infected	   patients,	   treatment,	   and	   decontamination	   due	   to	   this	  
opportunistic	  pathogen,	  improved	  treatments	  and	  meticulous	  hygiene	  are	  essential.	  	  
2.7. CDI	  treatments	  
2.7.1. Traditional	  treatment,	  antibiotics	  
C.	   difficile	   infections	   are	   on	   the	   rise	   with	   more	   aggressive	   strains	   being	   identified	   in	  
current	   outbreaks.	   	   Symptoms	   may	   include	   diarrhea,	   nausea,	   abdominal	   pain,	   decreased	  
appetite,	   and	   sometimes	   fever.	   	   Rehydrating	   and	   balancing	   electrolytes	   of	   patients	   with	  
diarrhea	   is	   necessary	   during	   treatment,	   as	  well	   as	   halting	   use	   of	   broad-­‐spectrum	   antibiotics,	  
when	   feasible.	   	   The	   first	   defense	   to	   exterminate	   the	   bacterial	   colonies	   responsible	   for	   CDI	  
includes	  the	  use	  of	  antibiotics.	  However,	  with	  only	  three	  effective	  antibiotics	  against	  C.	  difficile	  
and	  strains	   identified	  with	   resistance,	  other	   therapeutic	  options	  are	  under	   intense	  study.	  The	  
most	   promising	   alternative	   treatments	   include	   probiotics,	   toxin	   binding	   polymer,	   toxin	  
inhibitors,	  immunotherapy,	  and	  fecal	  implantation	  (Figure	  2.7).	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Until	  this	  year,	  there	  were	  only	  two	  traditionally	  prescribed	  antibiotics	  effective	  against	  
C.	  difficile,	  Vancocin	  (vancomycin)	  and	  Flagyl	  (metronidazole).	  	  Metronidazole	  is	  often	  the	  first	  
choice	  for	  CDI	  treatment	  with	  initial	  responses	  reported	  to	  be	  as	  high	  as	  95%	  in	  a	  randomized	  
trial,	  but	   it	   is	  not	  recommended	  for	  recurrent	   infections	   (321,322).	   	  Vancomycin	  has	   identical	  
responses	  in	  CDI	  patients	  undergoing	  a	  first	  round	  of	  antibiotic	  treatment,	  however	  it	  is	  usually	  
held	  as	  a	   last	   resort	  drug	   to	  avoid	  a	   rise	   in	   resistant	   strains	  of	  other	  opportunistic	  pathogens	  
and	   due	   to	   its	   high	   cost.	   	   The	   FDA	   recently	   approved	   DIFICID	   (fidaxomicin),	   developed	   by	  
Optimer	   Pharmaceuticals	   Inc.,	   after	   positive	   results	   in	   phase	   II	   and	   phase	   III	   trials	   (323,324).	  	  
The	  most	  pronounced	  difference	  between	  fidaxomicin,	  compared	  to	  the	  other	  two	  treatments,	  
is	   the	   reduced	   rate	   of	   relapse,	   an	   important	   hurdle	   in	   CDI	   treatment.	   	   Recurrent	   infection	   is	  
observed	   in	   ~20%	   of	   CDI	   patients	   caused	   by	   either	   reinfection	   or	   relapse.	   	   When	   a	   patient	  
experiences	  a	  second	  round	  of	  C.	  difficile	   infection,	  the	  chance	  of	  a	  third	  relapse	   increases	  to	  
50%,	  with	  an	  increased	  risk	  of	  chronic	  relapse	  (325).	  	  	  For	  a	  review	  on	  CDI	  antibiotic	  treatment	  
see	   (326).	   	  Unfortunately,	  although	  antibiotic	   treatment	   is	  effective	  at	  killing	   the	  pathogen,	   it	  
does	  not	  restore	  the	  protective	  microflora	  of	  the	  host.	  These	  healthy	  bacteria	  play	  a	  vital	  role	  in	  
competing	   with	   C.	   difficile	   by	   preventing	   colonization.	   	   This	   explains	   why	   probiotics	   have	  
positive	  results	  when	  combined	  with	  antibiotic	  treatment.	  
2.7.2.	   	  Novel	  therapeutics	  
Probiotics	  
Probiotics	  have	  shown	  success,	  when	  administered	   in	  conjunction	  with	  vancomycin	  or	  
metronidazole,	  in	  reducing	  the	  percent	  of	  patients	  that	  relapse	  after	  initial	  CDI	  (327).	  	  Relapse	  
occurs	  when	  the	  bacterial	   infection	   is	  not	  completely	  eliminated,	  or	  unharmed	  spores	  persist	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throughout	  treatment,	  which	  are	  able	  to	  easily	  recolonize	  once	  antibiotic	  pressure	  is	  halted	  due	  
to	  lack	  of	  competitive	  species	  (325).	  	  Probiotics	  allow	  colonization	  of	  protective	  organisms,	  able	  
to	  compete	  and	  block	  C.	  difficile	  colonization.	  	  	  
	  
Figure	  2.7.	  	  Defenses	  against	  CDI.	  	  To	  control	  spread,	  patients	  should	  be	  isolated	  and	  proper	  hygiene	  
must	   be	   in	   use.	   	  When	   treatment	   is	   considered,	   there	   are	   three	  main	   targets:	   destruction	   of	   the	  
infectious	   bacterium	   (use	   of	   antimicrobials),	   inhibition	   of	   colonization	   (reestablishing	  microflora),	  
and	   prevention	   of	   cell	   damage	   (inhibition	   of	   virulence	   factors).	   	   There	   are	  multiple	   targets	   when	  





The	  organisms	  most	  efficient	  at	   impeding	  C.	  difficile	   growth	  have	  not	  been	   identified;	  
leading	  to	  an	  alternative	  approach	  at	  restoring	  the	  gut’s	  symbiotic	  microflora	  population,	  fecal	  
transplantation.	  	  Success	  has	  been	  reported	  by	  treatment	  where	  feces	  from	  a	  healthy	  donor	  is	  
transplanted,	  delivering	  it	  into	  the	  duodenum	  of	  the	  patient	  with	  CDI	  (328-­‐330).	  	  The	  idea	  is	  to	  
restore	  the	  normal	  flora,	  without	  choosing	  specific	  organisms,	  since	  it	  is	  unknown	  which	  of	  the	  
entire	  gut	   flora	   is	   responsible	   for	  preventing	  colonization	  of	  C.	  difficile.	   	  Managing	  CDI	  by	  this	  
route	  is	  cost	  effective	  since	  the	  technology	  is	  simple,	  and	  targets	  the	  illness	  by	  flushing	  out	  C.	  
difficile	  by	  competition	  instead	  of	  repeated	  antibiotic	  use	  that	  leads	  to	  drug	  resistance.	  	  	  
Inhibition	  of	  virulence	  factors	  
In	  contrast	  to	  targeting	  the	  organism,	  it	  is	  conceivable	  that	  its	  virulence	  factors	  could	  be	  
inhibited	   to	   interfere	   with	   the	   cell	   damage	   and	   immune	   response	   associated	   with	   CDI.	  	  
Colonization	   of	   C.	   difficile	   leads	   to	   the	   release	   of	   virulence	   factors,	   large	   protein	   toxins,	  
responsible	  for	  tissue	  damage	  and	  immunological	  response.	  	  Targeting	  of	  the	  protein	  toxins	  has	  
been	   explored	   as	   a	   way	   to	   reduce	   selective	   pressure	   on	   the	   organism	   and	   resistance	   to	  
treatment,	   while	   blocking	   symptoms	   and	   assuming	   eventual	   recolonization	   of	   the	   gut	   will	  
eradicate	   C.	   difficile	   overgrowth	   naturally.	   	   Polymers	   have	   been	   designed	   and	   studied	   as	   a	  
method	  to	  catch	  and	  remove	  toxins	  before	  they	  damage	  cells.	   	  A	  recent	  review	  presents	  data	  
on	  toxin	  binding	  agents	  cholestyramine,	  Synsorb	  90,	  and	  tolevamer	  (331).	  	  The	  C.	  difficile	  toxin	  
binding	   polymer,	   tolevamer,	   has	   undergone	   phase	   II	   and	   phase	   III	   clinical	   studies,	   with	   data	  
collected	   from	   both	   the	   US	   and	   Europe	   (332).	   	   In	   vitro,	   the	   polymer	   was	   highly	   effective	   in	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binding	   C.	   difficile	   toxins	   and	   showed	   protection	   of	   CDI	   in	   a	   mouse	   model	   (333);	   however	  
results	  from	  clinical	  studies	  confirmed	  it	  is	  less	  effective	  than	  current	  antibiotic	  treatments.	  	  	  
2.8.	  	  Conclusions	  
C.	   difficile	   is	   responsible	   for	   most	   cases	   of	   antibiotic-­‐associated	   diarrhea	   in	   the	  
healthcare	  setting.	  	  CDI	  ranges	  from	  mild	  diarrhea	  to	  life	  threatening	  colitis,	  and	  is	  most	  often	  
treated	  with	  one	  of	  three	  antibiotics.	  	  An	  obstacle	  of	  CDI	  treatment	  is	  the	  high	  rate	  of	  relapse	  
suspected	  to	  be	  the	  result	  of	  incomplete	  eradication	  during	  treatment.	  	  With	  the	  emergence	  of	  
new	   strains	   with	   increased	   toxin	   production,	   increased	   antibiotic	   resistance,	   and	   more	  
community	   infections	  of	  healthy	   individuals,	  new	  and	  more	  effective	   treatments	  are	  needed.	  
Many	  of	  the	  alternative	  strategies	  for	  CDI,	  are	  lacking	  in	  research	  and	  trials.	  
2.9.	  	  Thesis	  statement	  
This	  thesis	  is	  focused	  on	  two	  major	  goals.	  	  First,	  found	  in	  Chapter	  3,	  the	  reprogramming	  
of	   TcdA	   to	   develop	   a	   protein	   delivery	   system.	   	   Such	   a	   tool	   would	   be	   extremely	   useful	   in	  
biotechnology	  and	  provides	  advantages	  to	  the	  currently	  available	  vehicles.	   	  Second,	  discussed	  
in	   Chapter	   4,	   the	   inhibition	   of	   TcdA	   induced	   cytotoxicity.	   	   This	   research	   involves	   in	   cellulo	  
characterization	  of	  modified	  peptides	  that	  were	  previously	   identified	  to	  bind	  the	  catalytic	  site	  
of	  TcdA	  and	  provide	  a	  novel	  therapeutic	  option	  in	  the	  treatment	  of	  CDI.	  	  
Cargo-­‐delivery	  system	  
The	  application	  of	  a	  vehicle	  with	  the	  capability	  to	  cross	  the	  cell	  membrane	  while	  towing	  
a	  cargo,	  which	  is	  released	  into	  the	  cytoplasm,	  is	  highly	  desirable	  for	  many	  reasons,	  as	  described	  
in	   Chapter	   1.	   	   Our	   understanding	   of	   TcdA	   prompted	   our	   attention	   toward	   its	   use	   for	   this	  
purpose.	   	  Our	  approach,	  discussed	   in	  Chapter	  3,	   involved	  replacing	  the	  TcdA	  catalytic	  domain	  
	  	  
71	  
with	  a	   reporter	  gene.	   	   Investigations	   into	   the	  chimeric	  proteins	  were	   initially	  directed	  toward	  
each	  functional	  domain.	   	   In	  vitro	  analysis	  was	  sufficient	  to	  detect	  CPD	  and	  reporter	  activities,	  
whereas	   immunocytochemistry	   was	   employed	   to	   detect	   cell	   binding	   and	   endocytosis.	   	   We	  
provided	   evidence	   of	   translocation	   by	   analyzing	   cell	   lysates	   for	   a	   reporter	   protein	   after	  
incubation	  with	   the	  chimeric	  protein.	   	  The	   large	  difference	   in	  molecular	  weight	  between	  Luc-­‐
TcdA	  (265.7	  kD)	  and	  luciferase	  (19.3	  kD)	  allowed	  separation	  of	  the	  two	  proteins	  by	  molecular	  
sieving,	  and	  was	  used	  to	  confirm	  membrane	  translocation	  and	  in	  cellulo	  CPD	  activity.	  	  	  
Toxin	  inhibition	  
Cytotoxicity	  of	  TcdA	  and	  TcdB	  leads	  to	  the	  symptoms	  that	  characterize	  CDI.	  	  Our	  goal	  is	  
to	  neutralize	   the	  cellular	  damage	  by	  TcdA	  and	  TcdB,	   therefore	  eliminating	   the	  CDI	   symptoms	  
while	   leaving	   the	   bacterial	   colonization	   to	   be	   eradicated	   upon	   reestablishment	   of	   the	   gut	  
microflora.	  	  In	  cooperation	  with	  other	  group	  members,	  the	  studies	  and	  discussion	  in	  Chapter	  4	  
are	  concentrated	  on	  defining	  the	  biological	  relevance	  of	  peptides	  that	   irreversibly	  bind	  to	  the	  
catalytic	   site	   of	   TcdA.	   	   	   For	   this,	   we	   proposed	   modifying	   a	   synthetic	   peptide,	   which	   was	  
previously	   reported	   by	   our	   group	   to	   bind	   the	   active	   site	   of	   TcdA,	   with	   a	   functional	   group.	  	  
Specific	   side	   chains	   were	   exchanged	   for	   allyl	   glycine,	   which	   were	   then	   reacted	   with	  meta-­‐
chloroperbenzoic	   acid	   to	   yield	   the	   epoxy	   derivative.	   	   After	   binding	   to	   the	   active	   site,	   we	  
expected	  the	  placement	  of	  the	  epoxide	  to	  be	  within	  close	  proximity	  of	  a	  nucleophile	  within	  the	  
active	   site	   of	   TcdA.	   	   Nucleophilic	   attack	   is	   expected	   to	   facilitate	   covalent	   attachment	   and	  
irreversible	   inhibition.	   	   Incubation	  of	   these	   synthetic	  epoxy-­‐peptides	  with	  mammalian	  cells	   in	  
the	  presence	  of	   TcdA	  was	  used	   to	  establish	   the	  practicality	  of	   their	   application	  during	  CDI	   in	  
living	  systems.	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3. Adaptation	  of	  TcdA	  for	  use	  as	  a	  protein	  translocation	  system‡	  
3.1. Introduction	  	  	  
Protein	   transduction	   is	   the	   process	   of	   transporting	   a	   polypeptide	   across	   the	   plasma	  
membrane	   into	   a	   living	   cell	   (59).	   The	   direct	   delivery	   of	   proteins	   into	   living	   cells	   is	   extremely	  
desirable	   from	   a	   biotechnology	   standpoint,	   but	   the	   lipid	   membrane	   provides	   a	   significant	  
barrier.	  The	  task	  of	  protein	  translocation	  must	  be	  approached	  delicately,	  as	  loss	  of	  membrane	  
integrity	   has	   devastating	   effects	   on	   the	   cell.	   	   Currently,	   the	  most	   common	  method	   used	   for	  
protein	   transduction	   is	   the	   addition	   of	   a	   cell-­‐penetrating	   peptide	   (CPP)	   at	   one	   end	   of	   the	  
protein.	   Naturally	   occurring	   CPPs	   are	   found	   on	   certain	   viral	   proteins	   such	   as	   the	   tat	   peptide	  
from	  the	  transactivating	  tat	  protein	  of	  HIV-­‐1	  and	  penetratin	  derived	  from	  the	  third	  helix	  of	  the	  
homeodomain	   of	   antennapedia.	   As	   described	   in	   chapter	   1,	   these	   peptides	   are	   rich	   in	   basic	  
amino	   acids	   and	   spontaneously	   enter	   eukaryotic	   cells	   (58,334).	   These	   systems	   have	   been	  
adapted	  to	  translocate	  peptides	  and	  small	  proteins	   into	  cultured	  cells.	  There	  are	  a	  number	  of	  
problems	  with	  these	  systems,	  however,	   including	  toxicity	  (63-­‐65),	  size-­‐dependence,	  variability	  
due	  to	  the	  chemical	  properties	  of	   the	  cargo	  protein	   (66,67),	  and	  a	   lack	  of	  cell	   type	  specificity	  
(68-­‐70).	  Furthermore,	   there	   is	  a	   tendency	   for	   these	  basic	  peptides	   to	   tow	  their	  cargo	  directly	  
into	   the	   nucleus	   due	   to	   their	   significant	   positive	   charge	   under	   cellular	   conditions	   (59).	   TcdA	  
naturally	   delivers	   a	   large	   catalytic	   domain	   into	   the	   cytosol	   of	   its	   target	   cells	   (8),	   so	  we	   have	  
investigated	  whether	  this	  protein	  can	  be	  repurposed	  to	  provide	  a	  vehicle	  to	  deliver	  alternative	  
cargo	  proteins	  into	  cells.	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
‡	  Sections	  of	  Chapter	  3	  have	  been	  previously	  published	  (191).	  
	  	  
73	  
The	   structure,	   function,	   and	   cell	   entry	   mechanism	   of	   TcdA	   is	   explained	   in	   detail	   in	  
chapter	  2.	  	  As	  this	  toxin	  is	  naturally	  engineered	  to	  deliver	  a	  large	  protein	  cargo	  directly	  into	  the	  
cytosol	  of	  target	  cells	  and	  carries	  its	  own	  protease,	  activated	  by	  intracellular	  small	  molecules,	  to	  
autolytically	  remove	  the	  translocation	  machinery	  upon	  internalization,	  TcdA	  is	  an	  ideal	  system	  
for	  adaptation	  into	  a	  transduction	  cassette.	  	  Here,	  we	  show	  that	  the	  glucosyltransferase	  domain	  
can	  be	  removed	  from	  recombinant	  TcdA	  and	  replaced	  with	  alternative	  cargo	  proteins	  (GFP	  or	  
luciferase)	  for	  direct	  cellular	  delivery	  of	  an	  active	  enzyme	  into	  target	  cells.	  	  
3.2. Experimental	  design	  and	  considerations	  
The	   tcdA	   gene	   and	   its	   chimeras	   are	   very	   large	   (265-­‐310	   kD),	   therefore	   conventional	  
cloning	   techniques	  were	   not	   always	   useful	   and	   required	   unusual	  methods	   and	  patience.	   The	  
pathogenic	  DNA	  is	  also	  under	  strict	  regulation	  to	  control	  genetic	  cross-­‐over,	  adding	  additional	  
restrictions	   that	   were	   applied	   to	   the	   cloning	   and	   handling	   of	   expressing	   strains,	   DNA,	   and	  
protein	  products.	  	  Also	  to	  be	  considered	  in	  this	  project,	  TcdA	  as	  a	  transport	  tool	  is	  designed	  for	  
use	   in	   living	  systems,	   so	  we	  do	  not	  want	   to	  carry	  over	  any	  contaminants,	   such	  as	  endotoxins	  
from	   gram-­‐negative	   expression	   systems.	   We	   chose	   to	   express	   the	   plasmids	   in	   Bacillus	  
megaterium	   (B.	   megaterium),	   which	   has	   many	   advantages.	   	   First,	   it	   is	   a	   Gram-­‐positive	  
bacterium,	   like	   C.	   difficile,	   the	   native	   organism	   that	   produces	   TcdA.	   	   Expression	   from	   the	  
pWH1520	   plasmid	   is	   tightly	   regulated	   by	   the	   xylose	   operon,	   and	   B.	   megaterium	   does	   not	  
contain	   alkaline	   proteases	   or	   endotoxins	   (335).	   The	   yields,	   even	   for	   large	   proteins,	   are	  





3.3. Chimera	  gene	  construction	  
3.3.1. Cargo-­‐TcdA	  	  
Fusion	   genes	  were	   constructed	   for	   recombinant	   expression	   of	   two	   chimeric	   proteins,	  
referred	  collectively	  as	  Cargo-­‐TcdA.	  	  The	  chimeric	  proteins	  have	  a	  reporter	  gene	  in	  place	  of	  the	  
TcdA	  GT	  domain.	  The	  reporter	  gene,	  encoding	  either	  emerald	  GFP	  or	  Gaussia	  priceps	  luciferase,	  
was	   fused	   to	   the	  N-­‐terminus	   of	   TcdA	   (before	   residues	   540-­‐2710)	   yielding	  GFP-­‐TcdA	   and	   Luc-­‐
TcdA	   (Figure	   3.1).	   	   A	   C-­‐terminal	   His6-­‐tag	   was	   included	   to	   facilitate	   purification.	   	   The	   cloning	  
scheme	   is	   illustrated	   in	   Figure	   3.2,	   and	   the	   details	   are	   described	   in	   section	   3.10.	   The	   exact	  
fusion	  site	  within	  TcdA	  was	  determined	  using	  secondary	  structure	  predictions,	  being	  careful	  to	  
interrupt	   neither	   putative	   secondary	   structure	   elements	   nor	   the	   CPD	   cleavage	   site	   between	  
L542/S543	  (296).	   	  The	  274	  kDa	  (GFP-­‐TcdA)	  and	  266	  kDa	  (Luc-­‐TcdA)	  proteins	  were	  detected	  at	  
their	  correct	  molecular	  masses	  by	  SDS-­‐PAGE.	  
3.3.2.	  	  MLD-­‐Luc-­‐TcdA	  
	   The	  membrane	   localization	   domain	   (MLD)	   includes	   TcdA	   residues	   1-­‐82,	   and	   has	   been	  
proposed	  to	  direct	  the	  GT	  domain	  to	  cellular	  targets,	  at	  the	  membrane,	  after	  cytosolic	  delivery	  
	  
	  
Figure	  3.1.	  Protein	   schematic	  of	  TcdA	  and	   three	   fusion	  proteins.	   	   Full	   length	  TcdA	   includes	  
multiple	  functional	  domains,	  indicated	  here	  by	  color	  and	  described	  in	  chapter	  2.	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(301).	   	   It	   is	   conceivable	   as	   well,	   that	   this	   membrane-­‐associated	   domain	   may	   play	   a	   role	   in	  
translocation.	  	  To	  better	  understand	  the	  role	  of	  the	  MLD	  in	  cargo	  delivery,	  we	  fused	  the	  coding	  
region	  to	  the	  N-­‐terminus	  of	  Luc-­‐TcdA,	  yielding	  MLD-­‐Luc-­‐TcdA.	  	  The	  gene	  construction	  scheme	  is	  
shown	  in	  Figure	  3.3.	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Figure	   3.2.	   Cloning	   scheme	  of	   cargo-­‐tcdA.	   The	   reporter	   gene	  was	   cloned	   into	   a	   pWH1520	  
vector	  using	  TOPO	  cloning.	  	  This	  plasmid	  was	  then	  digested	  with	  BamHI	  and	  SphI	  to	  open	  the	  
vector	  at	  the	  3’	  end	  of	  the	  cargo	  gene	  to	  ligate	  the	  tcdA	  gene	  sequence,	  excluding	  the	  coding	  
region	  for	  the	  GT	  domain,	  and	  the	  cat	  gene.	  	  Chloramphenicol	  screening	  identified	  colonies	  
with	  the	  correct	  plasmid,	  and	  final	  plasmids	  were	  the	  result	  of	  removing	  the	  cat	  gene. 
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Figure	   3.3.	   Cloning	   scheme	   of	  mld-­‐luc-­‐tcdA.	   	   The	   sequence	   encoding	   the	   membrane	   localization	  
domain	   was	   PCR	   amplified	   and	   cloned	   into	   the	   pWH1520	   vector,	   5’	   of	   the	   luciferase	   gene.	   	   The	  
resulting	  plasmid	  was	  digested	  with	  BamHI	  and	  SphI	  to	  open	  the	  vector	  at	  the	  3’	  end	  of	  the	  luciferase	  
gene	  to	   ligate	  the	  tcdA	  gene	  sequence,	  excluding	  the	  coding	  region	  for	  the	  GT	  domain,	  and	  the	  cat	  
gene.	   	   Chloramphenicol	   screening	   identified	   colonies	  with	   the	   correct	   plasmid,	   and	   final	   plasmids	  
were	  the	  result	  of	  removing	  the	  cat	  gene. 
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3.4. Cargo-­‐TcdA	  characterization	  
3.4.1.	  	  Reporter	  proteins	  
	   A	   reporter	   protein	   is	   one	   that	   is	   easily	   detected	   and	   not	   endogenous	   to	   the	   system	  
being	   studied.	   	   The	  protein	   can	  be	   chosen	  based	  on	   a	   function	   such	   as	   antibiotic	   resistance,	  
fluorescence,	   or	   enzymatic	   activity.	   	   Chloramphenicol	   acetyltransferase	   (CAT),	   GFP,	   β-­‐
galactosidase,	  and	  luciferase	  are	  commonly	  used.	  	  The	  studies	  in	  this	  chapter	  focus	  on	  a	  variant	  
of	   native	   GFP	   protein	   and	   the	   luciferase	   enzyme	   from	  Gaussia	   princeps.	   	   Emerald	   GFP	   and	  
Gaussia	   luciferase	  were	  chosen	  as	  reporter	  proteins	  because	  of	  their	   low	  detection	  limits	  and	  
ease	  of	  reporter	  detection	  (336,337).	   	  
Emerald	  GFP	  is	  a	  mutant	  of	  native	  GFP	  with	  5	  amino	  acid	  changes	  (336),	  emitting	  light	  at	  
509	  nm	  when	  excited	  at	  487	  nm	  (338).	  	  EmGFP	  is	  recommended	  as	  one	  of	  the	  best	  fluorescent	  
protein	  variants	  available,	  and	  the	  best	  green	  GFP	  variant,	  as	   its	  folding	  is	  more	  efficient	  than	  
GFP	  at	  37	  °C	  with	  better	  fluorescent	  performance	  (336).	  
	   Gaussia	   luciferase	   is	   the	  smallest	  of	  the	  coelenterazine-­‐utilizing	   luciferases	  (185	  amino	  
acids)	  with	  reported	  chemiluminescent	  detection	  observed	  at	  enzyme	  concentrations	  as	  low	  as	  
1	  amol	   (339).	   	  The	  sodium-­‐dependent	  enzyme	  does	  not	   require	  cofactors	   (ATP-­‐independent),	  
and	  catalyzes	   the	  oxidative	  decarboxylation	  of	  coelenterazine	   to	  produce	  the	  excited	  state	  of	  
the	   product,	   coelenteramide	   (337).	   	   When	   the	   excited	   coelenteramide	   relaxes	   back	   to	   the	  
ground	  state,	  blue	  light	  is	  emitted	  (470	  nm).	  
3.4.2.	  	  Cargo-­‐TcdA	  reporter	  characterization	  
Fusion	  of	  two	  proteins	  can	  sometimes	  lead	  to	  misfolding	  and	  loss	  of	  function.	  Given	  the	  
complexity	   of	   this	  multidomain	   protein,	   in	   which	   each	   domain	   has	   a	   critical	   function	   during	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translocation,	   this	   was	   potentially	   a	   serious	   concern.	   Thus,	   each	   functional	   aspect	   of	   the	  
chimera	  was	  tested	  independently:	  reporter	  activity,	  cell	  binding,	  autolytic	  cleavage	  and	  protein	  
translocation.	  	  	  
Proper	   folding	   of	   the	   reporters	   was	   tested	   using	   their	   luminescence	   properties.	   GFP-­‐
TcdA	  was	  immobilized	  on	  Ni-­‐NTA	  resin	  and	  fluorescent	  images	  were	  captured	  when	  the	  protein	  
was	  excited	  by	  green	   light	   (Figure	  3.4).	  Similarly,	  Luc-­‐TcdA	  was	   immobilized	  on	  the	  resin,	  and	  
adding	  substrate,	  coelenterazine,	  in	  luminescence	  reaction	  buffer,	  activated	  this	  enzyme.	  	  
Images	  of	   the	  chemiluminescent	   reaction	  were	  captured	   in	  a	  darkroom.	   	   In	  each	  case	  
the	   controls,	   GFP	   or	   luciferase	   proteins	   immobilized	   on	   resin,	   demonstrated	   comparable	  
luminescence	   properties	   indicating	   proper	   folding	   of	   the	   reporters	   in	   their	   chimeric	   context	  
prior	  to	  translocation.	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Figure	  3.4.	  	  Reporter	  proteins	  and	  Cargo-­‐TcdA	  reporter	  activity.	  	  Emerald	  GFP	  is	  a	  varient	  of	  
green	  fluorescent	  protein	  which	  emits	  light	  at	  509	  nm	  when	  excited	  at	  487	  nm	  (A).	  	  Gaussia	  
luciferase	   is	   the	   smallest	   coelenterazine	   utilizing	   luciferase	   and	   emits	   chemilumenescence	  
with	   substrate	   turnover,	   470	   nm	   (B).	   GFP-­‐TcdA	   fluorescence	   (C)	   and	   Luc-­‐TcdA	  




3.5. Cargo-­‐TcdA	   functional	   domain	  
analysis	  
3.5.1	  	  RBD	  and	  translocation	  	  
	   It	  was	  previously	  shown	  that	  TcdA	   is	  
able	   to	   bind	   to	   cells	   at	   4	   °C,	   but	   fails	   to	  
internalize	  due	   to	  membrane	   rigidity	  at	   this	  
low	  temperature.	   In	  contrast,	  at	  37	   °C,	  cells	  
rapidly	   take	   up	   the	   toxin	   (340).	   This	  
temperature	  sensitivity	  was	  used	  to	  test	  the	  
chimeric	   toxins	   and	   further	   probe	   the	  
internalization	   process.	   To	   separate	   issues	  
related	   to	   reporter	   function	   and	  
translocation	   proficiency,	   a	   monoclonal	  
antibody	   that	   cross	   reacts	   between	   nTcdA	  
and	   Luc-­‐TcdA	   was	   used	   for	   detection	   in	  
these	   experiments.	   	   When	   the	   fusion	  
protein,	  Luc-­‐TcdA,	  was	  only	  allowed	  to	  bind	  
the	  cell	  surface	  (4	  °C,	  Figure	  3.5,	  top),	  a	  clear	  
outline	  of	   the	   cell	  membrane	  was	  observed	  
with	  very	   little	   internal	  staining.	   In	  contrast,	  
when	  cells	  were	  treated	  with	  Luc-­‐TcdA	  at	  37	  
°C,	   both	   membrane	   and	   internal	   staining	  
	  
Figure	   3.5.	   Analysis	   of	   Luc-­‐TcdA	   cell	   binding	  
and	   endocytosis.	   	   Immunocytostaining	   with	  
anti-­‐TcdA	   after	   vero	   cells	   are	   incubated	  with	  
32	  nM	  Luc-­‐TcdA	  at	  4	  °C	  (top),	  37	  °C	  (middle),	  




was	  observed	   (Figure	  3.5,	  middle).	  As	  shown	   in	  Figure	  3.5,	  bottom,	  mild	   trypsin	   treatment	   to	  
digest	  surface	  bound	  proteins	  after	  incubation	  with	  Luc-­‐TcdA	  at	  37	  °C,	  provided	  further	  support	  
of	   endocytosis.	   	   As	   expected,	   predominantly	   internalized	   protein	  was	   observed	   after	   trypsin	  
treatment.	   	   These	   observations	   indicate	   that	   the	   RBD	   of	   Luc-­‐TcdA	   binds	   to	   cell	   surfaces	   and	  
induces	  endocytosis	  in	  a	  manner	  identical	  to	  nTcdA.	  Therefore,	  our	  evidence	  reveals	  that	  Luc-­‐
TcdA	  follows	  the	  same	  cell	  entry	  pathway	  into	  vero	  cells	  as	  the	  native	  toxin.	  
3.5.2.	  	  Active	  CPD	  of	  Cargo-­‐TcdA	  	  
After	   translocation	   into	   the	   cytosol,	   nTcdA	   undergoes	   auto-­‐proteolysis	   by	   the	   CPD	   to	  
release	  the	  enzymatic	  domain.	   	   In	  vitro,	   IP6	   induces	  this	  autoproteolytic	  cleavage	  of	  TcdA	  and	  
	  
Figure	  3.6.	   	  CPD	  activity	  of	  GFP-­‐TcdA.	   (A)	  CPD	  auto-­‐proteolysis	  of	  GFP-­‐TcdA	   is	   IP6	  dependanet	  
and	  proteolysis	   is	   increased	  by	  addition	  of	  DTT.	   	  1.7	  uM	  GFP-­‐TcdA	  was	   incubated	   in	  Tris/NaCl	  
buffer,	  pH	  7.5,	  250	  mM	  sucrose	  and	  supplemented	  with	  indicated	  DTT	  and/or	  IP6,	  overnight	  at	  
37	  °C.	   (B)	   IP6	   induced	  CPD	  cleavage	   is	   time	  dependant.	  Lane	  1	  and	  2	  are	  GFP-­‐TcdA	  (1	  µg)	  and	  
EmGFP	  (9	  ng)	  controls.	  Lanes	  3-­‐9	  are	  time	  points	  from	  the	  incubation,	  at	  37	  °C,	  of	  0.5	  µM	  GFP-­‐




TcdB	  (7).	  	  The	  ability	  of	  IP6	  to	  stimulate	  CPD	  activity	  was	  tested	  for	  both	  chimeric	  TcdA	  proteins.	  	  
By	   SDS-­‐PAGE	   separation	   and	   analysis,	   we	   have	   observed	   IP6-­‐induced	   proteolysis	   yielding	  
protein	  bands	  at	   the	  predicted	  molecular	  weight	  of	  CPD	  cleaved	  products,	   illustrated	  by	  GFP-­‐
TcdA	   cleavage	   in	   figure	   3.	   6.	   	   GFP	   is	   resistant	   to	   SDS	   at	   room	   temperature,	   so	   direct	  
fluorescence	  imaging	  of	  the	  gel	  is	  possible	  and	  shows	  free	  GFP	  accumulation	  as	  GFP-­‐TcdA	  signal	  
is	  reduced.	   	  This	  technique	  provides	  sensitive	  detection,	  with	  as	   little	  as	  1	  ng	  GFP	  observable.	  	  
Although	   we	   do	   not	   observe	   complete	   cleavage,	   approximately	   80%	   of	   the	   material	   was	  
processed.	   	   Treatment	   of	   GFP-­‐TcdA	   with	   10-­‐fold	   molar	   excess	   IP6	   shows	   time-­‐dependent	  
cleavage	  (Figure	  3.6,	  B).	  Similarly	  IP6-­‐induced	  CPD	  cleavage	  was	  observed	  by	  coomassie	  staining	  
of	  nTcdA	  and	  Luc-­‐TcdA.	  	  These	  results	  confirmed	  that	  GFP-­‐TcdA	  and	  Luc-­‐TcdA	  retain	  their	  ability	  
to	  undergo	  autolytic	  proteolysis	  simulated	  by	  IP6	  and	  therefore	  have	  the	  ability	  to	  release	  the	  
reporter	  domain	  from	  the	  translocation	  machinery	  after	  transduction.	  	  	  
3.6. Luciferase	  delivery	  via	  Luc-­‐TcdA	  	  
3.6.1.	  	  Detection	  of	  luciferase	  in	  lysates	  after	  delivery	  
The	  final	  test	  is	  whether	  the	  reporter	  proteins	  are	  capable	  of	  delivering,	  refolding,	  and	  
releasing	  active	  enzymes	  into	  the	  cytosol	  after	  transduction.	  We	  prepared	  both	  GFP-­‐TcdA	  and	  
Luc-­‐TcdA	  constructs,	  due	  to	  worries	  that	  the	  GFP-­‐TcdA	  might	  be	  difficult	  to	  translocate	  because	  
of	  its	  highly	  stable	  beta-­‐barrel	  structure.	  Direct	  cell	  imaging	  of	  Gaussia	  luciferase	  activity	  in	  the	  
cytosol	   is	   not	   possible	   because	   a	   critical	   disulfide	   bond	   required	   for	   activity	   is	   reduced	  
intracellularly	   (341).	   	   To	   circumvent	   this	   problem	   and	   investigate	   the	   presence	   of	   delivered	  
luciferase	  in	  cells	  after	  incubation	  with	  Luc-­‐TcdA,	  cell	  lysates	  were	  collected	  and	  analyzed	  after	  
translocation	  (Figure	  3.7).	  As	  a	  control,	  cells	  were	  incubated	  with	  His6-­‐tagged	  luciferase	  lacking	  
	  	  
84	  
the	   TcdA	   translocation	   machinery.	   Cells	   were	   washed	   to	   remove	   free	   protein	   and	   then	  
subjected	   to	   mechanical	   lysis	   to	   shear	   the	   cell	   membrane	   while	   leaving	   intact	   endosomes.	  	  
Detection	   of	   active	   luciferase	   in	   crude	   lysates	   after	   incubation	   with	   Luc-­‐TcdA	   exhibited	   high	  
levels	   of	   enzymatic	   activity,	   10-­‐fold	   stronger	   than	   that	   detected	   after	   control	   incubations	  
(Figure	  3.7,	  A).	  	  
In	  these	  lysate	  experiments,	  one	  cannot	  determine	  whether	  the	  reporter	  was	  free	  in	  the	  
cytosol,	  or	  remained	   in	  the	  endosome.	   	  Therefore,	  bafilomycin	  A1	  (baf)	  or	  brief	   incubation	  at	  
acidic	   pH	   (acid	   pulse)	   were	   used	   to	   manipulate	   protein	   uptake.	   	   Baf	   inhibits	   endosomal	  
acidification	   and	   therefore	   blocks	   the	   escape	   of	   TcdA	   from	   the	   endosome	   (295),	   whereas	  
lowering	   the	   pH	   of	   the	   extracellular	   environment	   to	   5.2	   drives	   cytosolic	   delivery	   across	   the	  
cellular	  membrane	  without	   use	   of	   the	   endosomal	   pathway	   (100,295).	   	   Lysate	   from	   the	   acid	  
pulse	   sample	  was	  expected	   to	  display	   the	  highest	   signal,	   since	   translocation	   is	  being	   coerced	  
across	  the	  cell	  membrane	  (Figure	  3.7,	  A).	   	   It	  was	  striking	  that	  the	  signal	  from	  this	  sample	  was	  
about	   half	   that	   of	   the	   other	   two	   samples,	   indicating	   that	   translocation	   across	   the	   cell	  
membrane	  may	  be	  less	  efficient	  than	  through	  endosomal	  uptake.	  	  When	  the	  crude	  cell	  lysates	  
were	  subjected	  to	  centrifugation,	  a	  substantial	  amount	  of	  luciferase	  activity	  was	  lost,	  indicating	  
that	   some	   of	   the	   material	   was	   either	   still	   within	   endosomes	   or	   failed	   to	   undergo	   autolytic	  
processing.	  The	  question,	  however,	   is	  how	  much	  of	  the	  material	  successfully	  made	  it	   into	  the	  
cytosol.	  
3.6.2.	  	  Size	  separation	  identified	  released	  luciferase	  after	  Luc-­‐TcdA	  delivery	  
Whereas	   mechanical	   lysis	   is	   expected	   to	   shear	   the	   cell	   membrane	   while	   leaving	  
endosomes	   intact,	   detergent	   lysis	   disrupts	   all	   membranes	   and	   thus	   frees	   luciferase	   within	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endosomes	  as	  well	  as	  that	   in	  the	  cytosol.	  For	  this	  technique,	  size	  separation	  can	  estimate	  the	  
proportion	  of	  the	  toxin	  chimeras	   in	  each	  compartment	  (Figure	  3.7,	  B).	   In	  the	  presence	  of	  baf,	  
Luc-­‐TcdA	   is	   expected	   to	   accumulate	   in	   the	   endosome	   as	   a	   265	   kD	   protein,	   and	   thus	  will	   be	  
retained	  by	  a	  membrane	  with	  a	  100	  kD	  molecular	  weight	  cut-­‐off	  (MWCO),	  whereas	  the	  24	  kD	  
luciferase	   produced	   by	   translocation	   and	   CPD	   processing	   will	   pass	   through	   this	   membrane.	  
Mammalian	  protein	  extraction	  reagent	  (M-­‐PER),	  a	  mild	  detergent,	  was	  used	  to	   lyse	  cells	  after	  
Luc-­‐TcdA	  incubation	  in	  the	  absence	  and	  presence	  of	  baf.	  	  Following	  filtration	  through	  a	  100	  kD	  
MWCO	  membrane,	   cell	   lysates	   were	   analyzed.	   Without	   baf,	   clarified	   lysates	   consist	   of	   73%	  
active	  luciferase	  and	  26%	  Luc-­‐TcdA	  in	  contrast	  to	  46%	  and	  56%	  when	  baf	  is	  included.	  	  Thus	  we	  
see	  a	  3:1	  ratio	  of	  cleaved/uncleaved	  material	  during	  translocation	  and	  a	  1:1	  ratio	  when	  material	  
is	   retained	   in	   the	   endosome.	   The	   background	   cleavage	   observed	   during	   baf	   treatment	   may	  
derive	  from	  2	  routes.	  Either	  we	  saw	  incomplete	  inhibition	  of	  endosomal	  uptake	  in	  the	  presence	  
of	  100	  nM	  baf	  or	  more	  likely,	  IP6	  from	  the	  cytosol	  was	  able	  to	  induce	  CPD	  activation	  during	  lysis.	  
Whatever	   the	   reason	   for	   the	   background,	   the	   results	   are	   still	   clear;	   a	   significant	   amount	   of	  
luciferase	  was	  translocated	  into	  the	  cell	  and	  released	  into	  the	  cytosol	  using	  the	  Luc-­‐TcdA	  fusion	  
construct,	  and	  this	  material	  followed	  the	  same	  route	  of	  cellular	  entry	  as	  nTcdA.	  	  It	  is	  of	  concern	  
that	   the	   reducing	  environment	  of	   the	   cytosol	  may	   irreversibly	   inactivate	  delivered	   luciferase;	  
this	  possibility	  needs	  to	  be	  determined.	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3.7. MLD	  destabilizes	  Luc-­‐TcdA	  when	  fused	  to	  the	  N-­‐terminus	  
A	  membrane	   localization	  domain	  (MLD)	  was	  recently	   identified	   in	  TcdA,	  and	  proposed	  
to	  direct	  the	  GT	  domain	  to	  the	  membrane	  after	  delivery	  (301).	  	  With	  respect	  to	  our	  TcdA	  fusion	  
constructs,	   the	  MLD	   is	   located	  at	   the	  N-­‐terminus	   (residues	  1-­‐82)	   and	  was	   removed	   in	  cargo-­‐
tcdA	  construction.	  	  To	  determine	  if	  these	  residues	  are	  also	  important	  for	  translocation	  through	  
the	  lipid	  membrane,	  we	  created	  MLD-­‐Luc-­‐TcdA	  by	  adding	  the	  MLD	  coding	  sequence	  to	  the	  N-­‐
terminus	  of	  Luc-­‐TcdA,	  and	  assessed	  cargo	  delivery.	  	  If	  the	  MLD	  plays	  a	  role	  in	  translocation	  we	  
would	  expect	  to	  observe	  an	  increase	  in	  luciferase	  activity	  in	  cell	  lysates	  after	  delivery.	  
	  
Figure	  3.7.	   	  Luciferase	  activity	  monitored	   in	  cell	   lysates	  after	   incubation	  with	  Luc-­‐TcdA.	   	   (A)	  
Luciferase	  activity	  was	  10-­‐fold	  higher	  in	  crude	  cell	  lysate	  when	  cells	  were	  incubated	  with	  Luc-­‐
TcdA	  vs.	  the	  control	  protein,	  luciferase.	  	  After	  clarification	  the	  signal	  was	  lost,	  indicating	  the	  
active	   enzyme	  was	   pelleted	  with	   the	  membrane	   fraction.	   	   (B)	   	   Clarified	   lysate	  was	   further	  
separated	  by	   size	  exclusion	  after	   Luc-­‐TcdA	   incubation.	   	  Without	  baf,	   Luc-­‐TcdA	   (265.7	  kD)	   is	  
able	   to	   translocate	   the	   reporter,	   releasing	   luciferase	   (19.3	   kD)	   from	   the	   toxin.	   	   This	   is	  
observed	  by	  higher	  activity	  in	  the	  flow	  through.	  	  When	  baf	  prevents	  translocation,	  luciferase	  
is	  not	  released,	  this	  is	  observed	  by	  a	  higher	  activity	  in	  the	  retained	  fraction. 
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However,	  we	  found	  that	  the	  addition	  of	  the	  MLD	  
to	  Luc-­‐TcdA	  destabilized	  the	  luciferase	  domain,	  yielding	  a	  
protein	   with	   a	   30-­‐fold	   decrease	   in	   luciferase	   activity	  
compared	   to	   Luc-­‐TcdA	   (Figure	   3.8).	   	   No	   increase	   in	  
luciferase	   activity	   was	   observed	   in	   cell	   lysates	   after	  
delivery	  via	  MLD-­‐Luc-­‐TcdA	  (data	  not	  shown).	   	  This	  result	  
could	  be	  explained	  by	  either	  of	   two	  explanations,	   first	   it	  
may	   refute	   the	   possibility	   that	   the	  misfolded	   luciferase,	  
from	   MLD-­‐Luc-­‐TcdA,	   could	   be	   folded	   into	   an	   active	  
structure	   by	   chaperones	   after	   cytosolic	   delivery.	   	   A	  
second	  explanation	  is	  that	  the	  MLD	  domain	  does	  not	  play	  a	  role	  in	  translocation.	  	  
3.8. Versatility	  of	  GFP-­‐TcdA	  	  
We	   believe	   the	   CPD	   event	   can	   be	   a	   potential	   target	   in	   defense	   against	   C.	   difficile	  
infection.	  	  In	  vitro,	  IP6	  induces	  the	  auto-­‐proteolytic	  cleavage	  of	  TcdA/B.	  	  TcdA	  processing	  yields	  
2	   products:	   the	   glucosyltransferase	   (66	   kD)	   and	   the	   CPD-­‐translocation-­‐CROP	   fragments	   (242	  
kD).	  	  We	  have	  developed	  a	  screening	  assay,	  using	  our	  GFP-­‐TcdA	  fusion	  protein,	  to	  observe	  the	  
proteolysis	   event	   as	   a	   technique	   to	   screen	   compounds	   of	   interest	   as	   inhibitors	   of	   TcdA	   and	  
TcdB.	   	  We	  imagine	  this	  assay	  will	  be	  valuable	  in	  identification	  of	  compounds	  to	  extracellularly	  
induce	  toxin	  cleavage,	  rendering	  the	  toxin	  inactive.	   	  As	  a	  defense	  mechanism,	  inactivating	  the	  
toxins	  will	  eliminate	  the	  symptoms	  of	  C.	  difficile	  infection,	  but	  not	  remove	  the	  pathogen.	  	  This	  
should	   not	   be	   a	   problem,	   since	   C.	   difficile	   will	   again	   be	   in	   competition	   for	   nutrients,	   and	  
	  
Figure	   3.8.	   MLD	   destabilizes	   Luc-­‐
TcdA.	   	   Activity	   of	   the	   luciferase	  
domain	   of	   MLD-­‐Luc-­‐TcdA	   (purple)	  




colonies	   will	   naturally	   be	   reduced,	   as	   the	   gut	   is	   reinoculated	   with	   “healthy”	   bacteria	   after	  
antibiotic	  treatment	  is	  ended.	  	  	  
An	   initial	   assay	  was	   used	   to	   determine	   proteolysis	   conditions,	   in	   which	   the	   reactions	  
could	  be	  analyzed	  by	  SDS-­‐PAGE	  fluorescence	  after	  GFP-­‐TcdA	  CPD	  activation.	  	  	  In	  efforts	  to	  make	  
the	   assay	   high	   throughput	   and	   relevant	   for	   screening	   a	   library	   of	   molecules,	   we	   used	   pre-­‐
determined	   conditions	   to	   develop	   an	   assay	   that	   could	   be	   performed	   in	   a	   96-­‐well	   plate	   and	  
analyzed	  by	  a	  plate	  reader.	  	  	  
	  
Figure	   3.9.	   	   Development	   of	   an	   assay	   to	   screen	   stimulators	   of	   TcdA	   auto-­‐processing.	   (A)	  
Structure	  of	  biotin	  and	  the	  linker	  after	  conjugation	  with	  an	  acceptor	  protein	  primary	  amine.	  	  
Biotin	   reagent	   used	   in	   protein	   labeling:	   Sulfo-­‐NHS-­‐SS-­‐Biotin	   (Sulfosuccinimidyl-­‐2-­‐
[biotinamido]ethyl-­‐1,3-­‐dithiopropionate).	  	  (B)	  Scheme	  of	  CPD	  cleagave.	  Biotin-­‐SS-­‐GFP-­‐TcdA	  is	  
bound	   to	   streptavidin	   presenting	   resin	   prior	   to	   incubation	   with	   IP6	   to	   induce	   CPD	   auto-­‐
processing.	   	   Lysates	  will	   contain	   released	  GFP,	  protein	   remaining	  on	   the	   resin	   is	   release	  by	  
reduction	   of	   the	   disulfide	  bond	   in	   the	   biotin	   linker.	   	   (C)	  Expected	   results	  after	   collecion	  of	  
supernatant	  under	  various	  conditions. 
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In	  development	  of	   this	   system,	  we	   initially	   utilized	  Ni-­‐NTA	  magnetic	   beads	   to	   capture	  
the	   fusion	  protein	  by	   its	  C-­‐terminal	  His6-­‐tag.	   	   Ideally,	   this	   system	  would	   immobilize	  GFP-­‐TcdA	  
and,	   upon	   CPD	   auto-­‐processing,	   the	   N-­‐terminus	   reporter	   protein	   would	   be	   released	   and	  
detectable	  in	  the	  supernatant.	   	  Our	  results	  reveal	  that	  the	  protein/resin	  interaction,	  Ni2+/His6-­‐
tag	   binding,	   is	   sensitive	   to	   in	   vivo	   proteolysis	   conditions	  with	   IP6.	   IP6	   binds	   heavy	  metal	   ions	  
	  
Figure	  3.10.	  	  Results,	  IP6	  induced	  auto-­‐cleavage	  of	  Biotin-­‐SS-­‐GFP-­‐TcdA.	  	  GFP	  is	  released	  by	  the	  
CPD	  domain	  (-­‐	  DTT)	  or	  full	   length	  protein	  is	  released	  by	  reducing	  the	  disulfide	  between	  the	  
biotin	   and	   GFP-­‐TcdA	   (+	   DTT)	   monitored	   by	   supernatant	   fluorescence	   (Top)	   or	   SDS-­‐PAGE	  
separation	  and	  fluorescence	  analysis	  (Bottom). 
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(cadmium,	   copper,	   lead,	  nickel,	   and	   zinc	   ions),	  which	  perhaps	  accounts	   for	   release	  of	   control	  
proteins	  in	  the	  presence	  of	  IP6	  (342).	  We	  next	  focused	  on	  the	  biotin/streptavidin	  interaction	  for	  
protein	  immobilization.	  	  	  
GFP-­‐TcdA	  was	  labeled	  with	  a	  biotin	  reagent	  that	  includes	  a	  disulfide	  bond	  in	  the	  linker	  
between	   the	  biotin	  and	   the	  protein	   (Figure	  3.9,	  A).	   	   The	  biotin	   labeled	  protein	  was	  bound	   to	  
streptavidin	   coated	   magnetic	   beads	   for	   the	   assay.	   	   After	   incubation	   under	   CPD	   proteolysis	  
conditions,	   the	   cleavage	  
products	   were	   collected.	   	   The	  
supernatant	   was	   expected	   to	  
contain	   the	   released	   reporter	  
protein;	   the	   remaining	   toxin	  
fragment,	   including	  
unprocessed	   full-­‐length	  
protein,	   will	   remain	   bound	   to	  
the	   magnetic	   bead	   (schematic	  
in	   Figure	   3.9,	   B).	   Reduction	   of	  
the	   disulfide	   linker	   released	   the	   remaining	   protein	   from	   the	   bead	   to	   assess	   activated	   vs.	  
inactivated	   CPD.	   The	   fractions	   were	   analyzed	   by	   a	   plate	   reader	   spectrometer	   to	   detect	  
processed	  vs.	  unprocessed	  protein	  by	  comparing	  fluorescent	   intensity	  of	  cleavage	  and	  elution	  
supernatants,	   respectively	   (figure	   3.10,	   A).	   	   Further	   investigation	   by	   SDS-­‐PAGE	   indicates	   that	  
most	  of	  the	  protein	  is	  unprocessed	  in	  these	  conditions,	  and	  only	  released	  from	  the	  bead	  after	  
denaturing	   the	   proteins	   with	   SDS	   loading	   buffer	   (figure	   3.10,	   B).	   	   While	   determining	   assay	  
	  
Figure	   3.11.	   	   IP6	   induced	   CPD	   auto-­‐proteolysis	   is	   Tween®	   20	  
sensitive.	   	   Fluorescent	   analysis	   after	   SDS-­‐PAGE	   separation	   of	  
Biotin-­‐SS-­‐GFP-­‐TcdA	   to	  detect	   IP6	   induced	  auto-­‐proteolysis	  +/-­‐	  
tween-­‐20	  detergent.	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conditions,	   we	   followed	   the	   manufacturer’s	   suggestions	   for	   protocols	   involving	   Streptavidin	  
coated	  magnetic	  beads,	  and	   included	  0.1%	  Tween®	  20	   throughout	   the	  assay.	  The	  addition	  of	  
Tween®	   20	   could	   be	   the	   reason	   for	  minimal	   proteolysis	   of	   the	   protein.	   It	  was	   observed	   that	  
Tween®	  20	  does	  not	  affect	  the	  fluorescent	  signal,	  yet	  it	  did	  affect	  the	  processing	  induced	  by	  IP6	  
(Figure	   3.11).	   	   A	   library	   of	  molecules	   could	   be	   screened	  with	   this	   assay	   to	   identify	   potential	  
TcdA	  inhibitors	  in	  the	  absence	  of	  Tween®	  20.	  	  
3.9. Conclusions	  	  
It	  would	  be	  advantageous,	  for	  therapeutic	  and	  research	  reasons,	  to	  develop	  a	  working	  
system	  to	  move	  various	  cargos	  across	  the	  cell	  membrane,	  to	  be	  released	  freely	  into	  the	  cytosol.	  	  
Here	  we	   provided	   evidence	   for	   the	   production	   of	   such	   a	   system	   using	   a	   bacterial	   toxin	   that	  
already	  has	  the	  machinery	  to	  enter	  and	  translocate	  a	  cargo	   into	  mammalian	  cells,	  where	   it	   is	  
released	  without	  additional	  residues.	  	  
Two	   cargo-­‐tcdA	   chimeric	   genes	   were	   constructed,	   expressed	   in	   B.	   megaterium,	   and	  
purified.	   	  Cellular	  delivery	  of	   luciferase	  by	  Luc-­‐TcdA	  has	  been	  studied	  extensively.	   	  As	   for	   the	  
GFP-­‐TcdA	  construct,	  we	  believe	  the	  stable	  structure	  of	  GFP	  may	  block	  translocation,	  as	  escape	  
through	  a	  membrane	  pore	   is	   expected.	   	   Clearly	   the	   fact	   that	   the	  GFP-­‐TcdA	   chimera	   failed	   to	  
show	  measurable	  cellular	  uptake	  indicates	  that	  the	  overall	  fold	  of	  the	  cargo	  is	  relevant	  to	  this	  
process,	  but	   the	   limits	   in	   terms	  of	   size,	   stability	  and	  other	  physical	  properties	  have	  yet	   to	  be	  
established.	  
Enzymatic	  activity	  of	  Luciferase,	  which	  we	  depend	  on	  for	  the	  luminescent	  signal	  of	  the	  
reporter,	  is	  dependent	  on	  an	  intramolecular	  disulfide.	  	  This	  disulfide	  is	  expected	  to	  be	  reduced	  
in	   the	   cytosol.	   	   This	   factor	   led	   us	   to	   analyze	   cell	   lysates	   after	   incubation	   with	   Luc-­‐TcdA	   to	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observe	   internalized	  protein.	   	   Analysis	   of	   clarified	   cell	   lysate,	   after	   incubation	  with	   Luc-­‐TcdA,	  
revealed	  that	  active	   luciferase	  was	  delivered	  to	  cells.	   	  We	  demonstrated	  that	  the	  protein	  was	  
delivered	  to	  the	  cytosol	  by	  detecting	  CPD	  cleavage	  products	  in	  cell	  lysates	  by	  size	  separation.	  	  	  	  	  
We	  are	  confident	  our	  Luc-­‐TcdA	  protein	  follows	  the	  cell	  entry	  route	  native	  to	  TcdA,	  as	  we	  
have	   employed	   immunocytochemistry	   to	   observe	   Luc-­‐TcdA	   bound	   and	   internalized	   after	  
incubation	  with	  vero	  cells.	  Further	  work	  may	  yield	  an	  improved	  system	  with	  increased	  delivery	  
by	  exploring	  TcdA	  sequence	  requirements	  and	  additional	  cargo	  domains.	  	  	  
3.10. Materials	  and	  methods	  
Biosafety	  level	  2	  material.	  	  
All	  procedures	  with	  tcdA	  DNA	  were	  carried	  out	  in	  a	  Biosafety	  level	  2	  lab	  (BL2)	  following	  
standard	   operating	   procedures	   (SOP).	   	   The	   protein	  was	   removed	   from	  BL2	   only	   after	   lysates	  
were	  sterile	  filtered	  and	  DNAase	  treated.	  
Cargo-­‐TcdA	  plasmid	  construction.	  	  	  
Emerald	  gfp	  and	  Gaussia	  luciferase	  genes	  were	  amplified	  from	  plasmids	  (pRSET/EmGFP,	  
Invitrogen,	  and	  pGLuc,	  LUX	  Biotechnology,	  respectively)	  using	  primers	  designed	  to	  add	  5’	  SpeI	  
and	  3’	  BamHI	   restriction	  sites.	  Genes	  were	  amplified	  with	  Taq	  DNA	  Polymerase	  (5	  Prime)	  and	  
cloned	  into	  the	  TOPO	  XL	  vector	  (Invitrogen).	  	  The	  TOPO	  plasmids	  were	  digested	  using	  SpeI	  and	  
BamHI	  (New	  England	  Biolabs)	  and	  the	  excised	  genes	  were	  ligated	  (Promega,	  T4	  DNA	  ligase)	  into	  
a	  modified	  pWH1520	  vector	  (343)	  using	  the	  Quick	  Ligation™	  Kit	  (New	  England	  Biolabs)	  to	  yield	  
pSK80406	  (gfp)	  and	  pSK80404	  (luciferase).	  	  	  
To	   complete	   the	   chimera	   construction,	   BamHI	   and	   SphI	   (New	   England	   Biolabs)	   were	  
used	   to	   remove	   the	   tcdA	   gene	   fragment	   coding	   for	   amino	   acids	   540-­‐2710,	   and	   the	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chloramphenicol	  acetyltransferase	  (cat)	  gene,	  from	  a	  modified	  pUC19	  plasmid	  containing	  rtcdA	  
(343).	   	   This	   fragment	   was	   ligated	   into	   pSK80406	   and	   pSK80404	   to	   create	   the	   reporter-­‐tcda	  
chimeras,	   pSK80408	   and	   pSK80410.	   The	   cat	   gene	   was	   subsequently	   removed,	   yielding	   final	  
plasmids	   pSK80409	   (gfp-­‐tcdA)	   and	   pSK80411	   (luc-­‐tcdA).	   	   These	   plasmids	   were	   verified	   by	  
sequencing.	  
Protein	  expression	  and	  purification.	  	  
The	   Bacillus	   megaterium	   Protein	   Expression	   System	   (MoBiTec)	   was	   used	   for	   the	  
expression	  of	  all	  proteins.	   	  Expression	  was	  induced	  by	  addition	  of	  1%	  xylose	  to	  1	  L	  cultures	  at	  
OD600	  ~0.3-­‐0.4.	  	  Cells	  were	  sonicated	  (5	  x	  30	  seconds)	  in	  lysis	  buffer	  (50	  mM	  sodium	  phosphate,	  
300	  mM	  NaCl,	  10	  mM	  imidazole,	  EDTA-­‐free	  protease	  inhibitor	  cocktail	  (Roche),	  pH	  8.0).	  	  After	  
clarification	   (14	  krpm,	  40	  min,	  4	   °C),	   the	  C-­‐terminal	  His6-­‐tag	  was	  used	   for	  affinity	  purification	  
(Hi-­‐Trap	   chelating	   HP,	   GE	   Healthcare),	   followed	   by	   size	   exclusion	   chromatography	   (HiLoad™	  
16/60	   SuperdexTM	   200	   prep	   grade,	   Amersham	   Biosciences).	   	   Purification	   was	   completed	   by	  
concentrating	   fractions	   and	   dialysis	   into	   storage	   buffer	   (50	  mM	   sodium	   phosphate,	   300	  mM	  
NaCl,	  pH	  7.4).	  	  
Ni-­‐NTA	  resin	  microscopy.	  	  
All	   microscope	   images	   were	   obtained	   using	   an	   Olympus	   IX	   1X71	   microscope	   with	   a	  
ROLERA-­‐XR	   Fast	   1394	   CCD	   camera.	   	   Images	   were	   processed	   with	   QCapture	   Pro51	   version	  
5.1.1.14	   for	  Windows.	   	   To	  bind	  proteins,	  Ni-­‐NTA	   agarose	   resin	   (QIAGEN)	  was	   incubated	  with	  
GFP,	   GFP-­‐TcdA,	   luciferase,	   or	   Luc-­‐TcdA	   overnight	  while	   rotating	   at	   4	   °C.	   	   Excess	   protein	  was	  
washed	   away	   prior	   to	   imaging.	   	   To	   visualize	   EmGFP	   or	   GFP-­‐TcdA,	   a	   few	   drops	   of	   resin	   with	  
bound	  protein	  was	  placed	  onto	  a	   slide	  under	  a	  cover	   slip,	  brought	   into	   focus,	  and	  signal	  was	  
	  	  
94	  
detected	  at	  509	  nm	  when	  excited	  at	  487	  nm.	  	  To	  image	  luminescence	  from	  Luc-­‐TcdA,	  the	  resin	  
was	  brought	  into	  focus	  in	  bright	  field	  without	  a	  cover	  slip,	  and	  then	  illumination	  was	  turned	  off.	  
The	  exposure	  time	  was	  increased	  to	  45	  seconds	  and	  a	  solution	  containing	  the	  substrate	  (native	  
coelenterazine	   (cnz),	   LUX	   Biotechnology)	   was	   added	   and	   luminescence	   was	   imaged	  
immediately.	  
Cell	  cultures.	  	  
Vero	  cells	  (adherent	  epithelial	  cells	  from	  the	  African	  green	  monkey,	  ATCC	  CCL-­‐81)	  were	  
cultivated	   in	   Eagle’s	  Minimum	  Essential	  Media	   (EMEM,	  ATCC)	   supplemented	  with	   10	  %	   fetal	  
bovine	   serum	   (FBS,	   ATCC),	   100	   units	   penicillin,	   100	   µg	   streptomycin,	   and	   0.25	   µg/mL	  
amphotericin	  B	  (antibiotic-­‐antimycotic,	  Invitrogen).	  	  Cells	  were	  maintained	  at	  <80	  %	  confluency,	  
and	   reseeded	  after	  being	   trypsinized	   (Trypsin-­‐EDTA,	  Cellgro)	  3	   times	  a	  week.	  Vero	   cells	  were	  
trypsinized	  and	  incubated	  in	  fresh	  media	  before	  being	  plated	  for	  experiments.	  	  	  
Cell	  lysate	  assays.	  	  
Vero	  cells	  were	  plated	  and	  washed	  as	  described	  above.	  	  The	  cells	  were	  incubated	  for	  60	  
minutes	  with	  200	  nM	   luciferase	  or	  Luc-­‐TcdA,	   in	   serum	  free	  EMEM.	   	  When	   indicated,	  100	  nM	  
Bafilomycin	  A1	  was	  included.	  	  For	  acid	  pulse	  experiments,	  the	  protein	  incubation	  was	  followed	  
by	  an	  exchange	  of	  media,	  into	  PBS	  at	  pH	  5	  and	  incubated	  5	  min	  at	  37	  °C,	  5	  %	  CO2.	  	  Cells	  were	  
then	  washed	  and	  the	  lysate	  was	  collected	  after	  mechanical	  or	  detergent	  lysis.	  	  	  For	  mechanical	  
lysis,	   cells	  were	  suspended	  by	  scraping	   into	  20	  mM	  Tris-­‐HCl	  pH	  7.4,	  300	  mM	  NaCl	   containing	  
EDTA-­‐free	   protease	   inhibitor	   cocktail	   (Roche),	   and	   the	   suspension	   was	   passed	   through	   a	   26	  
gauge	  needle	  15	  times	  (299),	  to	  yield	  crude	  lysate.	  	  For	  detergent	  lysis,	  100	  µL	  MPER	  (Thermo	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Scientific)	  was	  added	  to	  each	  well	  and	   incubated	  for	  5	  min.	  at	  room	  temperature	  with	  gentle	  
shaking.	  	  Crude	  lysates	  were	  clarified	  by	  centrifugation	  (14	  kRPM	  for	  60	  minutes	  at	  4	  °C).	  	  	  
Luciferase	   activity	   was	  monitored	   using	   a	   plate	   reader	   in	   luminescence	  mode	   (Tecan	  
GENios	  Plus	  multi	  label	  reader).	  	  Each	  sample	  to	  be	  measured	  started	  with	  reaction	  buffer	  in	  a	  
96	  well,	   flat,	  MicroFluor®	  2	  plate	  (Thermo	  Scientific);	   for	  a	   final	  concentration	  of	  20	  mM	  Tris-­‐
HCl,	  300	  mM	  NaCl,	  20	  mM	  Na	  EDTA	  pH	  7.4,	  and	  40	  µM	  cnz.	  To	  start	  the	  reaction,	  cell	  lysate	  was	  
added	  by	  multichannel	  pipette,	  and	   immediately	  measured	   for	   relative	   light	  units	   (RLU),	   gain	  
was	  set	  to	  150	  with	  orbital	  shaking	  for	  3	  seconds	  with	  no	  settle	  time	  at	  25	  °C.	  	  	  
For	   size	  exclusion	  of	   the	   lysate	   fraction,	  microcon	  YM100	  centrifugal	   filtration	  devices	  
were	   used	   (Millipore).	   	   Clarified	   lysate,	   after	   detergent	   lysis,	   was	   applied	   to	   the	   device,	  
following	  the	  manufacture’s	  protocol;	  the	  majority	  of	  the	  sample	  was	  filtered.	  	  Signal	  from	  each	  
fraction	  was	  corrected	  for	  incomplete	  filtration,	  and	  normalized	  to	  the	  initial	  sample.	  	  
Immunochemistry.	  	  	  
Vero	  cells	  were	  plated	  at	  5	  x	  104	  per	  well	  in	  a	  24	  well	  plate,	  in	  0.5	  mL	  Eagle’s	  Minimum	  
Essential	  Medium	  (EMEM)	  with	  10	  %	  fetal	  bovine	  serum	  (FBS),	   for	  24	  hours	   (37	  °C,	  5	  %	  CO2).	  	  
Each	  well	  was	  then	  washed	  with	  1	  mL	  serum-­‐free	  EMEM,	  then	  incubated	  60	  minutes	  with	  250	  
µL	  protein	  at	  32	  nM	  in	  serum	  free	  EMEM	  (4	  °C	  to	  bind	  the	  protein,	  or	  37	  °C	  to	  internalize	  the	  
protein).	  	  Cells	  were	  fixed	  by	  formalin	  treatment	  (10	  minute	  incubation	  at	  room	  temperature	  in	  
3.7	  %	  formalin	  in	  PBS),	  and	  then	  washed	  twice	  with	  1	  mL	  PBS.	  	  Nonspecific	  binding	  was	  blocked	  
(block	   buffer:	   PBS	   +	   0.1%	   triton	   x-­‐100,	   0.2%	   BSA,	   60	   minutes,	   shaking	   at	   4	   °C)	   before	   the	  
primary	   antibody	   was	   bound	   (mouse	   monoclonal	   anti-­‐TcdA	   (Abcam)	   diluted	   1:500	   in	   block	  
buffer,	  incubated	  60	  minutes,	  shaking	  at	  4	  °C).	  	  Each	  well	  was	  washed	  twice	  with	  1	  mL	  PBS,	  and	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the	  secondary	  antibody	  was	  allowed	  to	  bind	  (Goat	  anti-­‐mouse	  dylight-­‐549	  (Thermo	  Scientific),	  
1:5000	  dilution	  in	  block	  buffer	  and	  incubate	  60	  minutes,	  shaking	  at	  4	  °C).	  	  After	  three	  washes	  (1	  
mL	  PBS),	  cells	  from	  each	  well	  were	  imaged	  in	  mount	  solution	  (50%	  glycerol	  in	  100mM	  Tris,	  pH	  
8.0).	  
IP6	  induced	  autoprocessing.	  	  
Native	  TcdA	  (nTcdA,	  Techlab	  lot	  #1004051),	  Luc-­‐TcdA,	  or	  GFP-­‐TcdA	  was	  incubated	  with	  
IP6	  to	  induce	  autoproteolytic	  processing.	  	  In	  100	  µL	  total	  volume,	  2	  µM	  protein	  was	  incubated	  
at	  37	  °C	  overnight	  in	  20	  mM	  Tris-­‐HCl	  pH	  7.5,	  80	  mM	  NaCl,	  250	  mM	  sucrose,	  and	  supplemented	  
with	   5	   µM	   IP6.	   	   Samples	   were	   analyzed	   by	   SDS-­‐PAGE	   for	   protein	   cleavage.	   	   For	   in-­‐gel	  
fluorescence	   analysis	   of	   GFP	   and	   GFP-­‐TcdA,	   samples	   in	   SDS	   loading	   buffer	   were	   not	   heated	  
before	  separation;	  the	  SDS-­‐PAGE	  was	  scanned	  for	  fluorescence	  (532/526	  nm)	  using	  a	  Typhoon	  
9210	  imager	  (GE	  Healthcare).	  	  	  
Biotinylation	  of	  proteins.	  	  	  
Proteins	   were	   biotinylated	   following	   manufacturer’s	   protocol	   for	   sulfo-­‐NHS-­‐SS-­‐biotin	  
(Thermo	   scientific,	   21328).	   	   Excess	  Biotinylation	   reagent	   (30	  mM)	   to	  GFP-­‐TcdA	   (1.4	  mM)	   in	  a	  
total	   volume	   of	   2.0	   mL	   in	   PBS.	   	   Reactions	   were	   incubated	   on	   ice	   for	   2.5	   hours,	   and	   excess	  
biotinylation	  reagent	  was	  removed	  by	  extensive	  dialysis.	   	  Biotinylated	  GFP-­‐TcdA	  was	  found	  to	  
undergo	  auto-­‐processing	  to	  the	  same	  extent	  as	  the	  non-­‐biotinylated	  protein.	  Auto-­‐processing	  
was	  inhibited	  by	  0.1%	  Tween®	  20.	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4. Inhibition	  of	  TcdA/B	  as	  CDI	  treatment	  option	  
4.1. Background	  
CDI	   is	   a	   growing	   epidemic	   around	   the	   globe	   with	   few	   treatment	   and	   high	   rates	   of	  
relapse	   and	   reinfection.	   	   Infection	   is	   most	   often	   transmitted	   in	   healthcare	   settings	   through	  
transfer	   of	   robust	   spores	   that	   are	   not	   easily	   eradicated	   with	   common	   cleaners.	   	   Increasing	  
healthcare	   costs,	   high	   probability	   of	   relapse	   and	   reinfection,	   and	   identification	   of	   a	   hyper	  
virulent	   strain	   with	   increasing	   rates	   of	   antibiotic	   resistance	   that	   is	   found	   to	   infect	   younger,	  
healthier	   individuals	   (314,320)	  make	   it	   clear	   that	  more	   treatment	   options	  must	   be	   explored.	  	  
Alternative	   therapies	   have	   been	   studied;	   none	   have	   proven	   to	   be	   a	   superior	   therapeutic	  
solution	   to	   current	   antibiotics	   in	   use.	   	   Chapter	   2	   contains	   details	   of	   the	   currently	   used	   and	  
explored	   treatments	   against	   CDI.	   	   We	   hypothesize	   that	   targeting	   the	   toxins	   will	   induce	   less	  
stress	  on	   the	  organism,	  and	   therefore	   reduce	  selective	  pressure	   for	   the	  bacterium	  to	  mutate	  
and	  become	  resistant	  to	  treatment.	  	  This	  chapter	  explains	  the	  theory	  behind	  and	  success	  in	  the	  
development	  of	  a	   toxin	   inhibitor	   that	  we	  believe	  to	  be	  a	   likely	   lead	  compound	  toward	  a	  new	  
therapeutic	  agent	  against	  CDI.	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4.2. Identification	  of	  active-­‐site	  specific	  peptide	  inhibitors	  of	  TcdA	  
Our	   lab	   has	   identified	   peptides,	   using	   a	   phage	   display	   system,	   that	   bind	   the	   catalytic	  
domain	   of	   TcdA.	   	   The	   final	   collected	   peptides	   bind	   TcdA540,	   a	   truncation	   of	   TcdA	   including	  
residues	   1-­‐540	   (Figure	   4.1),	   in	   competition	   with	   one	   of	   the	   toxin’s	   native	   substrates,	   RhoA	  
(344).	   	   For	   further	   characterization	   of	   the	   peptides,	   there	  were	   two	   routes	   of	   interest.	   	   Our	  
options	   included	   using	  
synthetic	   peptides	   or	  
recombinant	   expression.	  	  
Synthetic	  peptides	  are	   labor	  
intensive	   and	   costly	   to	  
prepare,	   whereas	  
recombinant	   expression	   of	  
very	   small	   peptides	   (~1	   kD)	  
presents	   a	   recovery	  
challenge.	   	   To	   tackle	   both	  
avenues,	  we	  studied	  a	  select	  
group	   of	   synthetic	   peptides	  
while	  developing	  a	  recombinant	  expression	  system	  in	  parallel.	  	  	  
4.3. TcdA	  binding	  and	  activity	  assays	  
This	  section	  describes	  assays	  that	  are	  used	  in	  our	  lab	  to	  study	  TcdA	  activity	  in	  vitro	  and	  
in	   cellulo.	   	   Binding,	   GT,	   and	   GH	   activities	   are	   important	   functions	   and	   have	   been	   useful	   in	  
	  
Figure	   4.1.	   Schematic	   of	   TcdA	   and	   TcdA
540
	   proteins	   and	  
activity.	   	   Functional	   domains	   	   include	   the	   membrane	  
localization	   domain	   (MLD,	   gray),	   glucosyltransferase	   domain	  
(GT,	  red),	  cysteine	  protease	  domain	  (CPD,	  blue),	  translocation	  
domain	   (TD,	   orange),	   and	   receptor	   binding	   domain	   (RBD,	  
green)	  (A).	  	  The	  truncated	  protein,	  TcdA
540
,	  is	  expressed	  for	  in	  
vitro	  activity	  assays.	  	  In	  vitro,	  TcdA
540
	  catalyzes	  the	  transfer	  of	  




studying	   molecules	   for	   enzymatic	   inhibition.	   	   Biological	   relevance	   can	   be,	   and	   is	   typically,	  
assessed	  in	  cellulo,	  before	  animal	  models.	  	  
4.3.1. Binding,	  ELISA-­‐like	  plate	  assay	  
Since	  binding	  is	  necessary	  for	  enzyme	  inhibition,	  binding	  assays	  are	  a	  convenient	  way	  to	  
collect	  initial	  data	  from	  a	  large	  set	  
of	  sequences.	  	  Binders	  can	  later	  be	  
assessed	   in	  activity	  assays	   (see	  GT	  
and	  GH	   assays	   below).	   	   To	   detect	  
binding	   to	   TcdA,	   we	   employed	   a	  
plate	   binding	   assay	   similar	   to	   an	  
ELISA	   (enzyme-­‐linked	  
immunosorbent	   assay).	   Figure	   4.2	  
demonstrates	   the	   protocol	   where	  
TcdA540	  is	  incubated	  overnight	  in	  a	  
96-­‐well	   plate	   to	   facilitate	   binding	  
to	   the	   plastic	   surface.	  	  	  
Unoccupied	   surfaces	   are	   blocked	  
with	   milk	   or	   BSA	   solution	   before	  
adding	   the	   substance	  we	  wanted	   to	   test	   for	  TcdA	  binding,	   such	  as	   the	  M-­‐peptide-­‐GFP	   fusion	  
protein	  (construct	  explained	  below)	  or	  GFP	  as	  a	  control.	  	  Binding	  is	  assessed	  using	  detection	  of	  
the	   bound	   moiety,	   whether	   by	   GFP	   fluorescence	   or	   immunochemistry.	   	   Detection	   indicates	  
	  
Figure	  4.2.	  	  Detection	  of	  TcdA
540	  
binding.	   	  An	  ELISA-­‐like	  
binding	   plate	   assay	   is	   used	   to	   screen	   compounds	   and	  
identify	   those	   that	   bind	   the	   catalytic	   domain	   of	   TcdA.	  	  
TcdA
540
	  is	  incubated	  and	  allowed	  to	  absorb	  to	  the	  wells	  
of	   a	   96-­‐well	   plate,	   after	   washing	   excess	   protein	   and	  
blocking	   surfaces	   with	   milk	   protein	   or	   BSA,	   molecules	  
(phage	   displaying	   peptides	   of	   interest	   or	   recombinant	  
peptide)	   are	   allowed	   to	   bind.	   	   Signal	   intensity,	   from	  
antibodies	  against	  the	  phage	  or	  GFP	  fluorescence	  from	  
M-­‐peptide-­‐GFP,	   is	   plotted	   as	   a	   function	   of	   TcdA
540
	   or	  
molecule	  concentration.	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TcdA	   binding,	   and	   should	   be	   linear	   with	   concentration	   of	   TcdA540	   or	   the	   peptide	   being	  
evaluated.	  	  
4.3.2.	  	  Glucosyltransferase	  assay	  
TcdA	   hydrolyzes	   UDP-­‐
glucose	   and,	   in	   the	  presence	  of	  
substrate,	  transfers	  glucose	  to	  a	  
small	   signaling	   protein	   in	   the	  
Rho	   family	   of	   GTPases.	   	   We	  
most	   often	   study	   GT	   activity	  
with	   recombinant	   RhoA	   as	   a	  
substrate	   for	   in	   vitro	   assays.	  	  
Both	   proteins,	   TcdA540	   and	  
RhoA,	   are	   purified	   and	   studied	  
within	   14	   days,	   as	   initial	   rates	  
decline	   rapidly	   as	   the	   proteins	  
age.	   	  Our	  GT	  assay	   is	  optimized	  
to	   detect	   glucosylated	   RhoA	  
after	   TcdA540	   catalyzes	   the	  
transfer	  of	   radiolabeled	  glucose	  
from	  UDP-­‐[14C]-­‐glucose	   (Figure	   4.3).	   	   A	   standard	   curve	   is	   used	   to	   calculate	   the	   initial	   rate	   of	  
each	  reaction.	  	  A	  decrease	  in	  initial	  rate	  that	  is	  dependent	  on	  inhibitor	  concentration	  is	  qualified	  
as	  enzyme	  inhibition.	  
	  
Figure	   4.3.	   	   Glucosyltransferase	   assay.	   The	   TcdA
540
-­‐
catalized	   transfer	   of	   radiolabeled	   glucose	   to	   RhoA	   is	  
detected	   by	   filtering	   the	   reaction	   through	   a	   protein	  
binding	   membrane.	   	   Signal	   increased	   overtime,	   and	  
provided	  determination	  of	  the	  GT	  initial	  rate.	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4.3.3.	  	  Glucosylhyrolase	  assay	  
TcdA	  slowly	  hydrolyzes	  UDP-­‐glucose	   in	   the	  absence	  of	   substrate	   (345).	  We	  can	  detect	  
TcdA540	   mediated	   glucosylhydrolase	   (GH)	   activity	   in	   vitro	   using	   a	   coupled	   enzyme	   reaction	  
(188,346).	  	  In	  the	  presence	  of	  UDP,	  a	  product	  of	  UDP-­‐glucose	  hydrolysis,	  phosphoenolpyruvate	  
(PEP)	   is	  converted	  to	  pyruvate.	   	   In	   the	  conversion	  of	  pyruvate	  to	   lactate,	  NADH	   is	  oxidized	  to	  
NAD+.	   	   Since	   NAD+	  
does	   not	   absorb	   light	  
at	  340	  nm,	  monitoring	  
absorbance	   of	   NADH	  
at	  340	  nm	  allows	  us	  to	  
detect	   the	   UDP-­‐
glucose	   hydrolase	  
activity	  of	  TcdA	  (Figure	  
4.4).	   	   Similar	   to	   the	  
other	   assays,	   GH	   rate	  
is	   compared	   in	   the	  
presence	   and	   absence	  
of	  inhibitors.	  
4.3.4. 	  Cell	  protection	  
Although	  we	   can	   learn	   a	   great	   deal	   about	   enzymes	   in	   vitro,	   the	   biological	   application	  
must	  be	  tested	  in	  living	  systems.	  	  Animal	  and	  human	  trials	  are	  most	  valuable,	  yet	  screening	  in	  
cell	  culture	  provides	  a	  filter	  for	  initial	  studies.	  	  To	  determine	  in	  cellulo	  protection,	  we	  monitored	  
	  
Figure	   4.4.	   	   Glucosylhydrolase	   assay.	   	   An	   in	   vitro	   enzyme	   coupled	  
assay	  is	  used	  to	  monitor	  the	  GH	  activity	  of	  TcdA
540
.	  As	  UDP-­‐glucose	  
is	  hydrolyzed,	  UDP	   is	  released	  and	  utilized	  the	  the	  reaction	  shown.	  	  
The	  release	  of	  UDP	   is	   followed	  by	  a	  reduction	  in	  NADH	  absorption	  
(340	  nm). 
Phosphoenolpyruvate	   (PEP);	   uridine	   triphosphate	   (UTP);	  
nicotinamide	  adenine	  dinucleotide	  (NADH). 
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mammalian	  cell	  viability	  after	  recombinant	  TcdA	  (rTcdA)	   intoxication	  the	  absence	  or	  presence	  
of	  inhibitor.	  	  	  
Cell	   viability	   was	   monitored	   by	   morphology	   or	   a	   quantitative	   viability	   assay.	  	  
Morphology	   is	   easy	   to	   monitor	   with	   a	   microscope,	   as	   healthy	   cells	   remain	   adherent	   and	  
elongated	   whereas	   damaged	   cells	   lose	   adherence	   and	   become	   rounded	   (Figure	   4.5).	   The	  
viability	   assay	   our	   lab	   employed	   is	   a	   commercially	   available,	   luciferase-­‐based	   assay	   that	  
correlates	  the	  concentration	  of	  cellular	  ATP	  with	  cell	  health	  (Figure	  4.6).	  Cells	  were	  incubated	  




Figure	   4.5.	   	   Cell	   health	   monitored	   by	   morphology.	   	   Healthy	   Vero	   cells	   are	   adherent,	  
elongated,	   and	   form	  monolayers	   as	   observed	   in	   the	   buffer	   only	  microscopic	   images	   (left).	  	  
Morphological	  changes,	  rounded	  detaching	  cells,	  are	  observed	  in	  the	  presence	  of	  increasing	  
toxin	  concentration	  (top	  row)	  and	  increasing	  time	  (not	  shown).	  	  Cell	  protection	   is	  observed	  
with	  molecules	  that	  block	  TcdA-­‐induced	  cell	  rounding	  (bottom	  row,	  Bafilomycin	  A1	  (Baf	  A1)	  
inhibits	  endosomal	  acidicfication	  and	  therefore	  TcdA	  escape).	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Figure	  4.6.	  	  Cell	  health	  monitored	  by	  viability	  assay.	  	  Conditions	  for	  a	  viability	  assay	  used	  to	  assess	  cell	  
protection	   are	   vital.	   	   TcdA	   concentration	   and	   incubation	   time	   are	   the	   two	  most	   important	   influence	  
factors	  (A).	  	  The	  CellTiter-­‐Glo	  viability	  assay	  is	  based	  on	  the	  light	  read	  out	  which	  results	  from	  mixing	  a	  
luciferase	  enzyme,	  and	  the	  substrate,	  luciferin,	  with	  cell	  lysates	  (B).	  	  The	  turnover	  is	  dependent	  on	  ATP,	  
which	   is	   provided	   by	   the	   cells.	   	   Since	   cellular	   ATP	   is	   proportional	   to	   cell	   viability,	   and	   light	   output	   is	  
dependent	  on	  cellular	  ATP,	  light	  output	  is	  therefore	  proportional	  to	  cell	  viability	  (C).	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4.4. Recombinant	  expression	  of	  peptides	  for	  characterization	  
4.4.1. 	  Overview	  
A	  recombinant	  expression	  system	  is	  a	  convenient,	  fast,	  and	  low	  cost	  way	  to	  collect	  high	  
protein	   yields	   and	   easily	   manipulates	   sequences	   to	   build	   a	   library.	   	   For	   our	   purposes,	   the	  
development	  of	  a	  system	  for	  expression	  of	  a	  peptide	   library	  based	  on	  sequences	   identified	   in	  
the	  phage	  display	  experiments	  would	  be	  extremely	  useful	   in	  characterizing	  various	  sequences	  
for	   TcdA	   binding	   and	   inhibition.	   	   We	   faced	   two	   main	   challenges	   in	   this	   project,	   first,	   the	  
peptides	  are	   too	  small	   (~1	  kD)	   to	  be	  expressed	  and	  collected.	   	  Therefore	  we	   fused	  the	  seven	  
residues	  to	  a	  carrier	  protein,	  GFP,	  for	  ease	  of	  expression	  and	  purification.	  	  Second,	  recombinant	  
expression	  yields	  products	  with	  additional	  residues,	  such	  as	  the	  methionine	  residue	  encoded	  by	  
the	  start	  codon.	  	  This	  section	  details	  the	  techniques	  employed	  and	  evaluation	  of	  recombinantly	  
expressed	  peptides	  compared	  to	  their	  synthetic	  counterparts.	  
4.4.2. 	  M-­‐peptide-­‐GFP	  construct	  
In	   previous	   experiments,	   Sanofar	   Abdeen	   identified	   peptide	   sequences	   that	   bind	   TcdA	   in	  
competition	  with	  the	  substrate	  RhoA	  (344).	  These	  peptides	  were	  displayed	  from	  phage,	  with	  a	  
free	  N-­‐terminus.	   	  We	  therefore	  suspect	   that	   the	  N-­‐terminus	   is	   important	   in	   the	  peptide-­‐TcdA	  
binding	  interaction,	  so	  our	  first	  construct	  included	  the	  peptide	  sequence	  of	  interest	  fused	  to	  the	  
N-­‐terminus	   of	   emerald	   GFP	   (further	   referred	   to	   as	   GFP).	   	   This	   peptide-­‐GFP	   fusion	   also	   has	  
potential	   as	   a	   reporter	   in	   assays	   as	  we	  would	   observe	   peptide	   binding	   by	   following	   the	  GFP	  
fluorescence.	  	  	  
Initially,	   two	   peptides	   were	   chosen	   from	   Sanofar’s	   phage	   display	   binding	   data	   as	   “good	  
binders,”	  HQSPWHH	  and	  EGWHAHT.	   	  The	  sequence	   for	  each	  peptide	  was	  cloned	   into	   the	  M-­‐
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pep-­‐gfp	  construct	  with	  a	   linker	  of	  three	  glycine	  residues;	  to	  be	  further	  expanded	  into	  a	   larger	  
library	   after	   confirming	   the	   recombinantly	   expressed	   peptides	   behave	   similar	   to	   the	   phage	  
displayed	  peptides	  in	  our	  assays.	  	  
Conventional	   cloning	   and	   expression	   techniques	  were	   used	   to	   yield	   only	   one	   fluorescent	  
protein	  product	  when	  analyzed	  by	  SDS-­‐PAGE.	   	   LC-­‐ESI	  mass	   spectrometry	  data	  also	  confirmed	  
the	  identity	  of	  the	  purified	  protein	  as	  the	  expected	  product.	  	  Even	  though	  it	  is	  common	  for	  the	  
N-­‐terminal	   methionine	   to	   be	   cleaved	   from	   proteins	   expressed	   in	   E.	   coli,	   the	   LC-­‐ESI	   mass	  
spectrum	  indicates	  our	  protein	  is	  in	  intact	  with	  the	  methionine.	  	  It	  is	  a	  concern	  how	  this	  residue	  
will	  effect	  binding	  of	  our	  peptides	  to	  their	  target.	   Our	   results	   showed	   that	   the	   M-­‐pep-­‐GFP	  
construct	  does	  not	  bind	  to	  the	  catalytic	  domain	  of	  TcdA,	  which	  was	  further	  confirmed	  by	  a	  gel	  
shift	   assay	   under	   non-­‐denaturing	   conditions.	   These	   results	   indicated	   that	   peptide	   binding	   to	  
TcdA540	  does	  not	  tolerant	  a	  methionine	  residue	  at	  the	  N-­‐terminus.	  
4.4.3. 	  GFP-­‐TEV-­‐peptide	  construct	  
A	  new	  construct	  was	  designed	  following	  the	  finding	  that	  the	  N-­‐terminal	  methionine	  hinders	  
the	  binding	  of	  our	  peptides	  to	  TcdA540.	  	  A	  schematic	  representation	  of	  the	  construction	  of	  GFP-­‐
TEV-­‐pep	  or	  GFP-­‐TEV-­‐pep-­‐Arg8,	   is	  described	   in	  detail	   in	  the	  methods	  section,	  and	   illustrated	   in	  
Figure	   4.7.	   	   The	   final	   fusion	   gene	   sequence	   included	   an	  N-­‐terminal	  GFP	   followed	  by	   the	   TEV	  
protease	   site,	   ENLYFQG.	   The	   peptide	   sequences	   were	   constructed	   with	   and	   without	   a	   C-­‐
terminal	  poly-­‐arginine	   tag	   (Arg8).	   	   The	  poly-­‐arginine	   sequence	   is	  a	  CPP,	  CPPs	  are	  discussed	   in	  
Chapter	  1.	  	  Constructs	  including	  the	  Arg8	  tail	  were	  designed	  for	  in	  cellulo	  investigations,	  aimed	  
at	  cytosolic	  delivery,	  should	  it	  be	  required	  for	  TcdA	  inhibition.	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After	  TEV	  cleavage,	  the	  protease	  and	  GFP	  fragments	  were	  separated	  from	  the	  peptide	  
by	  affinity	  capture,	  as	  each	  protein	  encoded	  a	  His6-­‐tag.	  The	  peptide	  fraction	  was	  assessed	  for	  
TcdA	   GT	   and	   GH	   inhibition	   in	   vitro.	   	   Compared	   to	   the	   synthetic	   peptide,	   glucosyltransferase	  
inhibition	  was	  not	  observed	  via	  recombinant	  peptide.	  	  We	  again	  attributed	  this	  loss	  in	  activity,	  
likely	   due	   to	   loss	   of	   binding	   as	   was	   observed	   with	   M-­‐peptide-­‐GFP,	   to	   be	   the	   result	   of	   an	  
additional	  N-­‐terminal	  residue,	  this	  time	  it	  was	  a	  glycine	  left	  after	  TEV	  cleavage.	  	  To	  circumvent	  
the	   problems	   arising	   from	   additional	   N-­‐terminal	   residues	   on	   the	   recombinant	   peptides,	   we	  
utilized	  chemical	  cleavage	  by	  cyanogen	  bromide.	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Figure	  4.7.	  Recombinant	  peptide	  expression	  constructs.	   	  The	  center	  plasmid	  represents	  the	  
commercially	  available	  pRSET/emGFP	  plasmid	  as	   starting	  material	   for	   the	  GFP-­‐TEV-­‐peptide	  
construct	  (Top)	  or	  M-­‐peptide-­‐GFP	  construct	  (bottom). 
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4.4.4. 	  Cyanogen	  bromide	  cleavage	  of	  M-­‐peptide-­‐GFP	  
It	   is	  anticipated	   that	  our	  peptide	   inhibitors	  bind	   in	  a	   channel	  or	  pocket	  of	  TcdA540,	  where	  
additional	  residues,	  especially	  towards	  the	  N-­‐terminus,	  eradicate	  any	  binding	  interactions.	  	  Our	  
analysis	   of	   peptide	   inhibitors	   would	   benefit	   from	   a	   recombinant	   expression	   system	   yielding	  
small	  peptides	  without	  an	  N-­‐terminal	  residue.	  To	  this	  end,	  we	  analyzed	  peptide	  fragments	  after	  
chemical	  cleavage	  of	  M-­‐peptide-­‐GFP	  after	  treatment	  with	  cyanogen	  bromide.	  
Cyanogen	   bromide	   (CNBr)	   is	   a	   chemical	   reagent	   that	   cleaves	   peptides	   and	   proteins	   C-­‐
terminal	   of	  methionine	   residues	   (347,348).	   	   There	   is	   also	   a	  methionine	   residue	   between	   the	  
peptide	  and	  GFP	  therefore	  the	  products	  after	  CNBr	  cleavage	  include	  the	  peptide,	  released	  from	  
GFP,	  without	  additional	  N-­‐terminal	  residues.	  	  In	  vitro	  GT	  analysis	  revealed	  that	  the	  peptide	  did	  
not	   display	   similar	   in	   vitro	   inhibition	   as	   the	   native	   peptides,	   thus	   a	   second	   construct	   was	  
analyzed	  as	  a	  candidate	  for	  a	  peptide	  library	  recombinant	  expression	  system.	  
4.5. Synthetic	  peptide	  modification	  and	  characterization	  	  
4.5.1. Background	  
GTs	  catalyze	  the	  transfer	  of	  a	  monosaccharide	  to	  a	  glycosyl	  acceptor,	  usually	  an	  alcohol.	  	  
The	  glycosyl	  donors	  are	  often	  sugar	  nucleotides	  and	  acceptors	  include	  carbohydrates,	  glycans,	  
saccharides,	   inorganic	   phosphate,	   lipids,	   and,	   of	   most	   interest	   in	   our	   research,	   proteins.	  	  
Glucosyltransfer	   to	   a	   protein	   most	   often	   gives	   the	   O-­‐linked	   glycoprotein	   after	   transfer	   to	  
tyrosine,	  serine,	  or	  threonine.	  In	  some	  cases	  transfer	  to	  asparagine	  occurs	  yielding	  the	  N-­‐linked	  
glycoprotein	  (349).	   	  The	  glycosyl	  moiety	  can	  be	  transferred	  with	  stereochemistry	  retention	  or	  
inversion,	   depending	   on	   the	  mechanism,	   and	   is	   usually	   dependent	   on	   a	   metal	   co-­‐factor.	   	   A	  
proposed	  mechanism	  of	  TcdA/B	  GT	  is	  shown	  in	  chapter	  2.	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Interestingly,	  only	  three	  different	  folds	  are	  observed	  in	  comparing	  all	  GTs	  (350,351),	  and	  
many	   inhibitors	   have	   been	   identified.	   	   Some	   inhibitors	   are	   used	   as	   drugs,	   antibiotics,	   and	  
antifungal	  agents	  by	   inhibiting	  synthesis	  of	  essential	  cell	  wall	  components.	   	   	   In	  our	  case,	  a	  GT	  
inhibitor	   would	   be	   extremely	   useful	   but	   must	   be	   specific	   and	   effectively	   target	   the	   enzyme	  
extracellularly	   while	   withstanding	   endocytosis	   and	   translocation	   for	   complete	   intracellular	  
inhibition.	  
Since	  the	  natural	  acceptor	  of	  TcdA/B	  GT	  is	  a	  protein,	  we	  targeted	  peptides	  with	  active	  
site	  specificity	  using	  a	  phage	  display,	   leading	  to	  Sanofar’s	  paper	  (344).	   	  We	  provided	  evidence	  
that	   the	   peptides	   bind	   reversibly,	   and	   in	   competition	   with	   RhoA	   and	   UDP-­‐glucose.	  	  
Unfortunately,	   but	   not	   surprising,	   the	   peptides	   did	   not	   protect	   mammalian	   cells	   when	  
challenged	  with	  TcdA.	  	  We	  imagine	  peptides	  bind	  to	  the	  toxin	  extracellularly,	  but	  dissociate	  in	  
the	  acidified	  endosome	   leaving	   the	  GT	  domain	   to	   translocate	  with	   full	  enzymatic	  activity.	   	  To	  
develop	  these	  peptides	  into	  more	  potent	  inhibitors	  with	  therapeutic	  relevance,	  we	  considered	  
functional	  groups	  for	  irreversible	  binding.	  	  We	  therefore	  sought	  to	  identify	  residues	  within	  the	  
peptide	   sequence	   we	   could	  modify	   for	   covalent	   binding	   to	   the	   toxin	   without	   disrupting	   the	  
residues	  necessary	  for	  active	  site	  interactions.	  	  	  
Irreversible	   inhibitors,	  or	  suicide	  substrates,	  permanently	   inactivate	  target	  enzymes	  by	  
cross-­‐linking	   to	   a	   site	   that	   eliminates	   normal	   function.	   	   Our	   initial	   approach	   included	  
epoxidation	  of	  our	  peptides	  since	  previous	  reports	  of	  peptide	  and	  peptide-­‐like	  molecules	  with	  
epoxide	  modifications	  have	  been	  documented	  as	  effective	  glucosyltransferase	  inhibitors	  (352-­‐
356).	  	  The	  success	  of	  epoxides	  as	  effective	  enzyme	  inhibitors	  depends	  upon	  the	  presence	  of	  an	  
attacking	  nucleophile	  near	  the	  epoxide	  ring,	  within	  the	  active	  site,	  which	  then	  opens	  to	  form	  a	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covalent	   bond	   (354,357).	   	   Since	   the	   recombinant	   expression	   system	   was	   still	   under	  
construction,	  we	  relied	  on	  computational	  data,	  collected	  by	  Rebecca	  Swett,	  in	  determination	  of	  
which	  residues	  to	  modify.	  	  
4.5.2. Epoxidation	  of	  peptides	  
We’ve	   collected	  
in	   vitro	   and	   in	   cellulo	  
data	   from	   two	  
synthetic	   peptides,	  
EGWHAHTGGGC	   and	  
HQSPWHHGGGC.	   	   The	  
first	   seven	   amino	   acids	  
are	   the	   sequences	  
presented	   from	   phage	  
display.	  	  Three	  glycines,	  
the	  linker	  used	  in	  phage	  
dispay,	   and	   a	   cysteine	  
was	   also	   included.	  	  
Rebecca	   Swett	  
provided	  computational	  data	  on	  peptide-­‐TcdA	  binding	  and	  epoxide	  scanning	  of	  each	  position	  
with	   predicted	   contacts.	   These	   data	   were	   used	   to	   select	   two	   positions	   in	   HQSPWHHGGGC,	  
position	   5	   (W)	   or	   7	   (H)	   that	   increase	   the	   binding	   energies	   and	   provide	   an	   environment	   for	  
nucleophilic	  attack	  when	  the	  residue	  is	  substituted	  with	  an	  epoxide	  ring	  (Figure	  4.8).	   	  Sanofar	  
	  
Figure	  4.8.	   Synthetic	  peptide	   structures.	   	   EGWHAHTGGGC	   (green)	  
and	   HQSPWHHGGGC	   (blue).	   Residues	   of	   HQSPWHHGGGC	   that	  




Abdeen	   carried	   out	   the	   epoxidation	   reactions	   and	   product	   purification	   and	   characterization	  
(Figure	  4.9).	  
4.5.3. In	  vitro	  inhibition	  	  	  
	  	  The	   GT	   and	   GH	   assays	   described	   above	   were	   used	   to	   analyze	   in	   vitro	   inhibition	   of	   the	  
epoxide	  peptides,	  HQSPWHGepoxyGGGC	  and	  HQSPGepoxyHHGGGC.	   	  As	  expected,	   inhibition	  was	  
observed	  and	  comparable	  to	  the	  parent	  peptide,	  HQSPWHHGGGC.	  	  We	  next	  analyzed	  in	  cellulo	  
protection	  to	  gauge	  the	  worth	  of	  these	  molecules	  as	  C.	  difficile	  toxin	  inhibitors.	  
4.5.4. In	  cellulo	  inhibition	  
	  	  The	   cell	   protection	   assay	   is	   described	   above.	   	   In	   short,	   mammalian	   cells	   were	  
challenged	  with	  rTcdA	  at	  concentrations	  sufficient	  to	  induce	  cell	  death	  measured	  as	  a	  reduction	  
in	   cellular	   ATP,	   after	   48	   hours.	   	  When	   keeping	   TcdA	   concentrations	   constant,	   an	   increase	   in	  
ATP,	  signifying	  increased	  cell	  health,	  in	  the	  presence	  of	  inhibitor	  was	  considered	  cell	  protection.	  	  
Our	   data	   is	   presented	   in	   Figure	   4.10,	   demonstrating	   that	   the	   cell	   protection	   observed	   by	  
HQSPGepoxyHHGGGC	   is	  dependent	  on	   the	   concentration	  of	  epoxide	   inhibitor.	   	   The	  absence	  of	  
protection	  from	  HQSPWHGepoxyGGGC	  suggests	  the	  importance	  in	  the	  positioning	  of	  the	  epoxide	  
functional	  group.	  	  	  




Figure	  4.9.	  Allyl	  glycine	  and	  epoxy	  peptides.	  	  HQSPG
allyl
HHGGGC	  (A)	  and	  HQSPWHG
allyl
GGGC	  
(B)	  were	  synthetically	  prepared	  and	  oxidized	  with	  meta-­‐chloroperoxybenzoic	  acid	  (mCPBA)	  to	  
yield	  the	  epoxide	  peptides,	  HQSPG
epoxy









HHGGGC	  inhibits	  TcdA	  in	  cellulo.	  	  (A)	  CellTiter-­‐Glo	  data	  after	  48	  hour	  
incubation	  with	  the	  indicated	  concentration	  of	  	  synthetic	  peptide	  or	  modified	  peptide	  and	  (B)	  
images	  of	  Vero	  cells	  after	  a	  24	  hour	  incubation	  with	  the	  specified	  additive(s)	  demonstrate	  in	  
cellulo	  TcdA	   inhibition	  by	  HQSPG
epoxy









Previously	  identified	  7-­‐residue	  peptides	  were	  found	  to	  inhibit	  TcdA	  enzymatic	  activity	  in	  
vitro,	  but	  did	  not	  provide	  cell	  protection	  from	  rTcdA	  induced	  death.	  	  To	  assess	  various	  peptide	  
sequences,	   our	   goal	   was	   to	   build	   a	   recombinant	   peptide	   library	   while	   studying	   synthesized	  
peptides	  in	  parallel.	  
	  Two	   constructs	  were	   successfully	   cloned	  with	   various	   peptide	   sequences	   attached	   to	  
GFP.	  When	  the	  peptide	  was	  displayed	  N-­‐terminal	  of	  GFP,	  the	  additional	  methionine	  necessary	  
for	   translation	   initiation	  was	   found	  to	   inhibit	  binding	  to	  TcdA.	   	   Inhibition	  of	  TcdA	  activity	  was	  
not	  observed	  after	  cyanogen	  bromide	  cleavage	  of	  this	  protein.	  	  The	  second	  construct	  included	  a	  
protease	   site	   to	   release	   the	   peptide	   from	  GFP.	   After	   proteolysis	   a	   glycine	   remains	   at	   the	  N-­‐
terminus	  of	  the	  peptide.	  	  Our	  results	  indicate	  this	  glycine	  is	  also	  problematic	  in	  binding,	  and	  the	  
released	  peptide	  does	  not	  display	  inhibition	  of	  TcdA.	  	  Although	  other	  approaches	  may	  lead	  to	  
successful	   expression	   of	   proteins	   with	   a	   free	   N-­‐terminus,	   we	   found	   it	   not	   worth	   further	  
pursuing.	   	   Instead	   we	   focused	   our	   attention	   on	   a	   peptide	   with	   in	   vitro	   inhibition,	   and	  
modifications	  that	  lead	  to	  in	  cellulo	  protection	  from	  TcdA	  induced	  cell	  death.	  	  
Computational	  analysis	  provided	  information	  on	  important	  contacts	  made	  between	  the	  
inhibitory	  peptides	  and	   the	  predicted	  binding	   site	  of	  TcdA.	   	  These	  data	  allowed	  us	   to	  predict	  
peptide	   residues	   that	  were	  non-­‐essential	   in	  binding	  and	  could	  be	   replaced	  by	  an	  epoxide	   for	  
increased	   binding	   energy.	  Our	   aim	  was	   to	  modifying	   the	   peptides	  with	   functional	   groups	   for	  
more	   potent,	   irreversible	   inhibition.	   	   Two	   epoxy	   peptides	   were	   synthesized,	  
HQSPGepoxyHHGGGC	   and	   HQSPWHGepoxyGGGC,	   characterized,	   and	   analyzed.	   	   We	   found	  
mammalian	   cells	   were	   protected	   from	   TcdA	   induced	   cell	   death,	   up	   to	   95%,	   with	  
	  	  
115	  
HQSPGepoxyHHGGGC,	  but	  no	  protection	  was	  observed	  with	  HQSPWHGepoxyGGGC.	  	  These	  results	  
suggest	  that	  placement	  of	  the	  functional	  group	  is	  vital	  for	  the	  reaction	  with	  TcdA,	  and	  therefore	  
providing	  cells	  protection	  from	  infection.	  	  HQSPGepoxyHHGGGC	  is	  an	  exceptional	  lead	  compound	  
that	  must	   be	   further	   characterized	   to	   establish	   the	   residue	   of	   TcdA	   involved	   in	   the	   epoxide	  
attack	  and	  relevance	  in	  animal	  protection	  studies.	  
4.7. Materials	  and	  Methods	  
Plasmid	  construction	  and	  expression,	  pep-­‐gfp	  
The	   plasmid	   with	   emerald	   gfp,	   pRSET/EmGFP	   (Invitrogen),	   was	   a	   gift	   from	   Phil	  
Cunningham,	  WSU	   Biological	   Sciences.	   	   Primers	   were	   designed	   and	   ordered	   (IDT)	   for	   a	   site-­‐
directed	  mutagenesis	  (SDM)	  PCR	  reaction	  (5’:	  g	  gac	  gag	  ctg	  tac	  aag	  CAC	  CAT	  CAC	  CAT	  CAC	  CAT	  
taa	  ctc	  gag	  aag	  ctt	  gat	  ccg	  and	  3’:	  cgg	  atc	  aag	  ctt	  ctc	  gag	  tta	  ATG	  GTG	  ATG	  GTG	  ATG	  GTG	  ctt	  gta	  
cag	   ctc	   gtc	   c,	   lowercase	   indicates	   complementarity	   to	   the	   plasmid	   and	   uppercase	   indicates	  
mutated	  sequence)	  to	   insert	  a	  His6-­‐tag	  at	   the	  3’-­‐end	  of	  gfp.	  The	  resulting	  plasmid,	  pSK20401,	  
was	  subjected	  to	  a	  second	  SDM	  reaction	  used	  primers	  designed	  to	  add	  an	  NsiI	  restriction	  site	  to	  
the	  5’-­‐end	  of	  gfp	  (5’:	  cga	  att	  cgc	  cac	  cat	  gCA	  Tgt	  gag	  caa	  ggg	  cg	  and	  3’:	  cg	  ccc	  ttg	  ctc	  acA	  TGc	  atg	  
gtg	  gcg	  aat	  tcg),	  and	  yielded	  pSK20402.	  	  	  
To	   insert	   the	   peptide	   sequence	   at	   the	   5’-­‐end	   of	   gfp	   in	   pSK20402,	   complementary	  
primers	   were	   ordered	   with	   the	   coding	   sequence	   for	   the	   peptide,	   followed	   by	   sequence	  
encoding	   three	   glycine	   residues,	   and	   flanked	   by	   NdeI	   (5’)	   and	   NsiI	   (3’).	   	   The	   primers	   were	  
annealed	   using	   a	   thermocycler,	   three	   cycles	   of	   95	   °C	   for	   5	   min.,	   50	   °C	   0.5	   min.	   	   Annealed	  
primers	  (25	  µg)	  were	  digested	  with	  200	  units	  NdeI	  and	  150	  units	  of	  NsiI	  in	  NEB	  buffer	  3	  in	  200	  
µL	  total	  volume,	  as	  recommended	  per	  NEB	  double	  digest	  finder	  (http://www.neb.com).	  	  After	  a	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two	  hour	  incubation	  at	  37	  °C,	  the	  digested	  material	  was	  purified	  and	  concentrated	  following	  a	  
general	  phenol/chloroform	  extraction	  and	  ethanol	  precipitation.	   	  The	  plasmid,	  pSK20402,	  was	  
digested	  with	  the	  same	  restriction	  enzymes,	  and	  purified	  by	  column	  PCR	  purification	  (Qiagen).	  	  
The	   insert	  was	   ligated	   into	   the	  plasmid,	   at	   a	  15:1	   ratio,	  overnight	  at	  4	   °C.	   	   Electrocompetent	  
Top10	  cells	  (Invitrogen)	  were	  used	  for	  plasmid	  purification,	  and	  BL21	  (DE3)	  cells	  were	  used	  for	  
protein	   expression	   (Stratagene).	   Sequencing	   (Beckman	   CEQ8000)	   confirmed	   all	   plasmid	  
sequences.	   	   Protein	   expression	   followed	   the	   manufacturer’s	   protocol.	   Affinity	   column	  
purification	  yielded	  one	  fluorescent	  protein	  product,	  analyzed	  by	  SDS-­‐PAGE,	  at	  ~28	  kD.	  
Plasmid	  construction	  and	  expression,	  gfp-­‐tev-­‐pep	  
	  Primers	  were	  designed	  and	  ordered	  (IDT)	  for	  a	  SDM	  PCR	  reaction	  (5’:	  gca	  tgc	  TGT	  ACA	  
agg	  aga	  acc	  tgt	  act	  tcc	  agg	  gcc	  acc	  aaa	  gcc	  cct	  ggc	  acc	  acg	  gcg	  gcg	  gct	  gCA	  CTA	  GTt	  tct	  tcc	  tga	  tcc	  
cca	  agg	  gcc	  gcc	  gcc	  gcc	  gcc	  gcc	  gcc	  gcc	  gct	  aaC	  CTA	  GGg	  cat	  gc)	  to	   include	  an	  AvrII	   restriction	  
enzyme	  site	  at	  the	  3’-­‐end	  of	  gfp,	   resulting	   in	  pSK20409.	  This	  plasmid	  was	  digested	  with	  BsrGi	  
and	  AvrII	   (NEB),	  and	  purified	  by	  column	  PCR	  purification	  (Qiagen).	   	  To	   insert	  the	  TEV	  site	  and	  
peptide	   sequence,	   a	   set	   of	   complementary	   primers	  were	   annealed,	   as	   described	   above,	   that	  
contain	   the	   coding	   sequence	   for	   the	   TEV	   protease	   recognition	   site	   directly	   followed	   by	   the	  
coding	   sequence	   for	   the	   7-­‐mer	   peptide	   to	   be	   analyzed,	   followed	   by	   three	   glycine	   codons,	  
ending	   with	   either	   the	   sequence	   for	   eight	   arginines	   or	   a	   translocation	   terminator.	   	   In	   this	  
primer,	  after	  the	  peptide	  sequence,	  a	  unique	  restriction	  site	  for	  SpeI	   is	   included	  for	  exchange	  
the	  peptide	  sequences.	   	  The	  annealed	  primers	  (protocol	  described	  above)	  were	  digested	  with	  
flanking	  restriction	  enzyme	  sites,	  BsrGI	  and	  AvrII.	   	  The	  insert	  was	   ligated	  (T4	  DNA	  ligase,	  NEB)	  
into	  pSK20409,	  overnight	  at	  4	  °C,	  yielding	  pSK20410,	  which	  was	  used	  as	  the	  parent	  plasmid	  for	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the	  rest	  of	  the	  library.	  	  Digestion	  of	  pSK20410	  with	  BsrGI	  and	  SpeI	  was	  followed	  by	  ligation	  of	  an	  
insert	   with	   a	   different	   peptide	   sequence.	   	   Sequencing	   (Beckman	   CEQ8000)	   confirmed	   all	  
plasmid	   sequences.	   	   Electrocompetent	   Top10	   cells	   (Invitrogen)	   were	   used	   for	   plasmid	  
purification,	   and	   BL21	   (DE3)	   cells	   were	   used	   for	   protein	   expression	   (Stratagene).	   Protein	  
expression	   was	   followed	   by	   affinity	   column	   purification	   and	   yielded	   one	   fluorescent	   protein	  
product,	  analyzed	  by	  SDS-­‐PAGE,	  at	  ~28	  kDa.	  
TEV	  proteolysis	  	  
TEV	  proteolysis	  conditions	  were	  determined,	  following	  the	  manufactures’	  protocol.	  We	  
found	   3	   units	   of	   TEV	   to	   be	   sufficient	   for	   proteolysis	   of	   60	   µg	   of	   protein	   after	   an	   overnight	  
incubation	   at	   30	   °C.	   The	   peptide	   was	   separated	   from	   GFP	   and	   the	   TEV	   protease	   by	   affinity	  
chromatography,	   where	   both	   the	   GFP	   and	   TEV	   are	   His6-­‐tagged	   but	   the	   peptide	   is	   not.	  	  
Centrifugal	  concentrator	  devices	  were	  used	  to	  concentrate	  the	  peptide.	  
Glucosyltransfer	  assay	  	  
Glucosylation	  buffer	   (50	  mM	  HEPES-­‐K,	  100	  mM	  KCl,	  2	  mM	  MgCl2,	  2	  μM	  RhoA,	  15	  μM	  
UDP-­‐glucose	  (Sigma)	  and	  15	  μM	  UDP-­‐[14C]-­‐glucose	  (Perkin	  Elmer),	  pH	  7.5)	  was	  prepared	  fresh	  
and	  warmed	  to	  37	  °C.	  The	  reaction	  was	  initiated	  by	  addition	  of	  TcdA540,	  preheated	  to	  37	  °C.	  	  At	  
desired	   time	   points,	   8	   μL	   aliquots	   were	   removed	   and	   quenched	   into	   a	   final	   volume/	  
concentration	  of	  50	  μL,	  10	  mM	  disodium	  EDTA	  at	  pH	  8.0.	  	  The	  quenched	  samples	  (45	  µL)	  were	  
aspirated	   through	   a	   Biodyne®	   B	   high-­‐protein	   binding	   filter	   (96-­‐well	   plates,	   Nunc).	   	   The	   filter	  
membrane	  was	  washed	  extensively	  with	  wash	  buffer	   (50	  mM	  HEPES-­‐K,	  100	  mM	  KCl,	  pH	  7.5),	  
dried	  and	  imaged	  overnight	  in	  a	  phosphorimage	  cassette.	  Pixel	  intensities	  were	  compared	  to	  a	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standard	  curve,	  correlating	  pixel	  intensity	  to	  the	  concentration	  of	  glucosylated	  substrate,	  RhoA.	  	  
Initial	  rates	  can	  be	  determined,	  and	  compared,	  in	  the	  presence	  and	  absence	  of	  inhibitors.	  
Synthetic	  peptides	  
EGWHAHTGGGC	   and	   HQSPWHHGGGC	   were	   purchased	   from	   American	   Peptide	  
Company,	  Inc.	  with	  C-­‐terminal	  amide-­‐modifications.	  	  Purified	  peptides	  were	  collected	  following	  
reverse-­‐phase	   HPLC	   over	   a	   C18	   column	   (Beckman	   Coulter)	   with	   a	   0-­‐100%	   acetonitrile	   (0.1%	  
trifluoroacetic	   acid)	   gradient	   and	   lyophilization	   (344).	   	   Electrospray	   mass	   spectrometry	   was	  
used	  to	  identify	  each	  product.	  	  	  
Glucosylhydrolase	  assay	  	  
The	  GH	  assay	  was	  initiated	  by	  addition	  of	  rTcdA540	  to	  reaction	  buffer	  (50	  mM	  HEPES-­‐K,	  
100	  mM	  KCl,	  2	  mM	  MnCl2,	  2	  mM	  MgCl2,	  pH	  7.5)	  supplemented	  with	  0.5	  mM	  UDP-­‐glucose,	  0.2	  
mM	  NADH,	  1	  nM	  PEP,	  3	  units	  pyruvate	  kinase,	  and	  6	  units	  of	  lactate	  dehydrogenase	  at	  37	  °C.	  	  
Peptides	  were	  added,	  10	  nM	  HQSPWHHGGGC	  or	  1	  µM	  EGWHAHTGGGC,	  when	   indicated.	   	  An	  
Agilent	  8453	  UV-­‐vis	  spectrophotometer	  equipped	  with	  a	  circulating	  water	  bath	  maintaining	  the	  
reaction	   temperature	   at	   37	   °C,	   was	   used	   to	   monitor	   NADH	   absorbance	   at	   340	   nm.	   	   The	  
calculated	  relative	  rate	  (Vi/Vo)	  was	  used	  to	  determine	  GH	  inhibition	  by	  peptides.	  	  	  
Cell	  viability	  (CellTiter-­‐Glo)	  
Vero	  cells	   (1x104	  cells	   in	  EMEM	  supplemented	  with	  10%	  Fetal	  bovine	  serum	  (FBS,	  USA	  
Scientific)	   and	   1x	  Antibiotic-­‐Antimycotic	   (Invitrogen))	  were	   seeded	   in	   a	   96-­‐well	   tissue	   culture	  
treated	  plate	  (BD	  Falcon)	  and	   incubated	  24	  hours	  at	  37	  °C,	  5	  %	  CO2.	   	  Cells	  were	  washed	  with	  
serum	  free-­‐EMEM	  (SF-­‐EMEM)	  and	  exchanged	  into	  SF-­‐EMEM	  supplemented	  with	  0.2	  nM	  rTcdA	  
in	  a	  final	  volume	  of	  50	  µL	  (concentration	  of	  rTcdA	  may	  be	  adjusted	  dependent	  on	  potency	  to	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achieve	   desirable	   dynamic	   range	   in	   CellTiter-­‐Glo	   assay).	   	   To	   assess	   inhibitors,	   rTcdA	   and	  
inhibitor	   was	   pre-­‐incubated	   (15-­‐30	   min.	   at	   37	   °C,	   be	   aware	   incubating	   rTcdA	   at	   37	   °C	   may	  
reduce	   cytotoxicity	   so	   proper	   controls	   are	   crucial).	   	   After	   48	   hours	   (37	   °C,	   5%	   CO2)	   the	  
supernatant	   was	   exchanged	   for	   50	   µL	   fresh	   SF-­‐EMEM	   and	   brought	   to	   room	   temperature.	  
CellTiter-­‐Glo	   reagent	  was	  aliquoted	   into	  a	  96	  well	  plate	   to	  be	  added	   to	   the	   reaction	  plate	  by	  
multichannel	  pipette.	   	  A	  control	  well,	  without	  cells,	  was	  used	  as	  a	  zero	  point.	   	  We	  found	  that	  
exchange	   of	  media	   before	   the	   addition	   of	   is	   necessary	   to	   collect	   reproducible	   data,	   possibly	  
because	  this	  treatment	  removed	  additives	  that	  effected	  luciferase	  activity	  or	  it	  ensured	  all	  wells	  
were	  at	  equal	  volumes	  resulting	  from	  evaporation	  during	  incubation.	  Directly	  after	  the	  addition	  
of	  CellTiter-­‐Glo	  reagent	  the	  plate	  was	  agitated	  for	  two	  min.	  (Tecan	  GENios	  Plus	  settings:	  orbital	  
at	  moderate	  speed)	  followed	  by	  a	  ten	  min.	  incubation	  to	  allow	  the	  signal	  to	  stabilize.	  	  To	  collect	  
data,	   relative	   light	   units	   (RLUs)	   are	   detected	   using	   a	   Tecan	   GENios	   Plus	   reader	   (Pflum	   Lab	  
instrument:	   GENios	   Plus;	   Serial	   number:	   504000016;	   Firmware:	   V	   6.02	   16_06_2004	   Genios;	  
XFLUOR4	  Version:	  V	  4.51)	  and	  analyzed	  with	  Microsoft	  excel.	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5. Overall	  conclusions	  and	  remarks	  
Many	  life-­‐threatening	  diseases	  such	  as	  diphtheria,	  anthrax,	  and	  botulism	  are	  attributed	  to	  
the	  virulence	  factors	  of	  pathogenic	  bacteria.	  	  Through	  identification	  and	  characterization	  of	  the	  
exotoxins	   that	   cause	   disease,	   we	   gain	   a	   better	   understanding	   of	   how	   these	   protein	   toxins	  
function	  and	  can	  use	  this	  knowledge	  to	  aid	  our	  ability	  to	  build	  defenses	  and	  therapeutics.	  	  The	  
information	   can	   also	   be	   used	   to	   unleash	   the	   potential	   opportunities	   hidden	   within	   such	   a	  
fascinating	  system.	  	  Many	  researchers,	  including	  our	  group,	  have	  been	  intrigued	  by	  the	  intricate	  
workings	  of	   cytotoxic	  proteins	   from	  pathogenic	  bacteria.	   	  Research	  described	   in	   this	   thesis	   is	  
focused	   on	   both	   discovery	   of	   novel	   therapeutics	   targeting	   the	   virulence	   factors	   of	  C.	   difficile	  
and	  development	  of	  a	  cargo	  delivery	  system	  from	  TcdA.	  	  	  
Cargo	  delivery	  system	  
Over	   a	   hundred	   years	   ago,	   the	   potent	   cytotoxicity	   of	   bacterial	   toxins	  was	   presented	   as	   a	  
medicinal	   tool	   for	   targeted	  cell	  death	  with	  very	   little	  knowledge	  of	  how	  the	  proteins	  actually	  
work.	   	   Characterization	   over	   the	   years,	   with	   advances	   in	   techniques	   and	   technology,	   has	  
increased	  our	  understanding	  of	  such	  proteins.	  	  Exotoxins	  with	  intracellular	  activity	  are	  effective	  
only	   through	   cooperation	   of	   multiple	   functional	   domains	   including	   cell	   surface	   interactions	  
(binding	  domain),	   intracellular	  delivery	  (translocation	  domain),	  and	  disruption	  of	  cell	  signaling	  
(enzymatic	   domain)	   to	   cause	   cell	   death	   and	   clinical	   disease.	   	   The	   realization	   that	   separate	  
domains	   have	   individual	   function	   during	   intoxication	   has	   opened	   the	   field	   of	   protein	   toxin	  
research	   for	   many	   medicinal	   and	   research	   applications.	   	   Current	   research	   still	   reflects	   the	  
targeted	   cell	   death,	   or	   “magic	   bullet”	   concept,	   with	   additional	   interest	   in	   utilizing	   non-­‐toxic	  
domains	  for	  cell	  entry	  and	  cargo	  delivery.	  	  Anthrax	  toxin,	  Clostridial	  neurotoxins,	  and	  Clostridial	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glucosylating	  toxins	  are	  among	  known	  protein	  toxins	  that	  are	  currently	  under	   investigation	  as	  
cargo	   delivery	   systems.	   	   Still	   a	   relatively	   young	   field	   of	   study,	   several	   auspicious	   reports	   of	  
successful	  plasmid,	  peptide,	  protein,	  and	  functional	  enzyme	  cytosolic	  delivery	  were	  highlighted	  
in	  chapter	  1.	  	  Further	  advancement	  to	  generate	  an	  ideal	  cargo	  delivery	  system,	  with	  medicinal	  
and	   research	   applications,	   lies	   with	   the	   growing	   interest	   and	   further	   analysis	   of	   functional	  
domains	  to	  understand	  limitations	  and	  requirements	  of	  each	  protein	  toxin.	  
Our	  detailed	  understanding	  of	  TcdA	  has	  led	  to	  the	  development	  and	  investigation	  of	  a	  cargo	  
delivery	   system	   based	   on	   the	   toxin.	   	   Although	   TcdA	   is	   a	   large	   protein	   and	   not	   ideal	   for	  
recombinant	  expression,	  we	  chose	  to	  work	  with	  the	  system	  because	  of	  the	  benefits	  it	  offered	  in	  
cargo	  delivery.	  	  First,	  the	  gene	  sequence	  and	  activity	  domains	  have	  been	  identified	  providing	  us	  
the	  information	  needed	  to	  remove	  unnecessary	  residues,	  while	  retaining	  only	  functional,	  non-­‐
toxic,	   sequences.	   	   Second,	   the	   native	   protein	   delivers	   a	   large	   (66	   kD)	   enzyme	   across	   a	  
membrane	  and	  into	  the	  cytosol,	  indicating	  that	  the	  translocation	  mechanism	  can	  accommodate	  
proteins	  of	  this	  size,	  or	  possibly	  larger.	  	  Third,	  and	  possibly	  the	  most	  attractive	  feature,	  the	  CPD	  
releases	   the	   cargo	   protein	   only	   after	   it	   reaches	   the	   cytosol.	   	   Release	   of	   the	   protein	   after	  
delivery,	   without	   any	   additional	   fused	   sequence	   is	   an	   appealing	   characteristic	   that	   may	  
decrease	  the	  quantity	  of	  mis-­‐folding	  and	  increase	  polypeptide	  half-­‐lives.	  
We	  have	  presented	  data	  that	  verify	  our	  delivery	  system	  in	  Chapter	  3.	  	  After	  replacing	  the	  N-­‐
terminal	  enzymatic	  domain	  of	  TcdA	  with	   luciferase,	  we	  verified	  expression	  of	   Luc-­‐TcdA.	   	   This	  
fusion	  protein	  retained	  activity	  of	  the	  TcdA	  functional	  domains,	  RBD,	  CPD,	  and	  translocation,	  as	  
well	  as	  luciferase	  activity.	  	  The	  observation	  of	  luciferase	  activity	  in	  cell	  lysates	  after	  delivery	  by	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Luc-­‐TcdA	  demonstrates	   the	  successful	  delivery	  of	  not	  only	  a	  protein,	  but	  a	  catalytically	  active	  
enzyme.	  	  	  
This	   system	   holds	   the	   potential	   to	   be	   an	   adaptable	   tool	   for	  many	   purposes.	   	   To	   further	  
expand	   and	   build	   upon	   these	   initial	   results,	   additional	   investigations	   are	   necessary.	  	  
Determining	  the	  delivery	  efficiency,	  probing	  sequence	  requirements,	  and	  evaluating	  additional	  
cargo	  proteins	  would	  guide	  improvements	  to	  yield	  a	  more	  efficient	  system.	  	  	  
There	  are	  many	  ways	  to	  determine	  delivery	  efficiency.	  	  Investigators	  can	  collect	  molecules	  
after	   internalization	   and	   purify	   by	   affinity	   chromatography,	   identify	   by	   immunochemistry,	   or	  
detect	  in	  cellulo	  by	  detecting	  a	  reporter	  property.	  	  Our	  system,	  using	  Gaussia	  luciferase	  limited	  
our	   detection	   opportunities	   since	   the	   enzyme	   was	   found	   to	   be	   inactivated	   in	   the	   reducing	  
environment	   of	   the	   cytosol.	   	   Additionally,	   the	   only	   affinity	   tag	  was	   on	   the	   C-­‐terminus	   of	   the	  
chimeric	  protein	  and	  was	  not	  useful	  in	  collecting	  released	  luciferase,	  nor	  was	  the	  antibody	  for	  
luciferase	  sensitive	  enough	  for	  immunohistochemistry.	  	  This	  fusion	  construct	  was	  restricted	  to	  
detecting	   active	   enzyme	   and	   it	   is	   unclear	   the	   fraction	   of	   protein	   that	   remains	   inactive	   after	  
cytosolic	  delivery.	   	  The	  TcdA-­‐derived	  delivery	   system	  would	   likely	  be	   improved	  by	  a	   standard	  
technique	   to	   determine	   efficiency	   by	   using	   cargos	   that	   provide	   simple	   and	   quantitative	  
detection;	   this	   would	   allow	   comparisons	   across	   various	   cargo	   domains	   in	   exploring	   cargo	  
constraints.	  	  Addition	  of	  an	  N-­‐terminal	  epitope,	  for	  example,	  would	  serve	  this	  function.	  
Examining	   the	  delivery	   efficiency	  of	   various	   cargo	  proteins	  would	   aid	   in	  defining	   size	   and	  
structural	  constraints.	  	  Each	  of	  the	  translocation	  systems	  discussed	  within	  this	  thesis	  are	  limited	  
by	  factors	  such	  as	  toxicity,	  cell	   localization,	  cargo	  size,	  and/or	  cargo	  structure.	   	   	   It	   is	  probable	  
that	   a	   protein	   delivered	   by	   our	   TcdA	   system	   would	   be	   required	   to	   unfold	   for	   membrane	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translocation	   and	   refold	   upon	   cytosolic	   entry.	   	  We	  observed	   this	  with	   the	  GFP-­‐TcdA	  protein,	  
since	  translocation	  was	  not	  observed.	   	  GFP	   is	  structurally	  constrained	  and	  not	   likely	  to	  unfold	  
for	   threading	   through	   the	   trans-­‐membrane	   pore.	   	   Additional	   reporter	   proteins	   should	   be	  
explored	   to	   provide	   additional	   information.	   	   Although	   we	   initially	   focused	   on	   light	   emitting	  
reporters,	  other	  proteins	  may	  offer	  further	  understanding.	  	  Caspases,	  for	  example,	  would	  allow	  
detection	  by	  morphological	  changes,	  as	  well	  as	  immunochemistry.	  	  	  
TcdA	  is	  a	  very	  large	  protein	  and	  therefor	  elimination	  of	  non-­‐essential	  sequence	  is	  attractive	  
as	  it	  simplifies	  construction	  and	  may	  provide	  increased	  efficiency.	  	  Deletion	  analysis	  would	  aid	  
in	   identifying	   sequence	   requirements.	   	   Further,	   definition	  of	   each	  domain	  would	  provide	   the	  
opportunity	  to	  trade,	  or	  replace,	  a	  domain	  with	  that	  from	  another	  protein	  to	  build	  an	  adaptable	  
system.	  
TcdA	  inhibition	  
In	  addition	  to	  the	  development	  of	  a	  cargo	  delivery	  system	  based	  on	  TcdA	  fusion	  proteins,	  
our	   lab	   is	   also	   interested	   in	   identification	   of	   peptide	   inhibitors	   including	   modifications	   to	  
improve	  potency.	   	  Targeting	  the	  virulence	  factors	  provides	  advantages	  over	  other	  therapeutic	  
options.	  	  First,	  it	  removes	  pressure	  from	  the	  organism	  and	  reduces	  the	  chance	  of	  resistance	  to	  
therapy.	   	  Second,	  blocking	  the	  activities	  of	  virulence	   factors	   inhibits	  physiological	  effects,	  and	  
symptoms,	   allowing	   time	   for	   reestablishment	  of	   colonic	  microflora,	  which	  naturally	   eradicate	  
and	  suppress	  C.	  difficile	  overgrowth.	  
For	  almost	  ten	  years	  our	  lab	  has	  been	  interested	  in	  defining	  the	  mechanistic	  details	  of	  TcdA	  
to	   provide	   a	  more	   complete	   understanding	  of	   cell	   entry	   and	   cytotoxicity	   during	   infection.	   	   A	  
past	  member	  of	  our	  lab,	  Amy	  Kerzmann,	  developed	  assays	  to	  monitor	  the	  GT	  and	  GH	  activities	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in	   vitro.	   	  Her	   research	  defined	  a	  weak	  binding	  affinity	  between	  TcdA	  and	   its	   substrate,	  RhoA	  
(>104	   µM),	   and	   established	   a	   target	   for	   inhibition.	   	   Our	   lab	   became	   interested	   in	   the	  
identification	   of	  molecules	   that	   compete	  with	   this	   weak	   substrate	   binding.	   	   Sanofar	   Abdeen	  
identified	  peptides	  that	  bind	  TcdA	  GT	  domain	  in	  competition	  with	  RhoA	  using	  phage	  display.	  	  	  
Recombinant	   expressions	   of	   the	   peptides	   failed	   to	   be	   useful	   since	   additional	   N-­‐terminal	  
residues,	   such	   as	   methionine	   encoded	   by	   the	   start	   codon	   or	   glycine	   remaining	   after	   TEV	  
proteolysis,	  abolished	  binding	  to	  TcdA540.	  	  We	  then	  focused	  our	  attention	  on	  synthetic	  peptides,	  
and	  further	  examined	  two	  sequences	  for	  TcdA	   in	  vitro	  and	   in	  cellulo	   inhibition.	   	  Although	  the	  
phage	   binding	   experiments	   indicated	   EGWHAHTGGGC	   to	   have	   a	   lower	   KD	   than	  
HQSPWHHGGGC,	  we	  found	  it	  interesting	  that	  HQSPWHHGGGC	  has	  a	  lower	  Ki.	  	  We	  found	  both	  
synthetic	   peptides,	   EGWHAHTGGGC	   and	  HQSPWHHGGGC,	   inhibit	   GT	   and	  GH	   activity	   in	   vitro	  
but	  neither	  peptide	  displayed	  in	  cellulo	  TcdA	  inhibition.	  	  Theoretical	  data	  from	  docking	  models	  
allowed	  us	  to	  use	  estimated	  binding	  energies	  to	  revealed	  residues	  within	  HQSPWHHGGGC	  that	  
would	   tolerate	   functional	   group	   modifications,	   specifically	   exchange	   for	   an	   epoxide	   ring,	   to	  
provide	   irreversible	   binding.	   	   To	   explore	   the	   biological	   relevance,	   two	   epoxy-­‐peptides	   were	  
examined	  via	  cytotoxicity	  assays.	  	  One,	  HQSPGepoxyHHGGGC,	  provided	  up	  to	  95%	  cell	  protection,	  
whereas	  the	  other,	  HQSPWHGepoxyGGGC,	  was	  ineffective	  in	  the	  presence	  of	  TcdA.	  	  These	  results	  
imply	  that	  placement	  of	  the	  functional	  group	  is	  critical	  for	  inhibition.	  	  	  
The	  epoxide	  inhibitor	  we’ve	  prepared	  should	  be	  further	  explored	  as	  an	  effective	  treatment	  
against	   CDI.	   	   Footprinting	   experiments	   will	   identify	   the	   nucleophilic	   residue	   involved	   in	   the	  
epoxide	  attack	  and	  provide	   information	  on	  the	  position	  and	  orientation	  of	  the	  peptide	  within	  
the	  binding	  pocket.	   	  The	  hamster	  or	  the	  relapse	  mouse	  model,	  described	  in	  Chapter	  2,	  would	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define	   the	   effectiveness	   of	   the	   epoxy-­‐peptide	   during	   CDI	   infection	   and	   describe	   therapeutic	  
relevance,	  including	  mammalian	  toxicity	  and	  bioavailability.	  	  	  
The	  epoxidation	  reaction	  yields	  a	  mixture	  of	  stereoisomers.	   	  These	  were	  not	  separated	   in	  
our	   initial	   investigations.	   	   It	   is	   possible	   that	   separation	   of	   the	   stereoisomers	   would	   lead	   to	  
increased	  efficiency	  and	  specificity.	  	  	  
As	   a	   future	   drug,	   we	   need	   to	   consider	   route	   of	   administration.	   	   One	   epoxide	   drug,	  
Carfilzomib,	   has	   shown	   success	   and	   is	   currently	   in	   phase	   III	   clinical	   trials	   as	   a	   treatment	   for	  
Myeloma,	  cancer	  of	  the	  bone	  marrow.	  	  This	  tetrapeptide	  epoxyketone	  is	  administered	  through	  
slow	   intravenous	   (IV)	   drip,	   over	   2-­‐10	   minutes.	   	   Whether	   IV	   injection	   would	   be	   sufficient	   to	  
deliver	  our	  drug	  to	  the	  site	  of	   infection	  would	  need	  to	  be	  explored.	   	  Oral	   treatment	  could	  be	  
explored	  by	  protecting	  the	  peptide	  from	  degradation	  by	  encapsulation.	  	  
This	  thesis	  has	  highlighted	  the	   importance	  of	  bacterial	  protein	  exotoxins	  for	  both	  a	  better	  
understanding	   to	   combat	   the	   diseases	   they	   elicit	   and	   toward	   the	   engineering	   of	   powerful	  
medicinal	  and	  research	  tools.	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Virulence	  factors	  of	  pathogenic	  bacteria	  are	  to	  be	  blamed	  for	  life-­‐threatening	  infections	  
such	   as	   diphtheria,	   anthrax,	   botulism,	   and	   tentanus.	   	   In	   the	   case	   of	   enzymatic	   exotoxins,	  
disease	  arises	   from	  cytotoxic	  proteins,	  and	  cytotoxicity	   is	  acheived	  only	  after	   cell	   entry.	   	   This	  
intrinsic	  mechanism	  for	  cell	  entry	  is	  intriguing	  from	  research	  and	  medical	  views.	  	  Along	  with	  a	  
review	  on	  existing	  cargo	  delivery	  systems	  utilizing	  protein	  toxins	  and	  the	  usefulness	  of	  such	  a	  
system,	   here	   is	   described	   the	   first	   reported	   Clostridium	   difficile	   toxin	   A	   fusion	   protein,	  
luciferase-­‐TcdA,	  and	  evidence	  of	  the	  successful	  transport	  of	  an	  active	  enzyme,	   luciferase,	   into	  
the	  cytosol	  of	  vero	  cells.	  	  A	  feature	  that	  makes	  our	  system	  so	  attractive,	  is	  the	  auto-­‐proteolytic	  
event	  that	  releases	  the	  cargo	  protein	  after	  internalization.	  	  In	  addition	  to	  protein	  delivery,	  the	  
exciting	  success	  of	  a	  peptide-­‐based	  inhibitor	  is	  described.	  	  Almost	  complete	  inhibition	  of	  toxin	  A	  
was	   observed	   in	   cellulo	   by	   a	   peptide,	   identified	   to	   reversibly	   bind	   to	   the	   active	   site,	  
HQSPWHHGGGC,	   that	   was	   functionalized	   with	   an	   epoxy	   group,	   HQSPGepoxyHHGGGC.	  	  
Placement	   of	   the	   functional	   group	   is	   crucial	   for	   toxin	   inhibition.	   	   Through	   studying	   protein	  
	  	  
176	  
toxins	  we	  not	  only	  gain	  insight	  necessary	  for	  defending	  against	  deadly	  diseases,	  but	  we	  can	  also	  
learn	  to	  harness	  their	  distinctive	  properties	  for	  the	  development	  of	  novel	  biotechnology	  tools,	  
such	  as	  a	  protein	  translocation	  system.	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